








Nanostructured Zinc Oxide as drug 










Prof. Barbara Onida 
 
Doctoral Examination Committee: 
Dr. Gloria Berlier, Referee, Universitá degli Studi di Torino 
Dr. Francesca Bosco, Referee, Politecnico di Torino 
Prof. Michela Signoretto, Referee, Università Ca’ Foscari 
Prof. Flaviano Testa, Referee, Universitá della Calabria 
Prof. Enrica Verné, Referee, Politecnico di Torino 
 
 





I hereby declare that, the contents and organization of this dissertation 
constitute my own original work and does not compromise in any way the 











* This dissertation is presented in partial fulfillment of the requirements 
for Ph.D. degree in the Graduate School of Politecnico di Torino (ScuDo) 
  
   
  
"'This here's a _re_-search laboratory. _Re_-search means _look again_, don't 
it? Means they're looking for something they found once and it got away somehow, 
and now they got to _re_-search for it? How come they got to build a building like 
this, with mayonnaise elevators and all, and fill it with all these crazy people? What 
is it they're trying to find again? Who lost what?” 
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In this PhD thesis nanostructured ZnO (NsZnO) was studied to develop 
innovative drug carriers for future dermatological applications.  
In particular the novelty of the research was the use of a green organic-
solvent free route both for the production of the NsZnO and for the loading of 
of the Active Pharmaceutical Ingredients (API), by means of supercritical 
carbon dioxide (scCO2) technology. 
The first chapter deals with a general overview of the ZnO properties and 
applications in the biomedical field, offering a detailed description of the 
current state-of-art related to the use of ZnO nanostructures as drug delivery 
systems. Particular attention is focused on the existing studies of NsZnO in 
skin applications. 
The second chapter presents the scCO2 technology as an innovative and 
greener approach to perform the drug loading of a delivery system. The 
fundamental properties of the scCO2 are described in order to understand the 
mechanism of scCO2-mediated drug impregnation, since it is the drug loading 
method selected in this PhD research project. 
The third chapter illustrates the development of a green organic-solvent-
free route to prepare ZnO-based drug carriers. Two NsZnO materials with 
different morphologies were synthesized using wet organic-solvent-free 
processes and they were characterized to elucidate their morphological and 
physico-chemical properties. In this investigation, Clotrimazole (CTZ) and 
Ibuprofen (IBU) were selected as the drug models. For the first time, scCO2-
mediated drug impregnation was used in the loading of NsZnO materials.  
The fourth chapter describes the study of a third ZnO nanostructure, which 
consists in mesoporous ZnO particles. A simple synthesis was carried out, 
  
based on the on the hydrolysis of a zinc salt in basic alcoholic solutions. A 
material with a significant high surface area and a morphology suitable for the 
biomedical applications was obtained. Also in this case the scCO2 technology 
was studied as a greener alternative technology to carry out the drug loading 
of the mesoporous NsZnO. CTZ was selected as the drug model.   
The fifth chapter is focused on the study of the three developed NsZnOs 
from a biological point of view, in order to highlight their intrinsic biological 
properties. Particularly, their antimicrobial activity against different microbial 
strains were investigated, and the results were correlated with their physico-
chemical parameters. Also the in vitro Zn2+ release profiles from the NsZnO 
matrices were evaluated, simulating a release to the skin.   
The sixth chapter presents the research work carried out at the Lancaster 
University (UK). The main aim was the study of innovative materials for 
wound healing. Particularly, this section describes the development of 
biocompatible in-situ-forming composite hydrogels, based on natural 
polysaccharides, where one of the previously synthetized NsZnO was used as 
inorganic nanofiller.  The crosslinking mechanism, structure, morphology and 
swelling behavior of the in situ forming composite hydrogels were studied. 
Moreover, in vitro release of Zn2+from the formulations was simulated on 
synthetic skin and the cytotoxicity of the different component was carried out 
on a HaCat cell line.  
The seventh chapter describes the main results of a parallel research 
project carried out within my PhD studies. In particular, the proof of concept 
of an innovative dermatological formulation containing ordered mesoporous 
silica (OMS) was successfully demonstrated. The possibility to obtain a drug 
reservoir system, combining API-loaded OMS with a saturated solution of the 
same API was investigated obtaining outstanding results from both a physical-
chemical and biological point of view. The innovative formulation resulted in 
a sustained release of the drug lasting two times with respect to the commercial 
gel, which opens the possibility of reducing the daily number of 






1. Zinc Oxide nanomaterials as drug delivery systems............................. 1 
1.1. Introduction ..................................................................................... 1 
1.1.1 Biomedical applications of nanostructured ZnO....................... 7 
1.2 ZnO as drug carrier: the state-of-the-art ........................................ 15 
1.2.1 Pure ZnO drug carriers ............................................................ 15 
1.2.2 ZnO-composite drug carriers. ................................................. 20 
1.3 ZnO nanomaterials for skin applications ....................................... 24 
1.3.1 Skin structure and skin-particles interaction ........................... 24 
1.3.2. ZnO nanomaterials and skin: the state-of-the-art ................... 30 
1.4 Conclusions .................................................................................... 38 
1.5 References ...................................................................................... 39 
2. Drug delivery goes supercritical ........................................................... 51 
2.1 Introduction .................................................................................... 51 
2.2 Supercritical carbon dioxide: generalities and properties .............. 52 
2.3 Drug impregnation through supercritical Carbon Dioxide ............ 56 
2.4 ZnO and scCO2-assisted drug impregnation .................................. 60 
2.4.1 Models drugs ........................................................................... 61 
2.5 Conclusions .................................................................................... 65 




3. Green organic-solvent-free routes to prepare nanostructured zinc 
oxide carriers for pharmaceutical applications. .................................. 73 
3.1 Introduction .............................................................................. 73 
3.2 Experimental ............................................................................ 75 
3.2.1. Materials ................................................................................. 75 
3.2.2. Synthesis of nanostructured ZnO ........................................... 75 
3.2.3. Clotrimazole-loaded NsZnO materials .................................. 76 
3.2.4 Ibuprofen-loaded NsZnO materials......................................... 78 
3.2.5 Characterization ...................................................................... 78 
3.3. Results and Discussion ................................................................. 80 
3.3.1. Characterization of the NsZnO materials as such. ................. 80 
3.3.2 Characterization of the CTZ-loaded NsZnO materials ........... 83 
3.3.3 Characterization of the IBU-loaded NsZnO materials ............ 90 
3.4 Conclusions .................................................................................. 102 
3.5 References ................................................................................ 103 
4. Mesoporous ZnO as drug reservoir of clotrimazole: synthesis, drug 
loading and characterization ............................................................... 107 
4.1 Introduction .................................................................................. 107 
4.2 Experimental ................................................................................ 108 
4.2.1 Materials ................................................................................ 108 
4.2.2. Synthesis of nanostructured ZnO using the precipitation method
 .............................................................................................................. 108 
4.2.3. Drug loading of NsZnO-3 .................................................... 108 
4.2.4 Preliminary in vitro drug release study ................................. 109 
4.2.5. Characterization ................................................................... 110 
4.3. Results and discussion ................................................................ 111 
4.3.1. Characterization of NsZnO-3 as such .................................. 111 
4.3.2 Characterization of the CTZ-loaded NsZnO-3 ..................... 113 




4. 4 Conclusions ................................................................................. 122 
4.5 References .................................................................................... 124 
5. Antimicrobial  activity  of  NsZnO-1, NsZnO-2 and NsZnO-3 related 
to their physicochemical properties .................................................... 125 
5.1 Introduction .................................................................................. 125 
5.2 Experimental ................................................................................ 127 
5.2.1 Microbial strains and culture conditions ............................... 127 
5.2.2 Inocula preparation................................................................ 127 
5.2.3 In vitro antimicrobial assays ................................................. 127 
5.2.4. In vitro Zinc Ions release...................................................... 129 
5.3. Results and discussion ................................................................ 130 
5.4 Conclusions .................................................................................. 138 
5.5 References .................................................................................... 140 
6. Composite materials for wound healing: preparation and 
characterization of in situ cross-linking bionanocomposite hydrogels.
 ................................................................................................................ 143 
6.1 Introduction .................................................................................. 145 
6.2 Experimental ................................................................................ 147 
6.2.1. Materials ............................................................................... 147 
6.2.2. Synthesis .............................................................................. 147 
6.2.3. Preparation of chitosan stock solution ................................. 148 
6.2.4. Hydrogel Preparation ........................................................... 148 
6.2.5. Bionanocomposite Hydrogel Preparation ............................ 148 
6.2.6. In vitro swelling test ............................................................. 148 
6.2.7. Characterization ................................................................... 149 
6.2.8 In vitro Zin Ion release .......................................................... 149 
6.2.9. Cytotoxicity of CS, HA Derivatives, PEC Derivatives and 
NsZnO ................................................................................................... 149 
6.3. Results and discussion ................................................................ 150 
 Contents 
 
6.4. Conclusions ................................................................................. 161 
6.5 References .................................................................................... 161 
Conclusions and Outlooks ......................................................................... 165 
APPENDIX ................................................................................................. 169 
7. From the fundamental research to the Proof of Concept: an innovative 
dermatological formulation containing Ordered Mesoporous Silica for 
the administration of active pharmaceutical ingredients. ................ 171 
7.1. Introduction ................................................................................. 172 
7.2 Material and methods................................................................... 174 
7.3 Experimental ................................................................................ 175 
7.3.1. Drug loading into OMS ........................................................ 175 
7.3.2. Characterization of the AKS-loaded OMS .......................... 175 
7.3.3. Preparation and characterization of the AKS-OMS reservoir 
vehicle ................................................................................................... 176 
7.3.4 Preparation of the topical semisolid dosage form ................. 176 
7.3.5. Characterization of AKS-OMS@GEL ................................ 177 
7.3.6. In-vitro Release studies using vertical diffusion cells.......... 177 
7.3.7.  In-vitro permeation studies using vertical diffusion cells ... 178 
7.3.8. Microbiological activity studies ........................................... 179 
7.4 Results and discussion ................................................................. 180 
7.4.2. Characterization of the AKS-loaded OMS reservoir formulation
 .............................................................................................................. 182 
7.4.3. Characterization of AKS-OMS@GEL ................................ 183 
7.4.4. In-vitro Release studies using vertical diffusion cells.......... 185 
7.4.5. In-vitro permeation studies using vertical diffusion cells .... 187 
7.4.6. Microbiological activity studies ........................................... 189 
7.5 Conclusions .................................................................................. 193 
7.6. References ................................................................................... 194 
 Chapter 1 
Zinc Oxide nanomaterials as drug 
delivery systems 
1.1. Introduction  
 
In accordance with the European Commission, a “nanomaterial consists 
in an insoluble or biopersistant and intentionally manufactured material with 
one or more external dimensions, or an internal structure, on the scale from 1 
to 100 nm” 1. In the last decade, the use of nanomaterials has attracted much 
attention due to their small sizes and innovative structures that exhibit 
significantly improved physical, chemical, and biological properties compared 
to their bulk or molecular precursors 2. Metal oxides have found several 
applications in various fields of nanotechnology due to their excellent optical, 
magnetic, electrical, and chemical properties. Nanostructured metal oxides are 
interesting materials, because they can be synthesized with a very high surface-
to-volume ratio and with unusual morphologies that can be easily 
functionalized with different groups for the new applications. An increasing 
use of nanomaterials has been reported in biological- and medical-related 
applications such as imaging, sensing, target drug delivery, healthcare 
products, cosmetics, and food preservative agents due to better safety and 
stability compared to bulk precursors or their organic counterparts.  
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Zinc Oxide (ZnO) is a multifunctional material possessing unique physical and 
chemical properties, such as high chemical stability, high electrochemical 
coupling coefficient, broad range of radiation absorption and high 
photostability 3. It is classified as a wurtzite-type semiconductor (group II-VI) 
and piezo-electrical material, and possesses a broad band-gap energy of 3.1–
3.4 eV, a large excitation binding energy of 60 meV and a high thermal and 
mechanical stability at room temperature. Thanks to these outstanding 
properties ZnO is largely used in many attractive applications, ranging from 
electronic, optoelectronic, sensoristic and photocatalysis 4,5. Moreover, ZnO is 
listed by the Food and Drug Administration (FDA) as a Generally Recognized 
as Safe (GRAS) substance, due to its low toxicity, biocompatibility and 
biodegradability. Consequently, ZnO materials are attracting growing 
attention also in the biomedical field. 
ZnO exhibits three crystal structures named wurtzite, zinc-blende and an 
occasionally noticed rock-salt (Figure 1.1) 6.  
The hexagonal wurtzite structure possesses lattice spacing a = 0.325 nm and c 
= 0.521 nm, the ratio c/a * 1.6 that is very close to the ideal value for hexagonal 
cell c/a = 1.633. Each tetrahedral Zn atom is surrounded by four oxygen atoms 
and vice versa [43]. The structure is thermodynamically stable in an ambient 
environment and usually illustrated schematically as a number of alternating 
planes of Zn and O ions stacked alongside the c-axis. On the other hand, zinc-
blende structure is metastable and can be stabilized via growth techniques.  
 
 
Figure 1.1 ZnO crystal structures. Adapted from 6 
 
The variety of available ZnO nanostructures make it an interesting material for 
nanotechnology applications 7–10. In fact, in comparison to the bulk material, 
nanostructured ZnO has enhanced properties that can be exploited in many 
industrial area such as gas sensors, biosensors, semiconductors, piezoelectric 
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devices, field emission displays, photocatalytic degradation of pollutants, 
antimicrobial treatments and UV-blocker materials in cosmetics 11. The 
nanostructures of ZnO can be classified in one- (1D), two- (2D), and three-
dimensional (3D) structures (Figure 1.2) 3. One-dimensional structures make up 
the largest group, including nanorods 12,13, nanoneedles 14, nanohelixes, 
nanosprings and nanorings 15, nanoribbons 16, nanotubes 17, nanobelts 18, 
nanowires 19 and nanocombs 20. ZnO can be obtained in 2D structures, such as 
nanoplate/nanosheet and nanopellets 21. 3D structures of ZnO include flower, 
dandelion, snowflakes, coniferous urchin-like 3. This impressive assortment of 
ZnO particle structures plays a key role in making this material one of the most 
investigated metal oxides in the nanotechnology field. 
 
 
Figure 1.2 Different structures of ZnO, classified as one-dimensional (1D), two-
dimensional (2D) and three-dimensional (3D). Image modified from 22. 
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Synthesis approaches of nanostructured ZnO 
 
Nowadays, the environmental implications of a material synthesis are one of 
the most investigated issues in the material science field.  The need of 
synthetizing nanoparticles using eco-friendly, cost-effective, biocompatible 
and safe techniques has been one of the major focuses of this last decade. A 
wide number of synthetic techniques have been explored for the synthesis of 
ZnO 10,23–26. The choice of a suitable method mainly depends on the desired 
application, morphology and size. Here, a general overview of the most 
adopted approaches for the synthesis of nanostructured ZnO is reported. In 
accordance with a recent classification, it is possible to divide the synthetic 
routes to obtain ZnO nanomaterials as follows 22: 
i) Chemical methods 
Liquid phase synthesis  
Precipitation and coprecipitation methods are based on the reaction of a 
reducing agent (i.e. inorganic alkalis) with a zinc salt. The product 
typically consists in soluble or insoluble precipitate which is washed and 
calcined to obtain nanoparticles with the desired morphology and 
characteristics. 
Sol-gel techniques belong to the colloidal chemistry approach. Sols are 
colloidal solution consisting in solid nanoparticles suspended in a liquid 
phase, while gels are mostly formed by polycondensation methods 
followed by aging to achieve phase transformations and Ostwald ripening. 
The gels are dehydrated at high temperature and finally densified to obtain 
metal oxide nanoparticles. Sol-gel approach assures the pure and uniform 
nanostructured ZnO 27 to be obtained.  
In solvothermal and hydrothermal processes, precursors are dissolved in 
hot solvents or water under moderate to high pressure (1–10,000 atm) and 
moderately high to high temperature (100–1000°C). These processes are 
used to synthesize a variety of zinc nanostructures such as thin films, bulk 
powders, spheres (3D), rods (2D), and wires (1D).  
  
The above-mentioned methods offer several advantages, such as 
simplicity, low cost, repeatability and relatively mild operative conditions, 
which make them particularly suitable for the synthesis of nanostructured 
5 Chapter 1 
 
ZnO for biomedical applications, as in the synthesis of ZnO-based drug 
delivery systems. This aspect will be deepened in the paragraph 1.2. 
 
Gas phase synthesis   
 
In the spray pyrolysis method, a zinc salt precursor is formulated in 
aerosol droplets by flame heating. The droplets are dispersed in the gas 
and their sizes decreased by dehydration. Inert gas condensation methods 
are divided into physical vapor deposition (without catalytic interaction) 
and chemical vapor deposition (with catalytic interaction). Briefly, these 
techniques include evaporation of a zinc source inside a chamber by 
resistive heat. The vapors are forced to migrate into cooler chamber filled 
with inert gas, from where they are collected for further consolidation.  
 
 
ii) Biological methods  
 
The emerging trend of developing new green, more environmentally 
friendly and sustainable synthesis methods, have increasingly involved 
the metal oxides field, including ZnO. Green synthesis of ZnO have been 
attracted much attention due the possibility to use a reduced number of 
chemicals, resulting in more energy efficient and cost-effective 24,28 
processes. It is possible to classify the biological methods in plant-source 
mediated synthesis and microorganism-mediated synthesis. Briefly, in the 
former case, the mechanism is dependent on the secondary metabolites of 
the plant, which play a significant role as reducing agents for the 
conversion of metal salts (precursors) into metal or metal oxide 
nanoparticles. In the latter case, microorganisms are able to transform 
metal ions to metal or metal oxide nanoparticles through enzymes 
generated by cell activities.  
 
 
iii) Physical methods  
Physical/mechanical processes are mostly used for the industrial 
processes. Physical methods for the synthesis of ZnO nanoparticles 
include high energy ball milling, melt mixing, physical vapor deposition, 
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laser ablation, sputter deposition, electric arc deposition, and ion 
implantation 24.   
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1.1.1 Biomedical applications of nanostructured ZnO 
 
Because of its outstanding intrinsic properties, nanostructured ZnO fulfils a 
remarkable importance in many fields of applications. Many scientific reviews 
have been dedicated to list the main uses of ZnO, highlighting the remarkable 
versatility of this nanomaterial 3,24–26. For instance, ZnO nanostructures play 
key roles as fillers in the rubbers industries 3, can be used as conventional wide 
band-gap semiconductors in microelectronic devices and or employed for 
accelerating the degradation of water pollutants by means of their 
photocatalytic activity 29. Applications in energy storage and hydrogen storage 
have also been explored.  Since this thesis is focused on the development of 
ZnO nanomaterials as drug delivery systems, this paragraph highlights the 
biological-related properties of ZnO and its consequent applications. 
ZnO as antibaterial agent 
 
Antibacterial activity is defined as the action by which bacterial growth is 
destroyed or inhibited. It is also described as a function of the surface area in 
contact with the microorganisms 30. ZnO is an efficient antimicrobial agent and 
its activity is based on several mechanisms involving different chemical 
species. In the literature, three distinct mechanisms of action have been 
discriminated (Figure 1.3) 6,31–33:  
1. Photocatalytic antibacterial mechanism. Recognized as the predominant 
antimicrobial mechanism, it is based on the production of reactive oxygen 
species (ROS) because of the semiconductive properties of ZnO 32. The 
production of hydroxyl radicals, singlet oxygen and superoxide radicals are 
toxic to the cells because they damage many cellular constituents such as 
DNA, lipids, and proteins. Basically, when the ZnO nanostructures are 
illuminated by light with a photoenergy equal to or greater than its band-
gap energy, e − are promoted across the band gap to the conduction band, 
generating a hole (h +) in the valence band.  The e − in the conduction band 
exhibit strong reducing power, while the h + in the valence band possess 
an oxidizing power. These configurations are able to generate three main 
types of ROS, which mainly contribute to the oxidative stress in biological 
systems:  
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i) superoxide anion radicals O 2 
•− : generated when the electron reacts with 
molecular oxygen through a reductive process; 
 
 
Figure 1.3 Different possible mechanisms of ZnO-NPs antibacterial activity 6 
 
 
ii) hydroxyl radicals OH • : generated through an oxidative process when h 
+ can capture the e − from water and/or hydroxyl ions. OH • is known as 
the most reactive oxygen radical known because it rapidly reacts with a 
wide range of organic biomolecules, such as nucleic acids, lipids, 
carbohydrates, proteins, DNA and amino acids. The dominating 
recombination of two OH • radicals produces hydrogen peroxide (H2O2), 
which chemically interacts with bacteria. This mechanism has been 
proposed as the predominant mechanism underlying the antibacterial 
activity of ZnO. 
iii) singlet oxygen 1 O 2:  is mostly produced indirectly from aqueous 
reactions of superoxide anion radicals O 2 
•− .  They are not as strong as OH 
•, but act as mediator of photocytoxicity by irreversibly damaging the 
tissues, through biomembrane oxidation and degradation.  
  
 
2. Intrinsic antimicrobial properties of Zn2+ ions released by ZnO. Zinc 
is an essential element for microorganisms and higher organisms. It plays 
an important role in many vital cellular reactions at its low endogenous 
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concentrations (10−4 M in blood). Zn2+ ions are essentially nontoxic to 
higher organisms, because its concentration is physiologically regulated 
by several transporters. The antimicrobial properties of Zn2+ both against 
bacterial and fungal strains are well known. Briefly, increasing Zinc 
concentrations above the optimal levels, its homeostasis is perturbated, 
allowing Zn2+ to enter the cells. At this point, zinc becomes cytotoxic to 
prokaryotes (concentration >10−4 M). The antimicrobial activity of Zn2+ 
depends on its concentration and contact duration. Nevertheless, the 
contribution of Zn2+ to the antimicrobial activity of ZnO has been reported 
as the less efficient mechanism because the too low dissolution rate of ZnO 
particles 31. 
 
3. Destabilization of microbial membranes upon direct contact of ZnO 
particles with the cell walls. The direct contact of ZnO particles with the 
bacterial membrane may lead to penetration and disorganization of its 
structure, causing the loss of membrane integrity and malfunction of the 
permeability barrier. Nanostructured ZnO possesses large specific surface 
area and high surface energy that is adsorbed by the bacteria, altering their 
metabolism due to the altered exchange of matter and energy with the 
environment.  
 
The antibacterial response is significantly affected by various parameters, 
among which the morphology, size and concentration of ZnO nanostructures 
6,30.The shape-dependent activity is explained in terms of the percent of active 
facets in the nanoparticles. ZnO with different morphologies possesses 
different active facets, which lead to enhanced antibacterial activity 34. For 
instance, rod-structures of ZnO have (111) and (100) facets, while spherical 
nanostructures mainly have (100) facets. High-atom-density facets with (111) 
facets exhibit higher antibacterial activity. Moreover, the shape of ZnO 
nanostructures can influence their mechanism of internalization. Even though, 
rods and wires showed an enhanced penetration into the cell walls of bacteria 
with respect to spherical ZnO particles, rod-like structures possess a greater 
toxicity effect, because of their larger production of ROS in suspension, which 
cause disruption of cellular function and disorganization of membrane.  
For instance, Talebian and colleagues, who evaluated different ZnO 
nanostructures, assessed that the flower-shaped ZnO possessed a higher 
antibacterial activity than the spherical and rod-shaped ZnO nanostructures 35. 
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This was explained by the fact that higher surface interstitial defects reduce the 
electron or hole recombination and consequently increase the antibacterial 
activities. As far as the contribution of the polar facets of ZnO nanostructured 
to the antibacterial activity is concerned and in addition to the enhancement of 
internalization, it has been suggested, that the higher number of polar surfaces 
possesses higher amount of oxygen vacancies. Oxygen vacancies are known 
to increase the generation of ROS and consequently affect the photocatalytic 
activity of ZnO 6,36.  
Furthermore, the particle sizes and concentration of ZnO nanostructures play 
a key role in the antibacterial activity. Large surface area and high 
concentrations lead to an enhanced bactericidal response. ZnO particles with 
small sizes have been reported as the most active against bacteria, due to the 
high specific surface area exposed. Moreover, both the release of Zn2+ ions and 
the generation of H2O2, which are two of the main antibacterial mechanisms, 
were reported to be size and surface-dependent 37–40.  As for as the 
concentration of antibacterial agent is concerned, usually two different 
parameters are assessed: the minimum bactericidal concentration (MBC), 
which is defined as the lowest concentration of antibacterial agent that showed 
no bacteria growth in the medium, and the minimum inhibitory concentration 
(MIC), which is the lowest concentration at which colonies are observed on 
the surface of the medium. In other words, MIC is the concentration that 
prevents bacterial growth.  
 
It is worth noticing that the same mechanisms involved in the antibacterial 
activity of ZnO make this material active also against fungal pathogens. This 
dual-antimicrobial activity is fundamental in the multi-tasking role of ZnO 
nanomaterials and many research works have been addressed to investigate of 
this material from a biological point of view 41–45 . 
 
The antimicrobial properties of ZnO can be considered attractive for its use as 
an antimicrobial preservative of pharmaceutical or cosmetic formulations 46. 
Nevertheless, few research works have been addressed to this application. 
Favet and collaborators investigated the antibacterial activity of ZnO in 
comparison with parabens, in a zinc gelatin-based ointment 47. The role of ZnO 
as preservative in topical formulations was also investigated by Pasquet and 
colleagues, who studied the antibacterial activity of ZnO powders on five 
microrganisms strains used for the Challenge Tests 48. Even though the use of 
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ZnO as an antimicrobial preservative for pharmaceutical and cosmetic 
formulations has been scarcely investigated, its role as antibacterial agent in 
the food industry has also been considered 6. Particularly its application as 
antimicrobial agent in food active packaging against food-borne pathogens has 
been investigated 49. 
Moreover, it is worth noticing that ZnO can be considered as a promising and 
low-cost alternative to silver and gold nanoparticles, which are also popular 
for their pronounced antibacterial activity, but the use of which on the 
industrial scale is limited by their high cost 50. 
 
ZnO as antitumoral agent 
 
Nowadays, nanomedicine represents a promising solution in the anticancer 
field due to its advanced imaging and therapeutic properties, which allow early 
detection of cancer and more efficient treatments to be achieved 51. Many 
inorganic nanoparticles, such as iron oxide, titanium dioxide, cerium oxide, 
zinc oxide, copper oxide and silica have been being widely researched and used 
for anticancer therapy as-such or conjugated with anti-cancerous drugs or bio-
active molecules (i.e proteins and DNA). These nanomaterials have unique 
features, among which intrinsic selective cytotoxicity towards cancer cells, 
which make them a novel and efficient tool for anticancer therapy. Among all 
these nanomaterials, zinc oxide nanostructures are showing promising 
application and efficacy in cancer therapy due to their highly selective nature 
and potency towards cancer cells 52. The anti-cancerous activity of ZnO 
depends on its own properties, such as its biocompatibility and its selective 
cytotoxicity against cancerous cells in in vitro condition in comparison with 
other nanoparticles. Moreover, their surface can be furtherly engineered 
increasing this selectivity. One of the mechanisms of cytotoxicity of ZnO 
nanoparticles towards cancer cells is based on the unique ability of ZnO 
nanoparticles to induce oxidative stress. This property depends on the 
semiconductor nature of ZnO, which induces ROS generation, as described 
earlier, leading to oxidative stress and cell death.  ZnO is a suitable anticancer 
agent also due to the wide range of synthesis approaches available. For 
instance, the possibility to significantly reduce its size allows the intra-tumour 
concentration of nanoparticles after administration to be increase (enhanced 
EPR effect). 
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Furthermore, the electrostatic characteristics of ZnO nanoparticles make this 
nanomaterial an attractive candidate for anticancer therapy 29. At lower pH, 
protons from the environment are probably transferred to the ZnO particle 
surface, leading to a positive charge from surface ZnOH2+groups. In aqueous 
medium and at high pH, the chemisorbed protons (H+) move out from the 
particle surface leaving a negatively charged surface with partially bonded 
oxygen atoms (ZnO-). The isoelectric point of 9-10 indicates that the ZnO 
nanoparticles have a strong positive surface charge under physiological 
conditions. Thanks to its electrostatic nature, ZnO would be able to interact 
with the anionic phospholipids on the outer membrane of cancer cells, so 
promoting cellular uptake, phagocytosis and ultimate cytotoxicity. 
Significant examples of the application of ZnO-based drug delivery systems 





ZnO as UV blocker 
 
As a result of their ability to absorb UV radiation, ZnO nanoparticles are 
used in the cosmetic industry, typically in sunscreens and facial creams 53,54. 
Sunscreens are used to protect the skin against the harmful effects of solar 
ultraviolet (UV) radiation. When UVB (290 - 320 nm) rays together with UVA 
(320 - 400 nm) rays reach our skin, they can cause biological and metabolic 
reactions. These can range from short-term effects, such as UVB-induced 
vitamin D synthesis and, at higher doses, the insurgence of erythema, to long-
term effects which include different degenerative skin changes, such as actinic 
keratoses, skin cancer from epidermal cells and loss of the skin elasticity due 
to UVA producing reactive oxygen species (ROS). Nowadays, the 
combination of ZnO and titanium dioxide (TiO2) is frequently used in 
sunscreen products. Their UV-blocking mechanism depends on their ability in 
reflecting and/or scattering most of the UV-rays, as well as absorbing UV 
radiation because of their semiconductive properties. As inorganic physical 
sun blockers, ZnO and TiO2 assure the absence of skin irritation and 
sensitization, inertness of the ingredients, limited skin penetration and a broad-
spectrum protection, against both UVA and UVB. ZnO is generally used in the 
13 Chapter 1 
 
form of nanoparticles at the size of 30-200 nm. The surface of the nanoparticles 
can also be treated with inert coating materials to enhance their dispersion in 
sunscreen formulations (i.e. silicon oils) 55. Current examples of the application 




A biosensor system aims at the quantitative detection of certain parameters 
during the occurrence of complex biochemical reactions through a transducer 
coupled with a biologically derived recognition entity 32. The large surface-to-
volume ratio, nontoxicity, chemical stability, high catalytic activity, 
electrochemical activity, and excellent electron-communication features make 
ZnO nanostructures the best candidates for biosensor applications. For 
instance, ZnO aligned one-dimensional (1D) nanostructures are suitable 
materials for this application. In fact, they offer a large area for enzyme 
immobilization and direct channels for electron transport from the redox 
enzymes to the current collector. Moreover, ZnO nanostructures are 
particularly suitable for the absorption of some proteins through electrostatic 
interaction, due to the high ZnO isoelectric point of about 9-10.  Up to now, 
ZnO nanostructures have been applied in biosensors for the detection of several 
biomolecules, such as cytochrome C, uric acid, protein and glucose 56–59. 
 
ZnO in Bioimaging 
 
ZnO nanostructures, in particular in the form of Quantum Dots, are suitable 
candidates for the bioimaging applications, such as tracing live cells and real-
time monitoring of target tissues. The possibility to use this nanomaterial in 
bioimaging derives from its improved properties, in comparison with 
traditional organic fluorescent dyes. These range from photoluminescent 
activity, including broad-band absorption, a narrow and symmetrical emission 
band, a tunable emission wavelength, high stability against photo-bleaching, 
and its semiconductor nature 32. ZnO Quantum Dots are also characterized by 
excellent biocompatibility, good biodegradability, low cost and environment 
compatibility 60,61.  
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ZnO as drug delivery system 
 
Since this PhD project aimed at the study of ZnO nanostructures as drug 
reservoirs for future skin applications, the following sections of this thesis 
describe the application of ZnO nanomaterial as drug delivery systems. First, 
the current state-of-the-art of ZnO nanomaterial as drug delivery system is 
carefully taken in consideration. Second, a major focus of the use of ZnO-
based carriers on the skin and its application in wound healing is reported.  
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1.2 ZnO as drug carrier: the state-of-the-art 
 
Despite Zinc Oxide (ZnO) is a widely investigated material in many research 
fields, its application as a drug delivery system has begun to attract attention 
only in this last decade and it is considered at its nascent stage (Figure 1.4). In 
particular, in the last couple of years many research works have been dedicated 
to the development of ZnO materials as drug carriers thanks to its outstanding 
biocompatibility, giving new light to this outstanding material. Therefore, from 
a careful analysis of the literature, it has emerged that it would be possible to 
classify the main studies of ZnO as a material for drug delivery into two main 
categories: i) studies dealing with pure ZnO carriers and ii) studies on ZnO-
composites carriers (Figure 1.5). 
 
 
Figure 1.4 Analysis of the number of documents related to the use of Zinc Oxide as 
drug delivery system, in the range 1983 – 2018 62. 
 
1.2.1 Pure ZnO drug carriers 
 
The possibility to synthetize a wide range of ZnO nanostructures tuning 
their morphology and properties, has played a significant key role in the study 
of pure ZnO as a drug carrier. It is a matter of fact that a high surface area, 
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significant pore volume and uniform pore size distribution remarkably 
influence the carrier capability of firstly hosting a drug molecule and then of 
releasing it. 
 
Figure 1.5 Schematic representations of pure ZnO drug carriers in 
comparison with ZnO-composite carriers. The images were adapted from: A 
63, B 64, C 65, D 66 and E 60 
 
 In these last 5 years, different research groups have investigated the 
possibility to obtain highly performant pure ZnO drug carriers. Going through 
the literature, it has emerged that nowadays the study of ZnO particles as drug 
delivery system is particularly focused on the anti-cancer field 52. In fact, ZnO 
particles are being widely studied for their anti-cancerous properties, such as 
the selective cytotoxicity towards cancer cells. From the analysis of the 
published documents, it is evident that the development of pure ZnO carriers 
for the delivery of anti-cancerous molecules has been attracting large attention. 
In particular many researchers selected Doxorubicin as a drug model for their 
investigations. In 2017, for instance, some interesting results have been drawn 
by Tian and colleagues. Their study aimed at the development of a pure 
mesoporous ZnO carrier for the delivery of Doxorubicin Hydrochloride 67. 
They were able to obtain ZnO nanospheres (150 nm) via decomposition of a 
precursor by thermal treatment. As expected, the material presented large 
specific surface area (43.4 m2/g), narrow pore size distribution (6.2 nm) and 
good hydrophily. Tian performed the drug loading of the mesoporous ZnO by 
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a traditional soaking technique. Although any information related to the drug 
amount loaded into the ZnO nanospheres was provided in the paper, the in 
vitro release study reported a Doxorubicin release at pH 5 higher than that at 
7.4, which confers a pH-triggered behaviour on the system.  
A doxorubicin delivery system based on ZnO nanomaterials has also been 
the main object of investigation carried out by Liu and colleagues 68, who also 
obtained a pH-triggered drug release in acidic environment due to degradation 
of the carriers. In this second case the ZnO nanoparticles (about 50 nm) were 
prepared by reprecipitation method in ethanol, followed by an overnight drying 
step in vacuum. The drug loading was performed directly in the reaction vessel, 
just before the drying phase, by adding Doxorubicin in the ethanolic mixture. 
Also in this case, any information about the drug loading amount was provided.  
Vimala and collaborators proposed the development of green synthesized 
ZnO nanosheets, functionalized with polyethylene glycol and folic acid for the 
delivery of Doxorubicin and photothermal therapy against breast tumour 69. 
This research work has provided to remarkable results, since a functionalized 
ZnO material with an impressive BET surface area of 673.44 m2/g, with 
regularly distributed pores of size around 1.56 nm. ZnO nanosheets had an 
average size of 100 nm, and a high drug loading efficiency of 89% was 
reported (0.57 mg of drug per mg of the functionalized ZnO). As in previous 
works, a pH-triggered release of Doxorubicin from the functionalized ZnO was 
demonstrated, with an enhanced release at acidic pH.  
The same approach, was adopted by Cai and collaborators 64 who 
fabricated a ZnO quantum dots-based pH responsive drug delivery platform 
for intracellular controlled release of Doxorubicin. ZnO quantum dots (∼3 nm) 
were synthesized using the precipitation method. They were not used as-
synthetized, but modified with several functionalization groups, in order to 
improve the stability in physiological fluid. The Doxorubicin loading were 
performed through a traditional approach, incubating a drug solution with the 
carrier for a certain time. Doxorubicin loading of 30% into the modified ZnO 
QDs was calculated. Again, a higher drug release was achieved at low pH 
value, due to the the dissolution of the ZnO QDs and dissociation of 
drug−metal complex under acidic conditions. Similar results were presented in 
2011 by Muhammad and his research group, who investigated the 
functionalized-ZnO quantum dots for the delivery of Doxorubicin 70.  
Other functionalization approaches were also evaluated in order to 
enhance the anti-cancer treatments efficacy. The possibility to produce 
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PEGylated ZnO nanoparticles for drug delivery was investigated by Fakhar e 
Alam et al 71. In this case the PEGylated ZnO nanoparticles were loaded with 
protoporphyrin IX, by a simple drug solution addition to the particles. 
 A different ZnO nanostructure was proposed by Kumar and collaborators, 
who reported the production of mesoporous self-assembled ZnO ‘dandelions’ 
with spherical shape, as delivery systems for anticancer drugs and DNAs 72. 
Mesoporous self-assembled ZnO ‘dandelion’ capsules were synthesized by 
hydrolysis of a zinc precursor in the presence of a surfactant, followed by heat 
treatment of the hydrolysed dry powder. The results showed the formation of 
ZnO spheres, with a BET surface area of 230 m2/g and an average pore size of 
8.46-8.85 nm. Drug loading studies were performed through traditional 
soaking method, by using Doxorubicin and Rhodamine B, a fluorescent agent, 
as models. The loading efficiency of the two drugs in self-assembled ZnO 
‘dandelion’ was found to be equal to 10 mg/10 mg and 6.5 mg/10 mg of 
sample, respectively. The release of both the molecules was successfully 
demonstrated.  
In 2010, Mitra at collaborators investigated the development of porous 
ZnO nanorods, for the targeted delivery of Doxorubicin 73. For the synthesis of 
the material, a precipitation method followed by a drying step in vacuum was 
adopted. To improve the in vivo performance of the system, a further multi-
step chemical functionalization was performed. The drug loading procedure 
was carried out by traditional adsorption technique from an aqueous solution. 
The synthetized ZnO consisted in porous rod particles with an average size 
ranging from 30 to 70 nm. N2 adsorption and desorption analysis revealed an 
incredible high surface area of 305.14 m2/g with homogenously distributed 
pores of 5 nm. A remarkable high drug loading efficiency of 88% was 
observed, with 0.58 mg of Doxorubicin loaded per mg of functionalized ZnO.   
Also Barick and colleagues studied highly mesoporous spherical three 
dimensional ZnO nano-assemblies as potential delivery systems for 
Doxorubicin 74. They investigated a facile soft-chemical approach based on the 
ZnO nanocrystals precipitation from a precursor. The anticancer drug was 
loaded into the materials through traditional adsorption. The morphology of 
the ZnO particles resulted in discrete spherical shaped assemblies ranging from 
100-600 nm composed by connected nanocrystals of 20 nm. The average pore 
diameter was found to be 28 nm, while the BJH surface area and pore volume 
were around 27.5 m2/g and 0.22 cm3/g, respectively. The Doxorubicin loading 
efficiency was about 80%. The investigation highlighted that the release of the 
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drug molecules was strongly dependent on the pH of the release medium, with 
the possibility to obtain a pH-triggered release, which is advantageous in 
treatment of cancerous target site, where the relatively low pH might 
specifically stimulate the doxorubicin release. 
Danourobicin is another chemotherapy agent belonging to the same family 
as that of Doxorubicin. Its delivery from ZnO carrier was investigated by 
Haijun Zhang in its research work 75. ZnO was synthetized by solid state 
reaction at room temperature, while the drug loading was performed by simple 
overnight incubation of a drug solution with the aqueous suspension of ZnO 
nanorods. The encapsulation efficiency and loading efficiency of 
Daunorubicin were about 75% and 20%, respectively. The drug release was 
dependent on the pH of the medium, as in the case of Doxorubicin, with a slow 
and sustained rate (19%) at pH 7.4 and a much faster rate (87%) at pH 5.0.  
A further application of pure ZnO carrier in the antitumoural field was 
provided by the work of Kathun et al 76. In their study, ZnO nanoparticles were 
conjugated with trans-Resveratrol, an anti-proliferative and chemopreventive 
agent, for treatment of ovarian cancers. ZnO nanoparticles of about 5 nm were 
obtained by the co-precipitation technique. Nano-conjugation between 
Resveratrol and ZnO was obtained by incubating the two components together.  
Baskar et al conjugated L-asparaginase with zinc oxide nanoparticles, 
studying the cytotoxic effect on cancer cells 77. The zinc oxide nanoparticles 
conjugated with L-asparaginase was produced by the fungus Aspergillus 
terreus,  which is able to reduce zinc sulphate ions, to form ZnO, thanks to the 
proteins present in the fungal culture filtrate. 
Another remarkable contribution to the research of innovative pure ZnO 
drug carrier derives from the work of Bakrudeen and collaborators. The most 
recent investigation was focused on spheroidal mesoporous auto-fluorescent 
ZnO nanospheres, which are potentially able to target specific sites and to 
deliver drug molecules especially in cancer treatments 78. In this project, zinc 
oxide mesospheres were obtained by a multi-steps procedure, that involves the 
use of organic solvents. The BET specific surface area and the corresponding 
pore volume of the mesoporous ZnO were 16.56 m2/g and 0.0861 cm3/g, 
respectively. The average pore size was about 5 nm. Although any drug 
loading attempts were reported in this research work, the same author, 
Bakrudeen H. Bava, had published in 2013 a previous work, illustrating the 
fabrication of mesoporous ZnO nanospheres for the controlled delivery of 
Captopril, a drug used in the treatment of high blood pressure 63. In this 
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investigation, the ZnO particles were obtained by a soft-template based 
synthesis, using starch as the templating agent. The Captopril loading was 
performed through a traditional incubation method. The porous spherical-
shaped particles presented a diameter in the range of 200–500 nm. Each sphere 
resulted composed by smaller nanoparticles of about 20 nm-35 nm. The 
porosity of the system was confirmed by Nitrogen adsorption analysis, that 
revealed a BET surface area of 15.53 m2/g and a pore volume of 0.118 cm3/g. 
The average pore size was about 10 nm, which was enough to accommodate 
the captopril molecule, in fact the storage capacity was found to about 28%. 
The drug-loaded system showed the in vitro capability to control the release of 
molecules in different fluids over at least 24 h. 
In 2013 Palanikumar and coworkers synthetized different ZnO 
nanoparticles to study their behavior as drug delivery carrier for Amoxicillin, 
an antibiotic molecule with a broad spectrum of bactericidal activity 79. 
Traditional methods were applied for both the synthesis of the particles (low-
temperature approach) and the Amoxicillin loading (incubation from a 
solution). The particle sizes of the as-prepared ZnO were about 38 nm. A 
maximum drug loading of 87% was achieved after 120 minutes of incubation 
under stirring. The release of Amoxicillin was found to be controlled by the 
carrier, and to gradually increase over time. 
 
1.2.2 ZnO-composite drug carriers. 
 
In these last 5 years, a new research branch related to the use of ZnO 
materials as drug delivery systems has attracted increasing attention. It consists 
in the development of drug carriers based on the combination of ZnO and other 
materials, such as polymers, in order to enhance the properties of the overall 
system. For sake of completeness, some examples of these ZnO-based 
composite carriers are reported in this paragraph.  
In this last year much work has been addressed to study composite drug 
delivery systems, that contain ZnO. Zhao and collaborators proposed 
ZnO@polymer core−shell nanoparticles for the delivery of anti-cancerous 
molecules 80. In particular they investigated the loading of Isotreonin. 
ZnO@polymer core−shell nanoparticles were obtained through a multi-steps 
procedure that involve the use of several organic solvents. The particles sizes 
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were found to be equal to 100 nm and presented a drug storage capability of 
about 35 wt%.  
Another recent work took in consideration the development of ZnO-based 
core-shell nanoparticles for the pH-responsive drug delivery of Doxorubicin 
81. In this case, mesoporous ZnO particles were used as core of the system for 
the Doxorubicin storage, while the shell, which was composed by zeolitic 
imidazolate frameworks (ZIFs), was tuned up to prevent premature drug 
release in the physiological environment. Results showed that the obtained 
ZnO nanoparticles presented a diameter of 240 nm, which increased to 270 nm 
after the formation of composites core-shell nanoparticles. Also the specific 
surface area dramatically increased from 34.8 m2/g to 637.4 m2/g after the 
composite formation. As desired, the release of Doxorubicin was pH 
responsive with a higher amount and faster rate at lower pH. 
In their research work, Lin and collaborators fabricated fluorescein 
isothiocyanate (FITC)-loaded zinc oxide nanotubes onto indium tin oxide 
(ITO) -coated polyethylene terephthalate substrate as a smart electrically 
responsive drug release device 82. In this investigation a traditional 
precipitation synthesis of the ZnO nanotubes directly onto the ITO/PET 
substrates was adopted and the FITC molecules were loaded into the material 
by a soaking approach from a solution. This study demonstrated that the in 
vitro controlled drug release under an alternative electrical field of the FITC 
loaded onto the ZnO-based device was possible.  
A similar approach was also investigated by Yang and colleagues, who 
prepared a drug delivery device by electrodeposition of a glucose responsive 
bioinorganic composite onto the nanostructured ZnO on ITO substrate 83. 
Yang’s drug delivery device was thought for the delivery of Insulin and its 
release was triggered by the level of glucose, instead of an electrical field. The 
role of ZnO nanoparticles was to immobilize the glucose responsive 
bioinorganic composite due to their high isoelectric point (IEP ∼ 9.5) and 
biocompatibility. 
In order to address the issue of the poorly-soluble drug administration, a 
novel composite material composed by biocompatible polymers and ZnO 
nanoparticles as a delivery carrier for Curcumin, has been proposed by Dhivya 
and collaborators 65. The ZnO nanoparticles were synthetized through a 
traditional precipitation method. The preparation of the curcumin-loaded 
PMMA-PEG/ZnO bionanocomposite was carried out in free radical 
polymerisation by linking the PMMA-PEG copolymer with the ZnO 
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nanoparticles with the addition of surfactant agents. The average size of the 
bionanocomposite particles was found to be equal to 87 nm. This drug carrier 
was able to load a large amount of curcumin, that could be rapidly released at 
low pH, so increasing the bioavailability of curcumin and enhancing its 
anticancer efficacy.  
Another biocompatible polymer, the poly(lactic-co-glycolic acid) 
(PLGA), was instead proposed in combination with ZnO in the investigation 
of Stankovic 84. She studied PLGA nanocomposite spheres with immobilized 
nano-ZnO to obtain an innovative drug carrier for infectious diseases. ZnO 
nanoparticles were prepared via microwave assisted synthesis method and the 
composite material was produced by physicochemical solvent/nonsolvent 
approaches. Nanostructured ZnO powder resulted composed of uniform, 
spherical particles with an average diameter of approximately 63 nm.  
Moreover, Wei and collaborators also evaluated the possibility to combine 
PLGA and mesoporous ZnO 85. Their innovative idea consisted in creating a 
single carrier for multi-drug delivery in order to overcome the drug resistance 
and maximize the antitumor activity. For this purpose, ZnO/PLGA/gelatin 
electrospun composite fibers were fabricated, which were able to 
simultaneously encapsulate a hydrophilic (doxorubicin hydrochloride) and a 
hydrophobic drug (camptothecin).  Mesoporous ZnO was synthetized by a 
traditional method, and spherical particles of about 300 nm were obtained. The 
BET surface area was calculated to be equal to 84.78 m2/g and the pore size 
was about 6.75 nm. Particularly, the Doxorubicin was loaded into the 
mesoporous ZnO by a traditional method, which consisted in incubating a drug 
solution with the material for 24 hours. The drug loading resulted in around 
9.09 %. The Camptotecin was directly loaded into the polymeric fibers. In this 
way, the release of the two drugs was enabled with distinct rates: Camptotecin 
was released in a rapid rate while Doxorubicin showed a sustained and 
longterm release behavior because of the hindrance of mesoporous ZnO and 
PLGA/gelatin matrixes. 
Maiti and colleagues reported the drug loading and release profiles of a 
multifunctional composite material, which was based on magnetically active 
γ-Fe2O3 nanoparticles and optically active mesoporous ZnO nanoparticles 86. 
Daunorubicin hydrochloride, an anti-cancer drug, was selected as the drug 
model for their study. The composite was characterized by a BET surface area 
and the total pore volume of about 47 m2/g and 0.432 cm3/g, respectively. The 
average pore diameter was equal to 35 nm. The porous structure of ZnO 
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assured a high drug storage. In fact, the drug loading was around 76% after 60 
minutes of exposure of the composite to the drug solution. The larger amount 
of drug was released at pH~5.5, which is the intracellular pH of the cancer cells.  
Qiu and collaborators produced a Fe3O4@ZnO@Gd2O3:Eu multifunction 
composite nanoparticles 87. The role of each component was accurately 
evaluated: in this case upon irradiation the ZnO shells act in absorbing and 
converting microwaves to heat, so triggering the release of the loaded 
Etoposide drug. 
The possibility of combining ZnO and SiO2 is described in the work of 
Vijay B. Kumar 88. This investigation dealt with innovative mesoporous SiO2–
ZnO composite nanocapsules (90–150 nm) for the storage of biomolecules. 
The BET surface area and the pore diameter of the composite resulted in 230 
m2/g and ca. 2–8 nm, respectively. In order to test the loading efficiency of the 
SiO2-ZnO composite nanocapsules three different molecules were loaded into 
the materials: Rhodamine 6G, a fluorescent dye, Doxorubicin and DNA 
molecules.  The study highlighted the functionality of this promising 
mesoporous SiO2–ZnO nanoparticles as drug carrier. 
 
The above reported analysis of the literature, clearly highlights that the 
design of stimuli-responsive controlled drug delivery systems in cancer 
therapy is the most investigated challenge in the field of ZnO-containing 
composite materials, as it was already pointed out in the case of pure ZnO 
carriers.   
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1.3 ZnO nanomaterials for skin applications 
 
1.3.1 Skin structure and skin-particles interaction 
 
The skin is the largest organ of the human body and accomplishes different 
important roles, such as the body protection from external factors 89. Due to its 
high surface area (about 2 m2), the skin is constantly exposed to several 
pathogenic agents, which commonly cause cutaneous infections 90. 
Nevertheless, the skin impermeability to the drugs, which is mainly caused by 
the lipidic nature and cohesive structure of the stratum corneum, is a significant 
limitation in the treatment of these altered dermatological conditions 91. In the 
last years, drug delivery systems for topical administration have been proposed 
as possible solutions to overcome the skin route barrier. Several advantages 
result from the application of drug carriers onto the skin: for instance, they can 
enhance the dermatological formulations, so delivering both hydrophobic and 
hydrophilic drugs and allowing a controlled release for a prolonged time to be 
achieved. 
If the skin is to be considered a possible route of exposure to drug delivery 
systems, some aspects about its structure and composition have to be 
described. Briefly, the skin consists of two main layers: the epidermis and the 
dermis.  
The epidermis is the outermost part and is composed mostly (95%) by 
layers of stratified keratinocytes, which represent the predominant cell type in 
this layer. Keratinocytes undergo a differentiation process, keratinization, 
during which they move upward from the basal layer of the epidermis, stratum 
basale, to the outermost, stratum corneum. Here, the keratinocytes become 
anucleated with a flat shape, corneocytes, and are prevalently surrounded by 
an extracellular lipid matrix, enriched of proteins. The structure of this 
extracellular matrix is usually defined as “brick and mortar” 92,93, where the 
corneocytes represent the brick and the intercellular lipids represent the 
mortar. The epidermis lies on a basement membrane, which separates it from 
the dermis (0.1-0.4 cm).  
The dermis is composed of a network of dense and irregular connective 
tissue (collagen, elastic and reticular fibres) and different cell types, such as 
nerves, blood vessels and lymphatics. Vascular networks are absent in the 
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epidermis, which means that, to achieve a systemic drug delivery, penetrating 
the epidermis and reaching the dermis, is mandatory. In the viable epidermis 
there are also other cells with different roles, such as the melanocytes, which 
are melanin producers, the Merkel cells, which provide the sensory perception 
and the Langerhans cells, which possess an immunological function. In 
addition to the cellular components, there are appendages in the skin which 
include the pilosebaceous units (10–70 μm), such as the hair follicles and 
associated sebaceous glands, and the apocrine and eccrine sweat glands (60–
80 μm)92,94. 
 
Figure 1.6 Schematic representation of normal skin. This image has been taken 
by The web site of the National Cancer Institute (http://www.cancer.gov) 
 
When the diffusion of a molecule across the skin is considered, the stratum 
corneum (SC) represents the main physical barrier. Typically, SC has a 
thickness of about 10-20 µm 93 which depends on the body site, and is in direct 
contact with the outside environment. It is largely responsible for the physical 
barrier function of the skin and regulates the diffusion of water out of the skin. 
As previously described, the SC is a lipophilic medium, that is covered by an 
irregular and discontinuous layer of sebum secreted by the sebaceous glands, 
along with sweat, bacteria and dead skin cells. Obviously, this composition 
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favors the absorption of non-polar molecules through the skin. Moreover, the 
surface of the skin is characterized by the presence of furrows, which provide 
a reservoir for topically applied particles 93and where the large particles can 
also aggregate.   
Transport of substances across the SC occurs mainly by passive diffusion 
may be interrupted by appendages. Three possible routes may occur: i) the 
transcellular, ii) the intercellular and iii) the appendageal route (Figure 1.7). 
 
Figure 1.7 Transport routes of substances across the SC 93 
 
The transcellular pathway is currently considered as unlikely for most 
compounds, due to the repeated partitioning between lipophilic and 
hydrophilic compartments that a molecule should meet, including the almost 
impenetrable corneocytes intracellular matrix 93. The intercellular route is 
generally supported by penetrants, like small molecules, able to move freely 
within the intercellular spaces. In this case diffusion rates depend mostly by 
their lipophilicity, molecular weight or volume, solubility and hydrogen 
bonding ability 92. Despite the free movement of larger molecules or particles 
results to be physically restricted within the lipid matrix of the SC, the diffusion 
through intercellular lipids is more likely to occur for most solutes. The trans-
appendages pathway consists in a promising alternative mechanism to cross 
the SC despite the relative low density of these structures on the skin surface 
(ranging from about 50 follicles/cm2 in the majority of the body sites to about 
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290 follicles/cm2 in the forehead 95). Structural parameters such as the shape, 
the complex vascularization and the deep invagination of hair follicles 
transform them in suitable place for the mechanical accumulation and storage 
of substances. The hair follicles are based in the dermis, where blood and 
lymphatic vessels are located, so representing a possible approach to achieve 
a systemic effect. 
Despite the considerable interest in the use of particles as topical drug 
delivery carriers, there is a significant concern about the toxic consequences of 
their unwanted penetration. When a drug delivery system is administered to 
the skin, several factors affect this interaction (Figure 1.8). 
 
♦ Size. Dimensions are considered the most important parameter governing the 
interaction between a carrier and the skin. Skin penetration and transport route 
are strongly dependent on the size of the particles. Penetration of particles 
through the skin is an open debate and many investigations have been 
addressed on this topic, aiming at obtaining standard conclusions. Important 
rules have been set by the Scientific Committee on Consumer Products (SCCP) 
who concluded that only very small particles (<10 nm) could penetrate the skin 
and that there is no evidence for skin penetration into viable tissue for particles 
>20 nm, even if they can penetrate deeply into viable tissues 92. The same 
assumptions were drawn by Liang and coworkers, who brilliantly summarized 
the size effect on skin penetration. What emerges from their work is that only 
very small particles (4-6 nm), as Quantum Dots and TiO2 nanoparticles, 
penetrated in the deeper layer of epidermis after skin administration. Most of 
the evaluated cases showed no penetration into viable epidermis, reaching only 
the superficial layers of SC, due to aggregation phenomena on the skin surface 
or penetration into the hair follicles 93. Nevertheless, as suggested by Roberts 
and colleagues in their remarkable work, it is important to carefully consider 
the experimental conditions under which the skin penetration experiments 
were performed 96. A significative example has been given by Roberts, who 
compared the penetration of gold base nanoparticles through the skin of 
different species. For instance, rat and pig skin was more permeable than 
human skin due to different thickness and permeability.  
  





Figure 1.8 Schematic representation of the drug carriers properties affecting the 
interaction with skin. The image has been taken from 96. 
 
 
♦ Shape. Different morphologies can also affect the interaction between 
carrier and skin. A cornerstone example is represented by the flexible 
nanovesicles, which are particles able to deform in shape thanks to their 
structural composition 96,97. Briefly, these vesicles can elongate their starting 
spherical shape and squeeze through narrow channels. The enhanced skin 
penetration ability of the flexible vesicles, can be exploited to improve the 
permeation of many compounds. Another aspect related to the shape of the 
particles is the toxicity associated with some morphology. For instance it has 
been recently reported that a rod shape could involve more toxicity issues than 
other morphologies 30. 
 
♦ Surface properties. The surface charge can influence the carrier penetration, 
but its role is still unclear 98. However, since the skin is negatively charged on 
its surface under physiological conditions, consequently an enhanced 
electrostatic interaction with positively charged particles has been reported 93. 
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Another crucial aspect to be considered, it is that the skin is generally used 
as a route of administration for both local and systemic drugs. The former case 
is defined “topical administration” and consists in the administration of a drug 
to a particular spot on the outer surface of the body; the latter is defined 
“transdermal administration” and involves the administration through the 
dermal layer of the skin to the systemic circulation by diffusion. These 
definitions are given accordingly to the Food and Drug Administration 
monographs. 
As in other fields, drug delivery systems have reached significant 
improvements in the topical and transdermal administration of compounds 99. 
For instance, the use of skin drug carriers can reduce systemic side effects, 
being it an alternative to the oral route, and can allow a controlled or prolonged 
drug delivery to be achieved. On one hand, a topical formulation can be 
improved by the addition of a drug delivery system for innovative treatment of 
skin disorders, such as infective conditions (i.e. acne) so enhancing the drug 
penetration through the skin layers, where its effect is expected. On the other 
hand, transdermal formulations can help the drug permeation through the skin 
and enter the systemic circulation. 
 
Among the two above reported routes of skin administration, the 
possibility to enhance the local delivery of a drug through innovative drug 
delivery systems has been the driven force of this PhD thesis project. The next 
section deals with the state of the art related to the current studies of ZnO 
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1.3.2. ZnO nanomaterials and skin: the state-of-the-art 
 
For millennia Zinc oxide has been used in skin care applications, due to its 
intrinsic properties, such as its non-toxicity, biocompatibility and antimicrobial 
activity. The oldest reference about the use of this material could be dated back 
to 500 BC, when a ZnO-based healing salve, called Pushpanjan, was indicated 
in an Indian Medical Text for the treatment of the eyes and open wounds. 
Nowadays, ZnO is generally used to address several skin conditions, like 
burns, scars and irritations. ZnO is able to act as soothing and protecting agent, 
so creating a protective barrier on the skin. Thanks to this property, a ZnO is 
traditionally used as the main component of many baby-care products, such as 
powders and pastes, to treat diaper rash. In this case a ZnO film reduces the 
effects of bacteria and other irritants, which are present in urine and 
excrements, so protecting the delicate baby skin. Other popular uses of ZnO 
include its application as an active ingredient in anti-dandruff shampoos and 
in antiseptic ointments, due to its antibacterial properties. It is also used in 
rectal haemorrhoid creams to relieve itchiness and protect irritated tissues. 
Moreover, there is a growing attention on the topical use of ZnO to prevent 
acne through sebum reduction and anti-inflammatory action. 
As a result of the wide spread of nanotechnology, also cosmetics and 
pharmaceuticals have been revolutionised. Nanomaterials play a key role in 
the cosmetic and dermatological fields due to their nanometric size and 
potential applications. Among all the materials, also ZnO has been developed 
in different nanostructures to enhance its interaction with the skin and to 
improve the existing products. A careful analysis of the literature has been 
carried out aiming at determining the main studied roles of nanosized ZnO in 
topical application. Table 1.1 summarizes these findings.   
 
ZnO as a drug carrier for the skin 
 
Going through the literature, it has emerged that few research works have 
been dedicated to the evaluation of ZnO as a material for drug delivery to the 
skin. During the International Conference and Exhibition on Nanomedicine 
and Drug Delivery (May 29-31, 2017 Osaka, Japan) Markus and colleagues 
presented a poster focused on the development of a drug carrier for topical 
delivery composed by ZnO nanocomposites functionalized by hyaluronic acid 
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or carboxymethyl chitosan. The resulting flower-shaped nanocomposites were 
further loaded with a vegetal extract and functionalized with ginsenoside Rh2. 
The properties of the drug delivery system were deeply characterized, which 
resulted a promising carrier for the topical delivery of active substances to treat 
skin disorders and prevent skin cancer 100. 
The study of Huang and collaborators is a unique example of the use of 
ZnO nanoparticles as drug carrier on the skin 101. They developed a UV and 
dark-triggered drug delivery system for skin protection, that was based on ZnO 
nanoparticles as carrier for benzophenone-3, a UV-absorption molecule. The  
ZnO particles sizes were found to be 30-40 nm and were assembled into larger 
aggregates ranging from 500 to 1400 nm. The encapsulation efficiency and 
loading capacity of benzophenone-3 were about 53.68% and 133.61%. The 
benzophenone-3 was released almost completely released from the carrier, 
under 2 hours of UV. The drug loaded system reported low cytotoxicity to 
human keratinocyte cells and human skin fibroblasts. 
Nayak and collaborators developed ZnO nanorods for non-destructive 
drug delivery, to enhance the penetration of Albumin-Fluorescein 
isothiocyanate (FITC) across the skin. ZnO nanorods (lengths of 30–35 µm 
and diameters of of 200–300 nm) successfully facilitated FITC penetration 
through the skin along the channels formed by the nanorods. This work is a 
clear example of non-invasive and painless intradermal drug delivery achieved 
through the use of ZnO nanorods 12. 
 
ZnO as antibacterial additive in skin formulations 
 
Recently Sonia and colleagues proposed colloidal ZnO nanoparticles, 
which were obtained through an eco-friendly synthesis, as innovative additives 
for a cosmeceutical formulation. The nanocosmeceutical formulation was 
tested against clinical skin pathogens and significant inhibitory action was 
observed against Candida sp., which showed resistance against a commercial 
antifungal cream (2%) 102. Also, Raij and collaborators investigated the topical 
anti-infective properties of ZnO nanoparticles against Propionibacterium 
acnes, a gram positive bacillus normally present on human skin and that causes 
acne. The antibacterial effects of ZnO nanoparticles were tested as-such and 
after incorporation into cold cream. Results showed an effective and promising 
role of ZnO for topical applications in treating acne vulgaris 54. 
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Wiegand and coworkers investigated the role of ZnO as a smart additive 
to functionalize textile fibers, in order to improve the control of oxidative stress 
in atopic dermatitis, which is a chronic inflammatory disease characterized by 
the impairment of the skin-barrier function, the increase in the oxidative 
cellular stress and bacterial colonization 103. The antibacterial effect and 
biocompatibility of the Zn textile was evaluated in vitro, so demonstrating that 
the ZnO textiles possess very good biocompatibility and were well tolerated 
by the patients. 
The successful role of ZnO nanoparticles as a topical anti-infective agent 
was confirmed by Patil and colleagues in their research work. They showed 
that the administration of ZnO significantly reduced the skin infection caused 
by S. aureus. in mice; this resulted in improved skin structure, with a reduced 
bacterial load and a reduced tissues inflammation 50.  
 
ZnO in wound dressings 
 
As far as the applications of ZnO nanomaterials on the skin are concerned, 
a nascent application that is worth mention, consists in the addition of ZnO in 
wound dressing. A wound is defined as a disruption in the continuity of the 
epithelial lining of the skin or mucosa resulting from physical or thermal 
damage 104,105. A wound is generally classified as acute or chronic depending 
on the duration. An acute skin injury commonly heals at a predictable and fixed 
time (8-12 weeks), which depends on the extent of the damage in the epidermis 
and dermis layers of the skin. For instance, acute wounds can occur due to an 
accident or surgical injury. On the contrary, a chronic wound is an injury that 
fails to progress through the normal stages of healing and cannot be repaired 
in a prefixed time. Examples of chronic wounds are ulcers and burns. Wound 
healing is a dynamic and complex process of tissue regeneration and growth 
progress which is traditionally divided in different phases i) inflammation, ii) 
proliferation, and ii) remodeling 106. 
Nowadays, much research works have been focused on the development 
of innovative wound dressings, which are able to interact with the wounded 
skin, promoting its healing. A suitable material for wound dressing application 
should possess antimicrobial properties, should be biodegradable, 
biocompatible, non-toxic and non-allergenic. Moreover, an ideal wound 
dressing should also be able to preserve a moist environment at the wound 
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surface, to permit gaseous exchange, to defend the wound against 
microorganisms, to absorb the excess of exudates avoiding maceration and to 
reduce scar formation. Among the different types of wound dressing materials, 
synthetic and natural polymers, such as polyurethane, poly(vinyl alcohol), 
poly(lactic acid) and alginate, chitin, chitosan and collagen are the most 
investigated 32. During the wound healing process, the possible insurgence of 
infections represents one of the major issue, because of the negative 
consequences, such as exudate formation, improper collagen deposition and 
prolonged healing time. Furthermore, microorganisms can reach the deeper 
tissues through the wounded skin, causing internal infections. For instance,  S. 
aureus and E. coli have been listed among the major infection-causing 
bacteria 32,107. Moreover, it is worth to note that also wound dressing as such 
can cause an infection, if the material is not be able to absorb wound exudate 
or guarantee sterility.  To overcome these issues, the need of innovative wound 
dressings is compelling. 
In Material Science, bionanocomposites represent an emerging group of 
advanced materials that resulting from the combination of biopolymers with 
inorganic component 108. Particularly, the addition of ZnO nanostructures in 
the polymeric matrix has been investigated in order to impart novel 
functionality, such as antibacterial activity 6. Moreover, it has been 
demonstrated that topically applied ZnO act as a source of Zinc ions and this 
would improve, improving wound healing 109,110. In fact, zinc is an essential 
trace element in the human body. Among its functions, it acts as a cofactor in 
zinc-dependent matrix metalloproteinases that augment auto debridement and 
keratinocyte migration during wound repair. Zinc confers cytoprotection 
against reactive oxygen species and bacterial toxins. Zinc deficiency can lead 
to pathological conditions and delayed wound healing.  
Recently, many research works have been dedicated to the study of ZnO 
nanomaterials as inorganic fillers for bionanocomposite wound dressings. 
Several biocompatible materials have been studied; among all chitin and its 
derivatives are of particular interest for their capability of accelerating the 
healing processes. Going through the literature, it is evident that the 
combination of ZnO nanomaterials and chitosan represents one of the most 
promising solution in the field of innovative wound dressings 26,107,111–115. 
Furthermore, a wide range of polymeric matrices have also been evaluated, 
such as carboxymethyl cellulose hydrogels 116, poly (vinyl alcohol)117–119, 
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chitosan-gelatin 120, collagen and dextran hydrogels 121, cross linked sodium 
alginate-gum acacia hydrogels 122. 
 
ZnO as Skin penetration enhancer  
 
The role of ZnO as a skin penetration enhancer has also been studied. This 
application consists in the simultaneous skin administration of ZnO with 
another compound (i.e. drug) and not in its direct use as a drug carrier.  Shokri 
N. has been one of the pioneering scientist in this field. He dedicated 
significant research works to the study of ZnO as a skin enhancer in topical 
formulations. In 2014, ZnO and ZnO nanoparticles were compared as 
absorption enhancers for Ibuprofen, so demonstrating that both compounds 
could act as enhancers for transdermal delivery of Ibuprofen, with a higher 
efficiency for the ZnO nanoparticles 123. In the same year, Shokri and 
coworkers also investigated the enhanced skin permeation of solvents and 
surfactants due to the co-utilization of ZnO nanoparticles in topical products. 
ZnO resulted able to increase the permeation of  hydrophobic, oily and 
hydrophilic solvents and surfactants, which indicated a potential role in the co-
enhancement of drug absorption 124. The aim of the research work that was 
published two years ago by the same authors consisted in the evaluation of the 
skin permeation of albumin when co-administered with ZnO nanoparticles in 
comparison with Calcium Phosphate. In their work, the nanoparticles were not 
used as drug carriers, but were simultaneously administered separetely with 
the Albumin, but separated from it. Their enhancer effect depended on their 
position and stay in the skin layers, which helped the drug to cross the skin. 
Results showed that the enhancer effect of Calcium Phosphate nanoparticles 
was weaker than that of ZnO, because of the different skin distribution and 
solubility of the particles 125. 
 
ZnO as UV- Blocker in sun-screen formulations 
 
Doubtless, the most popular use of ZnO on skin applications is its addition 
in sunscreen products as a UV-blocker agent 53. In fact, ZnO is a broad 
spectrum UVA and UVB reflector, completely photo-stable. Due to its ability 
in blocking UVA (320–400 nm) and UVB (280–320 nm) rays of ultraviolet 
illumination it is often used as associate degree ingredient in sunscreen 
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products. Due to the frequent use of ZnO in commercial sunscreen 
formulations, many research works have been addressed to the study of the 
human epidermal skin penetration of ZnO and its zinc ion dissolution products, 
after the application of ZnO nanoparticles to human epidermis 53,126–131. 
Moreover, it is worthy of note that the European Commission has added ZnO, 
in both its nano and non-nano forms, to Annex VI of the EU Cosmetics 
Regulation only in 2016, thus allowing its use as a UV filter in cosmetic 
products. Different is the case of USA, where the Food and Drug 
Administration approved the use of nanoparticles in sunscreens in 1999. 
Nanosized ZnO particles are generally preferred by consumers because of the 
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Toxicity of ZnO on the skin 
 
Due to the active role of ZnO particles in many dermatological 
applications and its large use in sunscreen products, in this last decade an 
increasingly attention has been focused on whether the nanoparticles could 
penetrate the skin barrier and access the viable epidermis 53. Notwithstanding 
the prompted concern about this issue,”it is commonly accepted that passive 
penetration of ZnO nanoparticles into intact human skin is limited to the 
surface and upper layers of the stratum corneum” 96.  Many research works 
support this affirmation and a huge mole of investigations have been addressed 
to this purpose 55,130,134–136. Moreover, also ZnO and TiO2 nanoparticles 
penetration through UVB-damaged skin was investigated, observing only a 
slightly enhancement of the penetration; however transdermal absorption was 
not detected 131. 
Also the penetration of Zinc Ions released from topically applied ZnO has 
been deeply studied. One of the most interesting and recent work concerning 
this topic, is represented by the investigation of Holmes and colleagues. In 
order to figure out the level of penetration of ZnO particles in the skin and their 
toxicity, Holmes investigated different ZnO nanoparticle formulations 
commonly used in commercially available sunscreen products. Results showed 
that the ZnO in the formulations did not penetrate into the intact viable 
epidermis,  but displayed an enhanced increase of zinc ions in both the stratum 
corneum and the viable epidermis 137. 
 
Figure 1.9 Schematic representation of the postulated fate of the zinc ions 
absorbed by the skin after ZnO hydrolysis 137. 
   
The penetration of Zn through human skin after the application of 
sunscreens containing ZnO, was also reported in other investigations 138,139. 
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The proposed mechanism would be based on the hydrolysis of ZnO on the skin 
surface, due to its acidic pH, which is followed by Zn2+ ions penetration. 
On one hand safety of the topical applied ZnO nanoparticles results well-
established in the literature. On the other hand, some research works suggested 
a sort of toxicity of ZnO nanoparticles, due to their internalization by cultured 
human keratinocytes, which caused cytotoxic and genotoxic responses 140. 
Also Kokbec and colleagues reported the in vitro toxicity of ZnO and TiO2 
nanoparticles on keratinocytes over short- and long-term applications. They 
mainly demonstrated intracellular formation of radicals and alterations in cell 
morphology 141.  
Notwithstanding these isolated research works, carried out between the 2010 
and 2011, the investigation of Ryu and colleagues in 2014 assessed no 
evidence of toxicity after a 90-day repeated dermal application of ZnO in rats 
129. Moreover, the same conclusion was drawn by Virnardell and colleague, 
who dedicated their efforts in the study of nanosized ZnO potential cause of 
acute cutaneous irritation. In their investigation cultured HaCaT keratinocytes 
and a human skin equivalent were used, both with nano- and non-nano sized 
materials. In conclusion, they observed a non-irritation condition of the skin 
with both the nanosized ZnO and non-nano ZnO 142.  
 
1.4 Conclusions  
 
This chapter dealt with a general overview of the ZnO properties and 
applications in the biomedical field, offering a detailed description of the 
current state-of-art related to the use of ZnO nanostructures as drug delivery 
system. Particular attention was focused on the existing studies of NsZnO on 
skin applications. 
In conclusion, it emerged that despite of the growing attention focused on ZnO 
nanostructures (NsZnO), the study of NsZnO as drug delivery system is still in 
its nascent stage, particularly considering the administration to the skin. In 
order to fill this gap, this PhD thesis has been dedicated to the study of 
nanostructured ZnO as material to develop innovative drug carriers for future 
dermatological applications. 
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 Chapter 2  
Drug delivery goes supercritical 
Part of the information reported in this chapter has been previously 




Nowadays the huge consumption of organic solvents by the 
pharmaceutical industries is becoming a well-known issue 2 and each year a 
high amount of waste is produced 3. Two main issues derive from the use of 
organic solvents in pharmaceutical technologies: (i) the toxicity of residual 
solvents in the final products and (ii) the environmental impact 3. Therefore, in 
the last years even Life Cycle Assessment, which has been traditionally 
reserved to large scale continuous chemical and petrolchemical processes, has 
started to be applied to small scale batch pharmaceutical processes 4. 
The synthesis of Active Pharmaceutical Ingredients (APIs) is commonly 
considered the main step in which organic solvents are employed. 
Nevertheless, other sources of organic solvent wastes occur in the production 
of drug delivery systems, such as the synthesis of the carrier and the API 
loading 5. Green and sustainable chemical processes are then highly desired to 
develop organic-solvent-free production of drug-delivery devices.  
52 Chapter 2 
 
In the last decade, supercritical fluid technology has been emerging as an 
alternative to conventional drug loading techniques, such as the adsorption or 
impregnation from an organic solvent solution 6. Supercritical carbon dioxide 
(scCO2) is the most used supercritical solvent because of its unique chemical 
and physical properties. 
Since in this PhD research project, the scCO2 technology has been studied 
as an innovative approach to perform the drug impregnation of ZnO 
nanostructures, this chapter aims at highlighting the fundamental properties of 
the scCO2 in order to understand the mechanism at the basis of the scCO2-
mediated drug impregnation. 
2.2 Supercritical carbon dioxide: generalities and 
properties 
 
Supercritical fluids are defined as substances the pressure and 
temperature of which are raised above their critical values 7. Once above this 
critical point, they exist as a single phase with unique properties such as 
liquid-like densities and, hence, solvating characteristics that are similar to 
those of liquids, yet with mass transfer properties similar to gases.  
ScCO2 is the most commonly used supercritical fluid in drug delivery 
applications for a number of reasons. CO2 is an odorless, colorless, highly pure, 
safe, cost effective, nontoxic, nonflammable and recyclable gas with a 
relatively low critical point (Tc = 31°C; Pc = 74 bar). Above the critical point, 
CO2 is considered to be in its supercritical state. In Figure 2.1 the different 
phases of carbon dioxide are plotted in a pressure–temperature phase diagram.  
CO2 can exist under solid, liquid or gaseous phases and any modification of 
state can occur by changing pressure and temperature. Following the liquid–
gas phase boundary, if the pressure and temperature are increased, the density 
of the liquid phase is reduced and the density of the vapor is rised. At a point 
named the “critical point”, the two densities become equal and the liquid and 
vapor phases combine into a single phase.  
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Figure 2.1 Phase diagram of carbon dioxide7. 
 
 
As all supercritical fluids, scCO2 has physical properties (density, diffusivity, 
viscosity) in between those of a gas and a liquid; in particular, it has a liquid-
like solvent power and gas-like diffusivity 8. The density of scCO2 is close to 
that at its liquid state, which is in between 0.2 and 1.5 g/cm3, and its transport 
properties are close to those at its gas state 9. ScCO2 is generally considered as 
a “tunable” solvent. In fact, at pressures and temperatures not too far from its 
critical point, it has a high compressibility; therefore its density and hence its 
solvent power are easily adjustable over a wide range with a minimal change 
in temperature or pressure. For instance, at temperatures in the range from 25 
to 60 °C, the density evolves largely with a slight change of pressure 9. 
For the above-cited reasons, CO2 can then be considered an ideal substitute for 
many organic solvents thanks to its tunable solvent power and also because it 
simplifies the problem of solvent residues since it is gaseous at ambient 
conditions 10. 
 
Advantages and drawbacks 
 
On one hand, scCO2 offers remarkable advantages, such as its being readily 
available, cheap, non-flammable and non-toxic. Moreover, it is considered a 
green and highly versatile technology, that can potentially be used for the 
production of consumables, such as pharmaceutical and food products, as well 
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as for numerous processes, such as extractions, nanoparticle production and 
modification and polymer processing 6,11. 
The scCO2 technology offers advantageous operating conditions, such as rapid 
one step processing and moderate operating temperature, which is useful in 
case of thermo-sensitive materials. At the end of the supercritical technology 
process, no residual organic solvent is present, compared to the conventional 
techniques.  
On the other hand, the scCO2 presents some drawbacks, related to its 
physicochemical properties and to the required experimental set up. For 
instance, one of the most limiting factor is represented by the scarce ability of 
scCO2 in dissolving polar and ionic species, because it is a linear molecule with 
no net dipole moment. Consequently, it is not applicable for processing of all 
compounds 6,9. However, the addition of a cosolvent can increase the polarity 
of CO2 , so overcoming this drawback. For this purpose, ethanol is one of the 
most used cosolvents 9.  
Furthermore, the elevated pressure required and high maintenance costs can 
represent a limitation in the use of the scCO2 technology 
6.  
 
Applications of the scCO2 technology 
 
Traditional applications of scCO2 include extraction, drying and cleaning 
12.  Currently, the large-scale extraction through scCO2 is widely used in the 
food industry for the decaffeination of coffee or extraction of hops. Briefly, the 
material to be extracted is placed in a high pressure vessel, where temperature 
and pressure are regulated above the critical point. The circulating scCO2 can 
extract the desired compounds from the solid material, which are collected in 
another vessel, where they can be separated from the gas CO2 by reducing the 
pressure. Furthermore, scCO2 is also used in drying and cleaning from organic 
residuals. Due to the zero surface tension of scCO2, it can reach the valley of 
the narrow gaps of the material to be cleaned, and completely remove the 
organic residuals by dissolving them 13. The scCO2 technology is also widely 
used in the materials processing 12,14. For instance, it can be used in the 
micronization of powder materials (i.e. drugs) 15, processing of 3D aerogels 16 
and coatings 17,18, and exfoliation and intercalation of layered materials 12. As 
far as the applications of scCO2 technology in the pharmaceutical field are 
concerned, it plays a key role in a wide range of production and processing 
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processes. Particularly, scCO2 has been investigated in the design of 
micro/nanosized drug delivery systems, in the development of many 
techniques to achieved the enhancement of drug solubilization and as an 
innovative method to perform the drug impregnation of different materials 8,19. 
The mechanism at the basis of the scCO2-mediated drug impregnation is 
discussed in the following paragraph. 
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2.3 Drug impregnation through supercritical Carbon 
Dioxide 
 
In the pharmaceutical field, scCO2 finds application in many processes, 
among which the most investigated are the drug micronization and particle 
formation and the incorporation of drug in matrices. In particular, the scCO2 - 
based technology can represent an alternative and innovative method to load 
an Active Pharmaceutical Ingredient (API) into a support, in order to obtain a 
drug delivery system 
The impregnation process is generally considered as a batch process. 
Figure 2.2 reports a schematic representation of a possible experimental 
apparatus required to perform the drug impregnation through scCO2.  
  
Figure 2.2 Schematic representation of the experimental apparatus in which the 
scCO2 – mediated drug impregnation can be performed 20. 
 
Traditionally, the experimental set-up consists in a vessel, in which the 
API and the material are simultaneously placed. The temperature is controlled 
and the CO2 is pumped into the vessel until the desired pressure is reached. 
The impregnation can be carried on in static or stirring mode. The basic 
mechanism of scCO2-mediated drug impregnation process is based on the 
density and diffusivity properties of scCO2. In fact, thanks to their 
combination, it is possible to achieve the impregnation of a material with a 
solute (i.e. the drug), when placed in the same vessel and subjected to scCO2. 
In particular, due to its high density, scCO2 possesses a good solvent power, 
which allows the solubilization of several compounds to be achieved. 
Moreover, the high diffusivity of the scCO2 results in a high diffusion rate of 
the supercritical solution into any support placed in the vessel. 
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Briefly, the impregnation process involves three components, the CO2 as 
the solvent, the API and the material, and can be summarized in three different 
phases 9, as schematically represented in Figure 2.3: 
1. The dissolution of the solute into scCO2; 
2. The contact between the [CO2 + solute] solution and the material; 
3. The depressurization stage.  
 
Figure 2.3 Schematic representation of the three steps of the scCO2 mediated drug 
loading process. Adapted from 9 
 
 
When the scCO2 is selected as the solvent to perform the loading of a drug into 
a material, it is fundamental to consider some crucial aspects. Since CO2 is a 
not- polar molecule 11, scCO2 represents a good solvent for nonpolar and low 
molecular weight solutes, while a poor one for the hydrophilic, polar molecules 
or compounds that have a high molecular weight 21. After the drug 
solubilization in scCO2, the loading of the drug into the material begins, 
through the diffusion of the solution into the material matrix. The dissolution 
of the API (Fig. 2.3, phase 1) and the impregnation of the matrix (Fig. 2.3, 
phase 1) are performed simultaneously, at the same conditions of temperature 
and pressure. At the end of the process, the system is depressurized and the 
CO2 return gaseous. At the end of the scCO2-mediated impregnation process, 
the drug-loaded material is recovered. It is worth noticing that the obtained 
drug loaded material results free of any solvent, so being it a ready-to-use drug 
delivery system, that does not require any other purification process. 
The API-material interaction after the scCO2 impregnation can be 
classified into two opposite types. The former consists in a simple deposition 
mechanism, that is caused by the scarce interaction between the API and the 
material. It can also lead to crystallization of the API phenomena. The latter is 
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based on a stronger affinity between the API and the material, which occurs 
through Van der Waals or H-bonding interactions and can lead to high drug 
loading 9,22. 
The scCO2-mediated drug impregnation is regulated by both 
thermodynamic and kinetic parameters. Among the most influencing 
thermodynamic properties, temperature and pressure play a key role in the 
loading of an API into a material by mean of scCO2 
23. Particularly, it has been 
demonstrated that temperature and pressure can increase, decrease or not affect 
the drug loading, which depends on the API and material that are being 
considered 9. Nevertheless, the analysis of the literature suggests that 
increasing the temperature in isobaric condition is a good strategy to enhance 
the drug loading 24–27. Similarly, the increase of the pressure was observed to 
improve the drug loading in isothermal conditions through the increase of the 
solubility of the drug in CO2 and the CO2 sorption in the material 
26,28–30. Other 
parameters such as contact time and diffusivity have also to be taken into 
account 9. For instance, it has been demonstrated that the scCO2 can improve 
the diffusion of the drug into a polymer matrix through the “molecular 
lubricant” effect. The facilitation of the drug diffusion into the matrix, results 
in a possible enhancement of the impregnation process, with respect to 
traditional soaking techniques.  
 
Advantages of the scCO2 drug impregnation compared to 
conventional drug loading techniques  
 
As far as the advantages of the scCO2-mediated drug impregnation are 
concerned, interesting observations can be drawn in comparison it with the 
other drug loading techniques, i.e. the adsorption from solution. Going through 
the literature, the adsorption from solution method results to be the most used 
drug impregnation strategy. This method consists in incubating the carrier with 
a concentrated drug solution 31. Briefly, the drug is dissolved in a suitable 
solvent and the material is then dispersed in this solution. The adsorption from 
solution method can last several hours, during which the drug molecules are 
absorbed into the inner structure of the material. At the end of the process, the 
impregnated material requires several separation and purification steps to be 
recovered from the not-entrapped drug solution. These stages normally consist 
in several centrifugation processes, during which the drug-loaded carrier has 
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to be repeatedly washed with fresh solvent, followed by a filtration and drying 
phase to remove the remaining solvent.  
On one hand, the adsorption from solution method results easy-to-perform, 
reproducible and does not require any particular experimental set up. 
Furthermore, it is usually performed at room temperature, which is suitable for 
the loading of thermo-sensitive molecules. On the other hand, several 
drawbacks emerge from the applications of this approach. First, relatively high 
concentrations of drug in the initial solution are needed to achieve high loading 
percentages into the carrier. Second, the repeated purification and separation 
steps result to be time-consuming, and lead to high amounts of wasted drug in 
the filtration/centrifugation process.  In addition, the most challenging issue 
results to be the huge amount of solvent that is required to perform the 
adsorption from solution method. This is particularly alarming if we consider 
the high number of existing poorly-water soluble drugs, which require to be 
dissolved in organic solvents 32. As mentioned above, the use of organic 
solvents in pharmaceutical technologies leads to both health issues, which are 
related to the toxicity of residual solvents in the final products, and of course 
to a negative environmental impact.   
The scCO2 technology can be an innovative alternative to overcome all 
these disadvantages: 
- it is considered a green drug impregnation method; scCO2 is readily 
available, cheap, non-flammable and recyclable. All these properties 
make the scCO2 technology an environment-friendly approach. 
Moreover, scCO2 is not-toxic, thus it is particularly suitable for the 
processing of pharmaceuticals products, such as innovative drug 
delivery system, without any health issue; 
- scCO2 possesses a not polar profile, so resulting a good solvent for 
poorly-water soluble drugs. This represents an outstanding advantage, 
because of the possibility to completely replace the use of organic 
solvents in the processing of these not polar molecules; 
- at the end of the scCO2 - mediated drug impregnation a ready-to-use 
drug loaded material is obtained that does not require any purification 
process and is free from any organic solvents. This allows the operator 
to save time and avoid producing huge amounts of waste solvents;  
- scCO2 - mediated drug impregnation offers the possibility to tailor the 
operating parameters, such as temperature, pressure and time, on the 
basis of the selected API 9. This permits a better API-material 
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interaction to be obtained, with the API in amorphous state, which 
improves its dissolution profile and, consequently, its bioavailability. 
 
Notwithstanding the above reported remarkable advantages, some drawbacks 
in the use of this innovative technology could emerge. As aforementioned, for 
instance, one of the most limiting factor is represented by the scarce ability of 
scCO2 to dissolve polar and ionic species, since it is a linear molecule with no 
net dipole moment. Nevertheless, this limit can be overcome using a cosolvent, 
such as the ethanol, to increase the polarity of CO2 
6,9. Furthermore, the 
elevated pressure required and the high maintenance cost can represent a 
limitation in the use of scCO2 technology 
6.  
 
2.4 ZnO and scCO2-assisted drug impregnation 
 
Due to its unique features, drug incorporation through scCO2 was proposed 
in different research areas, which involve several materials. The drug loading 
of polymers by scCO2 assisted impregnation was widely reviewed 
9. 
Furthermore the use of the scCO2 processing has been investigated in the 
preparation of drug-cyclodextrin inclusion complexes 33,34. A few works can 
also be found in the field of porous materials, such as the inclusion of active 
pharmaceutical ingredients in ordered mesoporous silica by scCO2 
impregnation 35–38. Nevertheless, from a careful analysis of the literature, it has 
emerged that any research work was focused on the use of the scCO2 
technology to load APIs into ZnO based drug delivery systems, despite the 
growing importance of this material in this field.  
As aforementioned, this PhD thesis aimed at studying nanostructured ZnO 
(NsZnO) to develop innovative drug carriers for future dermatological 
applications. In this framework, the scCO2 technology was selected as an 
innovative approach to perform the drug impregnation into NsZnO. To the best 
of our knowledge, the scientific investigation described in this thesis represents 
the first study about the loading of drugs on NsZnO by means of scCO2 
1. In 
fact, even though a few research works report the combination of scCO2 and 
ZnO-based materials, this involves applications that are different from the API 
loading into delivery systems. For instance, supercritical CO2-assisted 
deposition processes 39–43 and synthesis processes are among the most 
investigated scCO2 applications that involve ZnO 
44–50. 
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2.4.1 Models drugs  
The aim of this section is to offer a general overview about the two model 
drugs used in this PhD thesis. The drug properties as well as previous 




Clotrimazole (CTZ) is a broad-spectrum antimycotic drug that is in 
widespread use for the treatment of Candida albicans and other fungal 
infections 51.   
 
 
Figure 2.4 Clotrimazole chemical structure (1-[(2-chlorophenyl) 
diphenylmethyl]-1H-imidazole). Molecular formula: C22H17ClN2. Molecular weight: 
344,8 g/mol 52 
 
It possesses a peculiar chemical structure (Figure. 1), since it contains four 
aromatic rings bonded to a tetrahedral (sp3 hybridized) carbon atom, causing a 
highly steric encumbrance on this atom. One of the aromatic groups is an 
imidazole ring, principally involved in many biological reactions. CTZ is a 
typical choice for the treatment of several skin infections caused by fungi, such 
as tinea pedis, that is well known as athlete’s foot condition. Doubtless, the 
most known use of CTZ is in the topical treatment of vulvovaginal and 
oropharyngeal candidiasis, mainly caused by Candida albicans. In Europe 
CTZ is available in topical cream and pessary formulations, under a variety of 
trade names. For the treatment of fungal skin infections, CTZ is usually 
formulated as a 1% cream, lotion, spray or solution. When addressed to the 
vaginal area, the CTZ concentration can increase up to 2 or 10% 51. According 
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to its traditional use in conventional topical formulations, CTZ was chosen for 
future skin administration within this PhD project as a good model drug to be 
loaded into the NsZnO. 
In the last decade, the use of CTZ in the pharmaceutical field has become 
increasingly important, due to its broad range of antimycotic activity. For this 
reason, the development of new approaches to formulate and deliver CTZ is 
playing a key role 51. Despite different studies of innovative greener 
approaches to load many API molecules into a wide amount of carriers have 
been reported 5, scarce research has been focused on new organic-solvent-free 
routes for the loading of CTZ. Since the most significant limitation in the CTZ 
utilization is represented by its low water solubility (29.84 mg/mL)52, CTZ is 
often used in association with a wide range of organic solvents, which are 
generally employed during the drug loading step of pharmaceutical delivery 
systems. It is worth noting and somehow alarming that dangerous solvents, 
such as methanol 53 and chloroform 54,55, are still considered in the CTZ loading 
step for the development of new delivery systems. According to the “ICH 
guideline Q3C (R6) on impurities: guideline for residual solvents”, which has 
been emended by the European Medicines Agency 56, both chloroform and 
methanol are solvents that should be limited in the pharmaceutical products 
because of their inherent toxicity (class 2 of this classification). Moreover, 
methanol has also been classified as one of the top four solvents used in the 
pharmaceutical sector with a dangerous impact on the environment and on 
health 3. 
 For all the mentioned above reasons, CTZ represents a good drug 
candidate for the scCO2 assisted impregnation. Previous studies of Gignone 
and colleagues 38,57 reported its incorporation by means of scCO2 into ordered 
mesoporous silica, and focused their research on the effect of the process 
conditions, such as time and pressure, on the incorporated amount. To the best 
of our knowledge no other examples of incorporation of CTZ into a porous 
solid matrix through scCO2 is available in the literature. 
  




Ibuprofen (IBU) is one of the most commonly used and most frequently 
prescribed not steroidal anti-inflammatory drug (NSAID) due to its prominent 
analgesic and antipyretic role 58.  
 
  
Figure 2.5 Ibuprofen chemical structure ((2RS)-1[4-(2-methyl propyl) phenyl] 
propionic acid). Molecular formula: C13H18O2. Molecular weight: 206.131 g/mol. 59 
 
Among the conventional routes of IBU administration, the oral one in the 
form of tablets, capsules, suspensions and solutions is the most common. 
Moreover, the topical application of IBU offers many alternative dosage forms 
(cream, gels, foam, spray solutions) for the management of musculoskeletal, 
joint and soft tissue injury pain. 60. 
In the last years, an alternative use of IBU that involves its application in 
the treatment of wounds has attracted attention in the biomedical field. In 
material science, several research works have been addressed to the 
development of innovative wound dressings, able to deliver IBU to the wound, 
which overcomes the main issues related to the wound healing process 61. For 
instance, it has been demonstrated that painful wounds could take longer time 
to heal, so leading to a lack of compliance by the patients. IBU and other 
NSAIDs are excellent pain-reducing agents and very small doses of IBU can 
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have an excellent local effect on the superficial wound compartment, without 
detectable systemic levels 62.  
This alternative use of IBU has been considered within this PhD thesis, 
where the IBU loading into ZnO nanostructures has been studied. Future 
applications of the IBU-loaded NsZnO developed in this research work could 
involve the combination of these drug delivery systems into composite 
dressings for wound healing treatment.  
 
A second crucial aspect considered in the choice of IBU as model drug in 
this thesis, concerns its solubility. It is worth noting that IBU, as the above 
described CTZ, displays a low solubility in water (0.021 mg/ml) 59. Due to its 
higher affinity for alcohols, the development of IBU delivery systems has often 
required the use of organic solvents, such as ethanol 63–65, methanol 66,67 and 
pentane 68. It has already been highlighted how this choice can lead to a 
dangerous impact on the environment and on health, due to the possible 
presence of organic solvents residuals in the final drug carrier 56.  
To overcome this limitation, the use of scCO2 technology has been widely 
investigated to load IBU into several materials. Cyclodextrins 69–72, silica 73,74 
and polymers 75–78 resulted to be among the most evaluated supports, which 
evidences the versatile role of this green solvent. To the best of our knowledge, 
the IBU loading into ZnO nanostructures by means of scCO2 have not been 
reported yet. 
The work of Shokri and colleagues is the only one that reports the 
combination between IBU and ZnO. Nevertheless, the aim of their research 
work was not the loading of the API inside the material, but the use of ZnO 
nanostructures as skin penetration enhancers in topical formulations 79. In that 
case IBU and ZnO were simultaneously administered to the skin, but not 
combined in a drug delivery system. 
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2.5 Conclusions  
 
Thanks to its outstanding properties, the scCO2 technology has attracted 
growing attention in many fields of application. In the formulation of 
innovative drug delivery systems, the scCO2 assisted drug impregnation is 
considered a valid alternative to the conventional drug loading methods. In 
fact, the scCO2 technology offers several advantages, such as its being a green 
drug impregnation approach, safe for both environment and the consumer 
health. Moreover, it represents a good solvent for poorly-water soluble drugs, 
so replacing the use of organic solvents. Through the scCO2 - mediated drug 
impregnation ready-to-use drug delivery systems can be produced, without any 
further purification process and free from organic solvents residues. The API 
loading mediated by scCO2 technology has been investigated with different 
materials, from polymers to cyclodextrins, which demonstrates the versatility 
of this approach. Nevertheless, the supercritical impregnation of 
nanostructured ZnO has never been studied, despite the growing importance 
of this material as a drug delivery system. This PhD thesis is going to present 
the results obtained during the first investigations on the use of the scCO2 
assisted drug impregnation into different ZnO nanostructures, using 
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 Chapter 3 
Green organic-solvent-free routes 
to prepare nanostructured zinc 
oxide carriers for pharmaceutical 
applications. 
“Part of the work described in this chapter has been previously published 
in Leone et al., 2018, Journal of Cleaner Production, 172, 1433-1439 1. 
3.1 Introduction 
 
This chapter deals with the development of a green organic-solvent-free 
route to prepare ZnO-based drug carriers. As mentioned above, ZnO was 
selected due to its intrinsic biological properties and its well-established use in 
dermatological and cosmetic products 2. Due to its low toxicity and high 
biocompatibility, ZnO has also been listed as a safe substance by Food and 
Drug Administration (21CFR182.8991). A large variety of methods were 
reported in the literature for the production of ZnO nanostructures with 
particles differing in shape, size and spatial structure 2. However, these 
methods result in many drawbacks, which include the use of toxic solvents, 
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generation of hazardous by-products and the imperfection of the surface 
structure. To the best of our knowledge the loading of drugs on NsZnO by 
means of scCO2 has not been reported yet. In order to fill this gap, the main 
objective of this work has been the development of an innovative organic-
solvent-free process which combines both the production of the NsZnO carrier 
and the drug loading phase of the Active Pharmaceutical Ingredients (API) 
(Figure 3.1). Two NsZnO materials with different morphologies were 
synthesized using wet organic-solvent-free processes and they were 
characterized to elucidate their morphological and physico-chemical 
properties. In this investigation, Clotrimazole (CTZ) and Ibuprofen (IBU) were 
selected as drug models.  
A scCO2 drug loading technique was used to load the two different API’s 
on the NsZnO so allowing the final material to be recovered without any 
solvent residue. Moreover preliminary in vitro dissolution studies were 
performed to verify the capability of the obtained materials to release the CTZ 
and IBU in view of future drug delivery applications.  
Eventually it must be pointed that, in the perspective of the industrial 
development of the supercritical fluid technology 3, the preparation route here 
proposed can be easily transferred to real pharmaceutical industry, which 
traditionally involves small-scale batch processes. However, the limitation of 
the present study is the lack of in vitro studies mimicking the biological 
environment and conditions envisaged for the applications of these systems, 
which will be investigated in future work. 
 
Figure 3.1 Schematic representation of the main steps involved in the 
organic- solvent-free route developed in 1. 
  




3.2.1. Materials  
All the reagents for chemical synthesis were purchased from Sigma-
Aldrich and used as received without further purification. Carbon dioxide with 
a purity of 99.998% was supplied by SIAD (Italy). Bidistilled water was used 
throughout this study. 
3.2.2. Synthesis of nanostructured ZnO  
Two different NsZnO materials were synthesized. For this purpose two 
wet chemical processes without any organic solvent were selected: chemical 
bath deposition and a soft-template sol-gel method. 
Chemical bath deposition 
The key mechanism of the chemical bath deposition (CBD) approach is 
based on the growth of layered inorganic materials, which contain Zn2+ ions, 
as precursors of ZnO. Many CBD processes that employ basic aqueous 
solvents and zinc salts for the fabrication of ZnO nanostructures have been 
reported in the literature due to several advantages, such as the easiness in 
preparation, cheap equipment, low deposition temperature (< 100 °C) and 
versatility 4–8.  
The CBD procedure here investigated was previously described by 
Kakiuchi and co-workers 9. ZnCl2 and urea were used as starting reagents in 
order to obtain zinc carbonate hydroxide hydrate (Zn4CO3(OH)·6H2O) with a 
nanosheet-like morphology, which is the precursor of ZnO. However, some 
changes have been here introduced in the recovery of the ZnO precursor before 
calcination.  
Zinc chloride and urea were dissolved in bidistilled water in order to 
achieve a final concentration of 0.05 M of Zn2+ and 1.0 M of urea. The pH 
value of the solution was adjusted to 4 by using hydrochloric acid. At the end 
of these preliminary operation steps a transparent and precipitate-free solution 
was obtained. The solution was kept under magnetic stirring at 80°C for 24 
hours using the reflux technique until the deposition of a white dense 
precipitate of Zn4CO3(OH)6·H2O was obtained. The suspension with the 
nanosheet-shaped ZnO precursor was carefully filtered allowing the precipitate 
to be separated on the surface of a cellulose filter (Whatman® qualitative filter 
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paper, Grade 3): a powder was then obtained instead of a film. Finally the 
precipitate was thermally treated by heating it at 300°C for 0.5 hour in a static 
oven to be transformed into zinc oxide. In the following sections the material 
obtained with the above described procedure is referred as NsZnO-1. 
Soft-template sol-gel method  
The use of a soft template in the synthesis of NsZnO materials has been 
scarcely investigated in the literature. Zinc acetate was selected as the zinc 
source and Pluronic F127 as the templating agent. A solution of Pluronic F127 
(10% v/v) in water was prepared. Zinc acetate was then added until a 
concentration equal to 0.8 M was obtained. An opalescent suspension was 
immediately formed and was left under magnetic stirring at room temperature 
for 2 hours. Finally the suspension was dried under vacuum and the dried 
residue was calcinated at 500°C for about 2 hours and 45 minutes with a 
heating rate of 3°C/min in order to remove the template and obtain zinc oxide. 
In the following sections the material obtained with the above described 
procedure is referred as NsZnO-2. 
 
3.2.3. Clotrimazole-loaded NsZnO materials 
Drug loading through supercritical carbon dioxide 
The supercritical impregnation process was carried out by contacting the 
drug and each of the two NsZnO materials in a static atmosphere of scCO2 at 
constant temperature and pressure. The apparatus and the experimental 
procedure adopted to achieve the incorporation of the drug into the NsZnO are 
described in a previous work 10. A tailored set-up, which was already used in 
a previous work 11, was applied to place the samples inside the supercritical 
impregnation vessel. First a pellet of the drug (100 mg) and a pellet of the 
NsZnO (100 mg) were prepared and introduced into a glass cylinder of 1 cm 
diameter. A disc of filter paper was placed between the two pellets to prevent 
their contact and guarantee an efficient recovery of the samples at the end of 
the drug loading process (Figure 3.2). Both the NsZnO and the drug were 
accurately pelletized using a manual hydraulic press to obtain small cylindrical 
pellets with a 9 mm diameter and a height ranging from 1 to 2 mm. Each glass 
device was supposed to contain one single combination of a NsZnO pellet and 
a drug pellet. The sample-loaded glass devices were placed inside a stainless 
steel vessel, which was put in an oven that kept all the system at constant 
temperature. To assure reproducibility the vessel can hold up to 5 homemade 
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glass cylinders and this endows different batches of the same sample to be 
obtained at the end of the impregnation process. To load the CTZ into the 
NsZnO materials, liquid CO2 was used to fill the vessel, then the temperature 
was increased to 100°C and additional CO2 was pumped to reach the target 
pressure (25.0 MPa): these operative conditions did not not affect the CTZ 
stability 12. The system was maintained at the above-reported conditions for 
several hours (around 12) to allow the drug to be dissolved in the scCO2 and 
diffuse into the NsZnO. At the end of the drug loading process, the apparatus 
was brought back to atmospheric pressure and cooled to room temperature. 
 
 
Figure 3.2 Schematic representation of the homemade device used to perform 
the incorporation of the drug by means of scCO2 (left side); picture showing the filled 
glass cylinder, ready for the incorporation process (right side. This images has been 
adapted from 1. 
Drug loading through traditional approach 
For comparison, incorporation of CTZ was also performed by traditional 
adsorption from ethanol solution 11. For this purpose, 50 mg of NsZnO were 
incubated with an ethanolic solution of drug (CTZ 60 mg/ml), under stirring 
for 24 hours, at room temperature. Then, in order to separate the drug loaded 
ZnO, the suspensions were centrifugated at 4000 rpm for 30 minutes. The 
quantitative analysis of drug hosted into NsZnO samples was performed by 
using TG analyses, between 20°C and 800°C in air (flow rate 100 mL/min with 
a heating rate of 10 °C /min) using a SETARAM 92 instrument. 
 
Preliminary in vitro drug release study 
A preliminary in vitro release study was performed to assess the ability of 
the drug-loaded NsZnO to release the drug. Multicompartment rotating cells, 
equipped with a hydrophilic dialysis membrane (Spectra/Por, Spectrum®, cut-
off 12000-14000 Da), were used to perform the in vitro release tests. The 
release profiles of CTZ-loaded NsZnO-1 sample was compared with that of 
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pure crystalline CTZ. A HCl 0.1 M solution was used as the receiving phase 
13. After fixed time intervals, the receiving phase was completely replaced by 
a fresh solution. The release study took approximately 2 hours. A quantitative 
analysis by UV spectroscopy at 254 nm was carried out in order to determine 
the amount of released drug on each withdrawn sample. 
 
3.2.4 Ibuprofen-loaded NsZnO materials 
Drug loading through supercritical carbon dioxide 
The impregnation of the NsZnO with IBU was performed following the 
same procedure of CTZ, but the final temperature and pressure were 35°C and 
10 MPa, respectively 14–17. 
Drug loading through traditional approach 
The adsorption from solution was also carried out in order to compare the 
supercritical impregnation of IBU into NsZnO with a conventional method. 
For this purpose, 50 mg of NsZnO were incubated with an ethanolic solution 
of IBU (30 mg/ml), under stirring for 24 hours, at room temperature 11. Then, 
a separation process was carried out in order to separate the drug loaded 
NsZnO from the not-entrapped drug solution (4000 rpm for 30 minutes). A 
quantitative analysis of the IBU in the supernatant phase was performed by 
using TG analyses, between 20°C and 800°C in air (flow rate 100 mL/min with 
a heating rate of 10 °C /min) using a SETARAM 92 instrument. 
Preliminary in vitro drug release study 
The ability of the drug-loaded NsZnO to release IBU was also tested by 
using the multicompartment rotating cells, equipped with a hydrophilic 
dialysis membrane (Spectra/Por, Spectrum®, cut-off 12000-14000 Da). The 
release profiles from the NsZnO-1 and NsZnO-2 samples loaded with IBU 
through scCO2 technique were compared. Phosphate buffered solution (pH 
7.4) was used as the receiving medium. At predetermined time intervals, the 
receiving phase was completely replaced by a fresh solution, and analyzed for 
IBU content at 263 nm, using a Beckam-Coulter DU 730 spectrophotometer. 
3.2.5 Characterization 
The physico-chemical characterization of the NsZnO samples was 
performed before and after the drug loading step, adopting a wide range of 
techniques, among which X-ray diffraction (XRD), thermogravimetry (TG), 
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differential scanning calorimetry (DSC), nitrogen adsorption isotherms, and 
field emission scanning microscopy (FESEM) coupled with EDS. 
XRD patterns were obtained using a PANalytical X’Pert (Cu Kα radiation) 
diffractometer. Data were collected with a 2D solid state detector (PIXcel) 
from 20 to 70 2θ with a step size of 0.001 2θ and a wavelength of 1.54187 Å. 
Crystallites size was determined according to Scherrer equation 18 by 
comparing the profile width of a standard profile with the sample profile. The 
Scherrer equation relates the width of a powder diffraction peak to the average 
dimensions of crystallites in a polycrystalline powder:  
 
Eq. 3.2:                                      D = Kλ/ β (2θ)hkl cos θ  
 
where β is the crystallite size contribution to the peak width (full width at 
half maximum) in radians, K (shape factor) is a constant near unit and D is the 
average thickness of the crystal in a direction normal to the diffracting plane 
hkl. 
Profile fits were performed using X’Pert High Score Plus, using Pseudo-
Voigt peak function with Kα1 and Kα2 fitting on a background stripped 
pattern. The sample-induced peak broadening β was determined by subtracting 
the instrumental peak width from the measured peak width. 
The instrumental broadening was determined using LaB6 powder (NIST 
SRM®660a, size of crystallites in the 2 μm to 5 μm range). 
TG analyses were carried out between 20°C and 800°C in air (flow rate 
100 mL/min with a heating rate of 10 °C /min) using a SETARAM 92 
instrument while the DSC measurements were performed under nitrogen flux 
(60 ml/min), in the range between 50° C and 200° C, with a DSCQ 1000 by 
TA Instrument.  
Nitrogen adsorption isotherms were measured using a Quantachrome 
AUTOSORB-1 instrument. Before the adsorption measurements, samples 
were outgassed for 2 h at 100° C. BET specific surface areas (SSABET) were 
calculated in the relative pressure range of 0.04–0.1. 
Infrared spectroscopy was carried out on a Thermo Scientific FTIR 
Spectrometer (Thermo Fisher Scientific Inc., USA). Spectra were recorded for 
16 scans in ATR mode at room temperature, with a 1 cm−1 resolution in the 
wavelength range of 4000 - 400 cm-1. Spectra were corrected for background 
and atmosphere using OMNIC software provided with the spectrometer. 
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FESEM images were recorded with a FESEM ZEISS MERLIN 
instrument, equipped with an EDS detector (OXFORD). 
For the measurement of CTZ concentration in the release tests a UV-Vis 
Beckman-Coulter spectrophotometer was used. 
 
3.3. Results and Discussion 
3.3.1. Characterization of the NsZnO materials as such. 
Figure 3.3 reports the FESEM images, at low and high magnification, of 
the NsZnO-1 sample. NsZnO-1 appears as aggregates of nanosheets with 
thickness of about 20 nm that are formed by the self-assembling of ovoid 
nanoparticles (around 15-20 nm). This morphology is in agreement with the 
mechanism growth proposed by Kakiuchi et al. 9.  
Figure 3.3 FESEM images of NsZnO-1 (magnification: 5.00 K X, 25.00 K X, 
250.00 K X) 
 
The morphology of NsZnO-2 is visible in Figure 3.4 at different 
magnification. The material appears in form of micrometric and sub-
micrometric aggregates of interconnected nanoparticles with heterogeneous 
size of tens nanometers. 
The presence of the nanometric particles might be explained considering a 
mechanism where the Pluronic F127 molecules would restrict the growth of 
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Figure 3.4 FESEM images of NsZnO-2 (magnification: 5.00 K X, 25.00 K X, 
250.00 K X) 
 
EDS analysis (data not shown) confirmed the presence of Zn and O at the 
surface in both samples. No occurrence of chloride is observed for NsZnO-1, 
from which the complete transformation of the ZnCl2 precursor can be inferred. 
Figure 3.5 reports the XRD patterns of both NsZnO materials, which 
reveal the occurrence of a highly crystalline single hexagonal phase of wurtzite 
structure. The five main reflection peaks (100), (002), (101), (102) and (110) 
and the intensity distribution of the peaks are consistent with those of the 
standard card for the hexagonal phase ZnO (JCPDS ICDD 36-1451). In both 
the XRD patterns reported in Figure 3.5 the characteristic peaks of the 
precursors cannot be detected: this means that pure ZnO can be obtained 
through the above-described synthetic methods. Comparing the XRD patterns 




Figure 3.5 XRD patterns of NsZnO-1 e NsZnO-2 
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Both materials show the typical hexagonal wurtzite structure. The 
crystallites size determined using the Scherrer equation (Eq. 3.2) are similar to 
values reported in Table 3.1. 
Table 3.1 Crystallite dimensions (nm) determined from application of the Scherrer 
equation to selected hkl reflections of NsZnO-1 and NsZnO-2 
 
hkl NsZnO-1 NsZnO-2 
100 15 38 
101 15 33 
102 16 24 
110 14 24 
 
N2 physisorption measurements were used to evaluate the specific surface 
area (m2/g) and the pore volume (m3/g) of the two samples. NsZnO-1 shows 
values of both parameters higher than those of NsZnO-2 (Table 3.2). These 
results are in agreement with the smaller particles size revealed for the former 
sample by FESEM and XRD data. 
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3.3.2 Characterization of the CTZ-loaded NsZnO materials  
ScCO2 was used to load CTZ inside the two NsZnO materials, TG analyses 
of the NsZnO materials loaded with CTZ (CZT@NsZnO) allowed the amount 
of CTZ to be evaluated, which corresponds to 17% w/w for CZT@NsZnO-1 
and 14% w/w for CZT@NsZnO-2, respectively (Table 3.2). 
 
Table 3.2 Surface area and pore volume values before and after the CTZ loading, 




Figure 3.6 shows the isotherms of both the NsZnO materials before and 
after the loading of CTZ through scCO2. The values of the surface area and 
pore volume values are reported in Table 3.2. As far as NsZnO-1 is concerned, 
the BET specific surface area decreased from 66 m2/g, for the as-synthetized 
material, to 22 m2/g, after CTZ loading, whereas the pore volume decreased 
from 0.230 cm3/g to 0.110 cm3/g. The BET specific surface area of NsZnO-2, 
instead, decreased from 19 m2/g to 6.7 m2/g and the pore volume decreased 
from 0.050 cm3/g to 0.003 cm3/g.  The BET specific surface area of NsZnO-1 
is lower than the value reported in literature for the nanostructured ZnO 
deposited in the film form on a glass substrate (88.5 m2/g) 9. As far as the 
sample NsZNO-2 is concerned, no comparison with the value reported in 
literature is possible because of the lack of this datum 19. 
The decrease of BET specific surface area and pore volume upon CTZ 
loading for both samples is ascribed to the adsorption of CTZ molecules on the 
surface of NsZnO materials. This confirms the feasibility of using the NsZnO 
as CTZ carrier. 
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Figure 3.6 Section A: N2 adsorption-desorption isotherms of NsZnO-1 before (1) and 
after (2) CTZ loading. Section B: N2 adsorption-desorption isotherms of NsZnO-2 
before (1) and after (2) CTZ loading 
 
XRD and DSC analyses were performed to investigate the form of the drug 
inside the NsZnO materials pores. Figure 3.7A reports the XRD patterns of 
CTZ@NsZnO-1 and CTZ@NsZnO-2. 
 
Figure 3.7 XRD patterns and DSC analyses of CTZ-loaded NsZnO materials after 
scCO2 impregnation process. Figure 6A shows the XRD patterns of CTZ@NsZnO-1 
and CTZ@NsZnO-2. Figure 6B reports the DSC curves of pure crystalline CTZ, 
CTZ@NsZnO-1 and CTZ@NsZnO-2. 
 
 
No additional diffraction peaks of the crystalline CTZ are observed in both 
cases. This evidences that the loaded drug molecules are not assembled in the 
crystalline structure. The same result was also confirmed by the DSC analysis. 
DSC curves for pure CTZ, CTZ@NsZnO-1 and CTZ@NsZnO-2 are shown in 
Figure 3.7B. Pure CTZ showed a sharp melting endotherm peak at 147 °C, in 
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agreement with what reported in the product data sheet. No evidence of this 
peak was observed in the DSC curve of CTZ@NsZnO-1 (curve A), suggesting 
a complete amorphization of the drug in the carrier.  The DSC curve of 
CTZ@NsZnO-2 (curve B) showed a dramatic decrease in the intensity of the 
drug melting peak, being only a very weak signal discernible. The 
disappearance or decrease in intensity of the drug endothermic peak is 
generally related to drug–material interactions and/or loss of drug crystallinity. 
The presence of a residual weak melting endotherm peak in the case of 
CTZ@NsZnO-2 is in agreement with the lower SSA (19 m2/g) with respect to 
CTZ@NsZnO-1 (66 m2/g). In fact, despite the higher amount of loaded CTZ 
in the latter sample (17 % w/w), complete amorphization is ascribed to the 
interaction between the drug molecules and the ZnO surface. From the content 
of CTZ (% w/w) the number of molecules of CTZ per gram of ZnO was 
evaluated and, using the SSA value, this was transformed into the number of 
molecules per nm2, which resulted to be equal to 5.4 for NsZnO-1. The 
significantly lower SSA value of NsZnO-2 accounts for its lower capacity to 
form CTZ-surface interactions, favouring partial CTZ self-aggregation in 
crystalline form. Indeed, the amount of molecules/nm2 in CTZ@NsZnO-2 
resulted to be equal to 15. 
 
FTIR spectroscopy was performed to i) confirm the successful loading of 
CTZ into NsZnO-1, selected as the sample with the higher CTZ content in 
amorphous form, and ii) to study the effect of the supercritical carbon dioxide 
on the NsZnO-1 surface. Figure 3.8 reports the FTIR spectra of NsZnO-1 as 
such, CTZ@NsZnO-1, NsZnO-1 as-such after a scCO2 treatment and 
clotrimazole. The as-prepared NsZnO shows several IR bands between 1700 
cm-1 and 1000 cm-1, corresponding to C=O stretching (1561 cm-1), C–O 
stretching (1155 cm-1 ) and C–H vibrations 20. The presence of these species 
could be ascribed to partially decomposed ZnO precursors (Zinc Carbonate 
Hydroxide Hydrate) originating from reaction intermediates. The broad band 
around 3400 cm-1 is attributed to O–H stretching, while the peak at 1641 cm-1 
corresponds to O–H bending 21. 
In order to evaluate the effect of the supercritical carbon dioxide on the 
NsZnO-1 surface, FTIR analysis was also performed on the sample as-such 
after a treatment in scCO2 for 12 hours, at 100°C and 25 MPa. The spectrum 
displays an intensity growth of the absorption region between the 1600 and 
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1100 cm-1 caused by the adsorption of CO2 on ZnO surface. This region can be 




Figure 3.8 FT-IR spectra of: NsZnO-1, CTZ@NsZnO-1(scCO2 loading), 
NsZnO-1 after a scCO2 treatment and crystalline clotrimazole 
 
.  
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The characteristic bands displayed in the FTIR spectrum of clotrimazole 
are consistent with the literature 11,23–25. The vibration bonds in an aromatic 
ring (Ar-H) are ascribed at 3050 cm-1, which is characteristic of bonds C-H, 
the peak at 1580 cm-1 conforms to the group C=N and the bands at 1480 cm-1 
and 1440 cm-1 are specific for the group C=C.  At 1300 cm-1 and 1200 cm-1 are 
visible peaks respond the vibration of bonds C-H. Another characteristic peak 
of CTZ corresponds to the functional group C-Cl at 750 cm-1 (region not 
shown). Notwithstanding the evident CO2 adsorption on the surface of the 
NsZnO-1 as -such after the treatment in scCO2, the FTIR spectrum of the 
CTZ@NsZnO-1, impregnated through scCO2 process, shows clearly the 
characteristic peaks of the drug. Moreover, the growth of the absorption region 
between the 1600 and 1100 cm-1 caused by the adsorption of CO2 on 
CTZ@NsZnO-1 surface results less intense than the NsZnO-1 as-such. From 
these experimental evidences, it is possible to draw significative conclusions: 
i) a successful loading of CTZ into NsZnO-1 was achieved by supercritical 
process; ii) during the drug impregnation by means of the scCO2, the drug 
played a protective function towards the NsZnO-1 surface, reducing the 
adsorption of CO2. 
 
For the sake of comparison, NsZnO-1 was also loaded with CTZ through 
a traditional approach, consisting in the adsorption of the drug from an 
ethanolic solution. Briefly the materials were incubated for 24 hours under 
magnetic stirring with a CTZ ethanolic solution. At end of the process, the drug 
loaded NsZnO-1 was separated from the not-encapsulated CTZ solution 
through a centrifugation process. The precipitate, consisting in the CTZ loaded 
material, was used to determine its drug content. In order to evaluate the 
amount of CTZ, TG analyses of the NsZnO materials loaded with CTZ 
(CTZ@NsZnO-1) were performed both after scCO2 impregnation and after 
traditional adsorption loading from ethanolic solution. The characteristic 
curves are shown in Figure 3.9. The percentages calculated as loss of weight 
after TG analysis indicated that the drug loading corresponded to 17% w/w and 
11%, after scCO2 technique and traditional adsorption, respectively. In 
conclusion, it is worth of noting that a significant advantage in term of CTZ 
amount was gained using the supercritical approach in comparison with the 
traditional one. This advantage combined to the possibility to avoid organic 
solvents during the drug loading step makes the use of scCO2 a promising route 
to develop ZnO-based reservoir of drug. 
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Considering the drug loading amount of the sample CTZ@NsZnO-1 
loaded with supercritical technology, it is important to underline that the loss 
of weight (≈ 7%) obtained from the TG analysis of the sample NsZnO-1 as-
such after scCO2 treatment (Fig.3.9, red curve) could be ascribed to the loss of 
CO2 adsorbed onto the material surface. This result confirmed the evidence 
collected by FTIR analysis (Fig. 3.8), from which the adsorption of CO2 on the 
NsZnO-1 surface after the supercritical treatment was clearly displayed by the 
spectrum. Nevertheless, notwithstanding this evidence, it is important to take 
into consideration that the drug plays a protective role towards the NsZnOs 
surfaces, decreasing the adsorption of CO2. This assessment clearly emerged 
from the FTIR analyses of the drug loaded samples and was also reported in 
other research works 15. Consequently, it is reasonable to consider that the loss 
of weight of the sample CTZ@NsZnO-1 is mostly related to the amount of 
CTZ hosted inside the NsZnO-1 nanostructure and only in a small part to the 
contribution of CO2.   
 
 
Figure 3.9 TG analyses of NsZnO-1 as-such (black curve), NsZnO-1 as-such 
after scCO2 treatment (red curve), NsZnO-1 loaded with CTZ after scCO2 (green 
curve) and after traditional approach (blue curve) 
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Preliminary in vitro drug release study 
Previous results showed the possibility to load CTZ molecules into NsZnO 
materials by means of scCO2. The capability of releasing the loaded CTZ was 
also investigated. For this purpose, an in vitro release study of CTZ from 
NsZnO-1, i e. the sample showing the higher CTZ content in amorphous form, 
was carried out using a multi-compartmental rotating cell. Figure 3.10 reports 
the cumulative percentage release curves of CTZ both from CTZ@NsZnO-1 
and unsupported pure CTZ. The release profile of CTZ from CTZ@NsZnO-1 
shows a fast release in the first 10 minutes of the test, where the amount of 
CTZ released by CTZ@NsZnO-1 was about 15 µg. Then the quantity of 
released drug kept slightly increasing over time until it was approximately 
doubled. This trend was significantly different from the release profile of 
unsupported CTZ. In fact, in this case the quantity released after 10 minutes 
was less than the half of that released by CTZ@NsZnO in the same time. At 
the end of experiment, the final quantity of released CTZ was about 25 % of 
that released by CTZ@NsZnO-1. These results show that CTZ is not 
irreversibly confined in the NsZnO material and that NsZnO can act as a drug 
delivery carrier, ensuring a fast release of a larger CTZ amount in comparison 
with the unsupported crystalline drug. This might play a key role in several 
biological applications where the bioavailability of poorly-water-soluble drugs 
is still a challenging issue. A possible explanation of this behaviour is the 
amorphous nature of CTZ hosted in the NsZnO sample. Amorphization of 
drugs on carriers has been already reported in literature. Several matrices were 
investigated such as mesoporous silica 11,26,27, cyclodextrins 16,28–30 and 
polymers 10. It is widely accepted that the amorphization of the drug molecules 
plays a key role in increasing their dissolution rate and solubility, which are 
two fundamental parameters that affect the subministration of poorly-water-
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Figure 3.10 In vitro drug-release profiles of clotrimazole from pure crystalline 
clotrimazole and CTZ@NsZnO-1. 
 
3.3.3 Characterization of the IBU-loaded NsZnO materials  
The development of a green organic-solvent-free route to prepare ZnO-
based drug carriers has been successfully demonstrated using CTZ as drug 
model 1. In order to demonstrate the robustness of this approach, the same 
study was carried out selecting a different API molecule. In particular, IBU 
was used as drug candidate for this further investigation. A scCO2 process was 
performed to load IBU inside the two NsZnO materials and the samples were 
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Table 3.3 Surface area and pore volume values before and after the IBU loading, 




Figure 3.11 shows the isotherms of both the NsZnO materials before and 
after the loading of IBU through scCO2. The values of the surface area and 
pore volume values are reported in Table 3.3. As already observed in the case 
of Clotrimazole, a reduction of the values of BET specific surface area and 
pore volume after scCO2 process was determined. Particularly, as far as 
NsZnO-1 is concerned, the BET specific surface area hugely decreased from 
68 m2/g, for the as-synthetized material, to 8 m2/g, after IBU loading, whereas 
the pore volume steeply decreased from 0.230 cm3/g to 0.04 cm3/g. The BET 
specific surface area of NsZnO-2, instead, decreased from 12 m2/g to a value 
minor that 2 m2/g, with an almost total occlusion of the pore volume (≈ 0 
cm3/g). As mentioned above, the decrease of BET specific surface area and 
pore volume upon IBU loading for both samples is ascribed to the adsorption 
of IBU molecules on the surface of NsZnO materials. As in the case of CTZ, 
the feasibility of using the synthetized NsZnO as carriers of IBU was 
confirmed. Moreover, the use of these ZnO nanostructures resulted versatile 
and potentially usable with different types of molecules.  
 
As further demonstration, XRD analyses were performed to investigate the 
form of the IBU inside the NsZnO materials pores, after both the drug loading 
approaches. Figure 3.12 reports the XRD patterns of IBU@NsZnO-1 and 
IBU@NsZnO-2, compared with the materials as-such and with the pure 
crystalline drug. From the results, it is possible to draw some important 
observations: firstly, both materials keep showing the typical hexagonal 
wurtzite structure after the drug loading procedures. Secondly, no additional 
diffraction peaks of the crystalline IBU are observed in both cases, evidencing 
that the loaded drug molecules are not assembled in the crystalline structure. 
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This represents a further proof that scCO2 can be considered as much efficient 
as the traditional drug loading methods, with the advantage of being a greener 
and cleaner approach. It is widely accepted that the amorphization of the drug 
molecules plays a key role in increasing their dissolution rate and solubility 1. 
Moreover, since the same conclusions were drawn in the case of CTZ, also the 
versatile role of scCO2 in acting as solvent for the drug loading of different 
molecules into ZnO-based carrier has been confirmed. These represent 
outstanding findings, considering that, to the best of our knowledge, this is the 
first time that the loading of drugs on NsZnO by means of scCO2 has been 
studied. Particularly, it is worth of noting that the XRD patterns confirmed the 
lack of reactivity between ZnO and the CO2 used as solvent in the drug loading 
phase. This result has not been taken for granted, considering that the reaction 
between ZnO and CO2, to give ZnCO3 as final product, is a well-known 
phenomenon 31,32. To deepen this evidence, XRD analysis was performed on 
both the ZnO nanostructures after a treatment with scCO2, carried out for 12 
hours, at 35°C and 10 MPa. Figure 3.13 shows that in both cases the hexagonal 
wurzite pattern of ZnO was preserved, and any new peaks were detected, 
demonstrating the missed phase transformation of ZnO in ZnCO3. 
 
 
Figure 3.11 Section A: N2 adsorption-desorption isotherms of NsZnO-1 before (1) 
and after (2) IBU loading. Section B: N2 adsorption-desorption isotherms of NsZnO-
\2 before IBU loading.  
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Figure 3.12 Panel A: XRD patterns of: NsZnO-1 after synthesis, IBU@NsZnO-1 
after scCO2 drug loading, IBU@NsZnO-1 after traditional drug adsorption and pure 
IBU. Panel |B:  XRD patterns of: NsZnO-2 after synthesis, IBU@NsZnO-2 after 
scCO2 drug loading, IBU@NsZnO-2 after traditional drug adsorption and pure IBU. 
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Figure 3.13 XRD spectra of NsZnO-1 and NsZnO-2 before and after a treatment in 
scCO2 (12 hours, 40° C, 10 Mpa). 
 
 
FTIR spectroscopy was performed to confirm the successful loading of 
IBU into both the ZnO nanostructures, after the scCO2-mediated impregnation. 
Figure 3.14 reports the FTIR spectra of NsZnO-1 and NsZnO-2, before and 
after IBU loading (IBU@NsZnO-1 and IBU@NsZnO-2), in comparison with 
the spectrum of ibuprofen. Both the as-prepared NsZnO show a series of IR 
peaks between 1650 cm-1 and 1400 cm-1, corresponding to C=O stretching, 
while at lower wavelength C–O stretching and C–H vibrations are present  20. 
The presence of these species could be ascribed to the partially decomposition 
of ZnO precursors originating during the calcination treatment. This 
interpretation is coherent considering that the spectrum of NsZnO-1 displays a 
less intense peaks in the carbonate region in comparison with NsZnO-2: in fact, 
in the latter case the amount of organic template (Pluronic F127), modelling 
the ZnO particles formation, is much higher than the ZnO precursors (Zinc 
Carbonate Hydroxide Hydrate) from which NsZnO-1 is originated. The broad 
peak around 3400 cm-1 is attributed to O–H stretching, while the peak at about 
1650 cm-1 corresponds to O–H bending 21. The FTIR spectrum of pure 
ibuprofen clearly shows an intense peak at around 1710 cm-1, ascribed to 
carbonyl-stretching of isopropionic acid group, while the bands at around 
2900-2800 cm-1 correspond to hydroxyl group of carboxylic acid. As is evident 
from the graphs, in both the spectra of IBU@NsZnO-1 and IBU@NsZnO-2, 
the characteristic bands of ibuprofen at around 2900-2800 cm-1 are present, 
while the strong carbonyl stretching at 1710 cm-1 steeply decreases in the 
IBU@NsZnO-1 spectrum and disappears in that of IBU@NsZnO-2. This 
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change in the ν(C=O) spectral region could be attributed to a successful IBU 
incorporation into NsZnO samples 33. Moreover, from the IBU@NsZnO-1 
spectrum is evident that the ν(C=O) of IBU loaded into the material results 
shifted to high wavenumber region at 1738 cm−1 compared to the 
corresponding band of pure IBU (at 1710 cm−1). This phenomenon is 
consistent with other results in the literature and could be ascribed to the 
breakage of the ibuprofen–ibuprofen interactions that are intrinsic in the solid 
form of this drug 15,34. This evidence confirms the results obtained with the 
XRD analysis, emphasising the lack of solid crystallinity of the IBU after 
supercritical fluid impregnation. 
As previously observed with CTZ, the IBU case study confirmed the 
possible protective function of the drug towards the NsZnO surfaces in 
reducing the adsorption of CO2, since also in this case the carbonates region is 
not predominant, and the CO2 did not react with ZnO to originate ZnCO3.  







Figure 3.14 FT-IR spectra of: NsZnO-1 and NsZnO-2 before and after scCO2-
mediated drug loading (IBU@NsZnO-1 and IBU@NsZnO-2) in comparison with the 
pure ibuprofen. 
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NsZnO-1 and NsZnO-2 were also loaded of IBU through a traditional 
approach, consisting in the adsorption of the drug from an ethanolic solution. 
Briefly the materials were incubated for 24 hours under magnetic stirring with 
an IBU ethanolic solution. At end of the process, the drug loaded NsZnOs were 
separated from the not-encapsulated IBU solution through a centrifugation 
process. In order to evaluate the amount of IBU, TG analyses of the NsZnO 
materials loaded with IBU (IBU@NsZnO) were performed both after scCO2 
impregnation and after traditional adsorption loading from ethanolic solution. 
The characteristic curves are shown in Figure 3.15. The percentages calculated 
as loss of weight after TG analysis indicated that after scCO2 technique the 
drug loading corresponded to 7% w/w for IBU@NsZnO-1 and 9% w/w for 
IBU@NsZnO-2, respectively, while after traditional adsorption the drug 
loading was found to be 9% w/w for IBU@NsZnO-1(trad) and 3% w/w for 
IBU@NsZnO-2(trad) (Table 3.4). Considering the drug loading amount of the 
sample IBU@NsZnO-1 loaded with supercritical technology, it is important to 
underline some considerations. As mentioned above, the loss of weight (≈ 7%) 
obtained from the TG analysis of the sample NsZnO-1 as-such after scCO2 
treatment (Fig. 3.15, panel A, red curve) could be ascribed to the loss of CO2 
adsorbed onto the material surface. This result confirmed the evidence 
collected by FTIR analysis (Fig. 3.8), from which the adsorption of CO2 on the 
NsZnO-1 surface after the supercritical treatment was clearly displayed by the 
spectrum. Nevertheless, notwithstanding this evidence, it is important to take 
into consideration that the drug plays a protective role towards the NsZnOs 
surfaces, decreasing the adsorption of CO2. This assessment clearly emerged 
from the FTIR analyses of the drug loaded samples and was also reported in 
other research works 15. Consequently, it is reasonable to consider that the loss 
of weight of the sample IBU@NsZnO-1 is mostly related to the amount of IBU 
hosted inside the NsZnO-1 nanostructure and only in a small part to the 
contribution of CO2.  In conclusion, from the previous considerations it is 
possible to assess that the amount of IBU impregnated inside the sample 
NsZnO-1 after supercritical process, ranges from 14% (Fig. 3.15, panel A, 
green curve) to 7% (Fig. 3.15, panel A, red curve) not considering the CO2 
adsorption or considering the CO2 adsorption, respectively. 
Similar conclusions can be drawn for the sample IBU@NsZnO-2, even if 
the extent of CO2 adsorbed on the material as-such (Fig.3. 15, panel B, red 
curve A) resulted to be minor than the sample NsZnO-1 (about 1.4%). 
98 Chapter 3 
 
Consequently, the amount of IBU impregnated inside the sample NsZnO-2 
after supercritical process, ranges from 10% (Fig. 3.15, panel A, green curve) 
to 9% (Fig. 3.15, panel A, red curve) not considering the CO2 adsorption or 
considering the CO2 adsorption, respectively. 
Furthermore, it is worth of noting that a remarkable advantage in term of 
IBU amount hosted into both the NsZnO samples emerged using the 
supercritical approach in comparison with the traditional one. This advantage 
combined to the possibility to avoid organic solvents during the drug loading 













Table  3.4. Comparison between the amount of IBU incorporated in NsZnO-1 
and NsZnO-2 after scCO2 techniques and traditional absorption. 
 
  







   
IBU@NsZnO-1 7-14 9 
IBU@NsZnO-2 9 3 





Figure 3.15 Panel A: TGA curves of: NsZnO-1 as-such, NsZnO-1 as-such after 
treatment in scCO2, IBU@NsZnO-1 after scCO2 drug loading and IBU@NsZnO-1 
after traditional drug loading. Panel B: TGA curves of: NsZnO-2 as-such, NsZnO-2 
as-such after treatment in scCO2, IBU@NsZnO-2 after scCO2 drug loading and 
IBU@NsZnO-2 after traditional drug loading  
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Preliminary in vitro drug release study 
 
The in vitro release study was aimed simply at verifying the possibility of 
release the drug from the NsZnO carriers, assessing the lack of irreversible 
adsorption or occlusion of IBU molecules in the material. For this purpose, the 
ability of NsZnO-1 and NsZnO-2 in releasing the loaded IBU was investigated 
using a multi-compartmental rotating cell. Figure 3.16 displays the cumulative 
release curves of IBU from IBU@NsZnO-1 and IBU@NsZnO-2. As it is 
evident from the overall trend, the two ZnO-based carriers were able to release 
the same amount of drug in 6 hours. Nevertheless, the release profile of IBU 
from IBU@NsZnO-1 results lower during the first intervals investigated. A 
possible explanation for the different drug release profiles emerged from the 
two ZnO nanostructures, could be attributed to their different morphology 
affecting the delivery of the drug molecules. In fact, NsZnO-2 possess a 
simpler structure, based on spherical aggregates of nano-ovoidal particles. The 
total pore volume included among these nanoparticles is significantly lower 
than that of NsZnO-1 (Table 3.3), which could indicate an outer arrangement 
of the drug molecules on its surface. On the contrary, NsZnO-1 is characterized 
by a well-structured overlapping of nanosheets, which create a larger pore 
volume in between. The diffusion of drug molecules from this structure could 
require longer time than in the case of NsZnO-2.  
As the total percentage of IBU released in respect to the loading is 
concerned, the results indicated that over than the 50% of the drug was released 
from both the NsZnOs in 6 hours (data not shown). 
In conclusion, this preliminary in vitro release study clearly showed that 
IBU is not irreversibly confined in the NsZnO materials, confirming the role 
of NsZnO as drug delivery carrier, as previously demonstrated in the CTZ case 
study 1.  
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Figure 3.16 In vitro drug-release profiles of Ibuprofen from IBU@NsZnO-1 (light 
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3.4 Conclusions 
An organic-solvent-free route to obtain a NsZnO reservoir of API was 
studied. 
Two NsZnO materials with the hexagonal wurtzite structure and different 
morphologies were synthesized using wet organic-solvent-free processes. In 
particular, existing approaches reported in the literature for the synthesis of 
nanostructured ZnO films or nanosheets were properly modified to prepare 
novel NsZnO particles. 
CTZ and IBU were loaded into NsZnO through scCO2 impregnation and, 
at the best of our knowledge, this is the first time that a technology employing 
supercritical carbon dioxide was used for the drug loading of ZnO-based 
carriers, in order to obtain ready-to-use drug loaded materials.  
The physico-chemical characterization of NsZnO before and after the 
loading of the APIs revealed that the scCO2 process does not significantly 
affect the structure of the materials. A protective role of the drug molecules 
towards the NsZnO surface during the supercritical process was highlighted. 
The CTZ and IBU loading for the two NsZnO materials was significantly high, 
in comparison with those obtained through traditional absorption method. 
XRD and DSC analysis revealed that the APIs are distributed in the NsZnO 
carrier in amorphous form.  
The capability of the materials in releasing the APIs was investigated. 
Results revealed that both CTZ and IBU are not irreversibly confined in the 
NsZnO support and that NsZnO can act as a drug delivery carrier. This might 
play a key role in several biological applications where the bioavailability of 
poorly-water-soluble drugs is still a challenging issue.  
The reported results support the idea that the novel production routes here 
proposed to obtain NsZnO drug delivery carriers are feasible and can be a 
promising solvent-free alternative to the conventional ones since they are 
easily adabtable to batch small-scale pharmaceutical industrial process.  
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 Chapter 4  
Mesoporous ZnO as drug 
reservoir of clotrimazole: 
synthesis, drug loading and 
characterization 
4.1 Introduction  
As previously described, the different nanostructured ZnO materials 
investigated in this thesis have been thought for a dermatological application. 
The fundamental idea is focused on the development of a multitasking ZnO 
based drug delivery carrier, biologically active on the skin for its intrinsic 
properties, and able to deliver a pharmaceutical molecule.  
This chapter deals with a research work addressed to the study of a third 
type of nanostructured ZnO material (NsZnO-3).  Despite of NsZnO-1 and 
NsZnO-2 have been obtained with organic solvent-free synthesis methods 1, 
the approach adopted in this investigation consisted in a widely adopted 
precipitation synthesis, based on the hydrolysis of a zinc salt in basic alcoholic 
solutions. Since this method is based on difference mechanisms for the ZnO 
synthesis from the previously described materials, possible differences in 
terms of morphology, crystalline structure, porosity and capability in releasing 
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the drug were evaluated. Clotrimazole (CTZ) was selected as drug model in 
this investigation. Two different techniques were adopted for the incorporation 
of the drug, consisting in supercritical CO2 (scCO2) and impregnation from 
solution. A careful characterization of the physical-chemical profile of the 
material was performed, as-such and after the drug incorporation, using a wide 
range of techniques, such as X-ray diffractometry (XRD), Nitrogen adsorption 
(BET), Fourier transformed infrared spectroscopy (FT-IR), Field 
electronically-scanned microscopy (FESEM) and Ultraviolet-Visible 
Spectroscopy. Furthermore, a preliminary evaluation of the biological profile 
of this material was defined, performing an in vitro CTZ release study. 
4.2 Experimental 
4.2.1 Materials 
All the chemicals were purchased from Sigma Aldrich (Italy) and were of 
analytical grade, used as received. Carbon dioxide with a purity of 99.998% 
was supplied by SIAD (Italy). Bidistilled water was used throughout this study.  
4.2.2. Synthesis of nanostructured ZnO using the precipitation 
method 
In order to synthetize NsZnO-3, a traditional precipitation approach was 
selected. The procedure was adopted from 2 and modified. Firstly, two separate 
suspensions were prepared, dissolving 14.75 g of Zinc Acetate Dihydrate 
((CH3COO)2 Zn·2H2O) in 60 ml of methanol and 7,4 g of Potassium 
Hydroxide in (KOH) in 32 ml of methanol. Then the two suspensions were 
mixed, under magnetic stirring, at room temperature. Secondly, the reaction 
was run at 60° C for 3 days, in reflux. At the end of this procedure, in order to 
separate the ZnO white precipitate, the suspension was centrifugated for 15 
minutes at 4000 rpm and subsequently washed three times, to eliminate the 
KOH excess. Finally, the white precipitate was dried in oven at 40°C for 24 
hours. 
4.2.3. Drug loading of NsZnO-3 
CTZ was selected as drug model in this investigation. The drug loading 
phase was performed using two different techniques: incorporation with 
supercritical CO2 and traditional impregnation from solution. 
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Drug loading through supercritical carbon dioxide 
The supercritical impregnation process adopted in this research work for 
the loading of clotrimazole into NsZnO-3, was the same described in the 
Chapter 3 of this thesis (for further details see Chapter 3, paragraph 3.2.3). 
Drug loading through traditional impregnation 
The drug loading of NsZnO-3 was also carried out through a traditional 
impregnation method, as described in 3. For this purpose, 50 mg of NsZnO 
were incubated with an ethanolic solution of clotrimazole (60 mg/ml), 
under stirring for 24 hours, at room temperature. Then, in order to separate the 
drug loaded ZnO, the suspension was centrifugated at 4000 rpm for 30 
minutes. The supernatant solution was then analyzed and the amount of 
entrapped clotrimazole was determined with the Equation 2.1 and the loading 
capacity of the material was determined by the Equation 2.2. 
 
Eq. 2.1.  Entrapment efficiency % =  




The quantitative analysis of clotrimazole was performed by using a UV-
VIS spectrophotometer (PerkinElmer Lambda 5) detecting the absorbance 
value at 254 nm. 
4.2.4 Preliminary in vitro drug release study 
The ability of the drug-loaded NsZnO-3 to release clotrimazole was 
demonstrated with an in vitro released study, based on the use of a 
multicompartment rotating cell.  Three different samples were tested. 
Particularly, the release profiles of the NsZnO-3 loaded with CTZ through 
scCO2 process (CTZ@NsZnO-3 scCO2) and that of NsZnO-3 impregnated with 
CTZ by traditional approach (CTZ@NsZnO-3 trad) was compared with pure 
crystalline CTZ. A hydrophilic dialysis membrane (Spectra/Por, Spectrum®, 
cut-off 12000-14000 Da) was used to separate the samples from the receiving 
phase, consisting in a citrate/buffer/ Tween 80 solution 4. After fixed time 
intervals, the receiving phase was completely replaced by a fresh solution. The 
experiment was performed for 8 hours. A quantitative analysis by UV 
spectroscopy (PerkinElmer Lambda 5) at 264 nm was carried out in order to 
determine the amount of released drug on each withdrawn sample. 
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4.2.5. Characterization 
The characterization of NsZnO-3 was carefully performed before and after the 
drug loading phase. Particularly, a wide range of techniques were adopted in 
order to define both the physical-chemical properties of the material and its 
biological behavior. The structure and morphology of the samples were 
investigated using a field emission scanning electron microscope (FESEM) 
ZEISS MERLIN. XRD patterns were obtained using a PANalytical X’Pert (Cu 
Kα radiation) diffractometer. Data were collected with a 2D solid state detector 
(PIXcel) from 20 to 70 2θ with a step size of 0.001 2θ and a wavelength of 
1.54187 Å. Crystallites size was determined according to Scherrer equation 5 
by comparing the profile width of a standard profile with the sample profile. 
The Scherrer equation relates the width of a powder diffraction peak to the 
average dimensions of crystallites in a polycrystalline powder:  
 
D = Kλ/ β (2θ)hkl cos θ 
 
where β is the crystallite size contribution to the peak width (full width at half 
maximum) in radians, K (shape factor) is a constant near unit and D is the 
average thickness of the crystal in a direction normal to the diffracting plane 
hkl. 
Profile fits were performed using X’Pert High Score Plus, using Pseudo-Voigt 
peak function with Kα1 and Kα2 fitting on a background stripped pattern. The 
sample-induced peak broadening β was determined by subtracting the 
instrumental peak width from the measured peak width. In order to perform 
the FTIR analysis, the materials were pelletized as such, without KBr. The 
auto-supported pellets were analyzed using a Bruker Equinox 55 in the 
wavelength range of 4000 - 400 cm-1. Spectra were recorded in different 
conditions: at room temperature and atmospheric pressure and after an 
outgassing step at room temperature after high vacuum (10 -3 Pa) treatment for 
1 hour.  
Thermal gravimetric analysis TG analyses were carried out between 20°C 
and 800°C in air (flow rate 100 mL/min with a heating rate of 10 °C /min) 
using a SETARAM 92 instrument.  
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4.3. Results and discussion 
4.3.1. Characterization of NsZnO-3 as such 
The aim of this investigation was to synthesize and characterize a 
nanostructured ZnO material able to act as drug reservoir. A traditional 
precipitation method was adopted and NsZnO-3 was obtained starting from 
Zinc acetate dehydrate (Zn(CH3COO)2 · 2 H2O) as a precursor and a solution 
of Potassium Hydroxide (KOH) in methanol (CH3OH) as solvent. Generally, 
methanol is selected in this type of synthesis for two main reasons. Firstly, it 
has a high dielectric constant and low ligand affinity 6, which make it an 
excellent solvent for Zinc acetate dehydrate, an electrolytic salt commonly 
used for synthesizing colloidal ZnO nanoparticles. Secondly, methanol can act 
as ligands to help to control the morphology of ZnO. For instance, it is reported 
that methanol is a better solvent than other alcohols for growing spherical ZnO 
crystals 6, which is an important parameter in biological applications. During 
the precipitation synthesis in basic conditions, a sequence of different chemical 
reactions take place. Briefly, the complete hydrolysis of zinc acetate in 
equilibrium with condensation reactions endows to the formation of a colloidal 
suspension of ZnO particles.  The hydrolysis of Zinc Acetate in solution 
produces acetate ions and zinc ions, helped by the heating. The abundance of 
electrons in the oxygen atoms makes the hydroxyl gr$oups (-OH) of alcohol 
molecules bond with the zinc ions. The overall chemical reaction to form ZnO 
nanopowder as follow: 
 
(Zn(CH3COO)2·2H2O) + 2KOH  ZnO + 2CH3CO2K + H2O 
 
During the hydrolysis reaction, also the intermediate Zinc hydroxide 
acetate is formed in the presence of H2O and OH ions, that is transformed into 
ZnO during the reaction 7. After the synthesis, the sample was washed and then 
dried in an oven. At the end of this treatment, a white powder was obtained. 
NsZnO-3 as such was carefully characterized, before the loading with CTZ. 
Figure 4.1 displays pictures of the as-prepared NsZnO-3, collected through 
FESEM analysis. At lower magnification, the material appears in form of 
micrometric platforms (≈ 10 μm) without any precise shape. However, 
increasing the magnification, it is possible to observe a sub-micrometric 
organization of this larger aggregates in smaller spherical nanoparticles with 
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homogenous size (≈ 20 nm). The morphology obtained in this investigation 
can be considered suitable for a biological application, not including any rod-
like particles, often related to toxicological issues.. 
Figure 4.1. FESEM images of NsZnO-3 as synthesized, at different magnification (from 




Figure 4.2 reports the XRD patterns of NsZnO-3 as such.  A highly 
crystalline single hexagonal phase of wurtzite structure was confirmed. The 
five main reflection peaks (100), (002), (101), (102) and (110) and the intensity 
distribution of the peaks are consistent with those of the standard card for the 
hexagonal phase ZnO (JCPDS ICDD 36-1451). The characteristic peaks of the 
synthesis precursors do not appear in the XRD pattern of NsZnO-3, meaning 
that pure ZnO can be obtained through the above-described synthetic method. 
Moreover, the crystallites size determined using the Scherrer equation are was 
about 18 nm (Table 2.1). 
 
 
Table 4.1 Crystallite dimensions (nm) determined from application of the 
Scherrer equation to selected peaks position of NsZnO-3 
 






FTIR spectroscopy was performed on the as-prepared NsZnO-3 after a 
treatment in vacuum at room temperature for 1 hour. Panel B of the Figure 4.2 
reports the FTIR spectrum obtained. The main peaks displayed are consistent 
with the literature 2. In particular, the presence of O–H and C=O groups on the 
surface is evident.  The broad peak around 3400 cm-1 is ascribed to the O–H 
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stretching, while the narrower peak at 1413 cm-1 can be assigned to O–H 
bending 8. The peaks at 1583 cm-1 and at 1334 cm-1  can be related to carbonate-




Figure 4.2. X-ray diffraction pattern (panel A) and FTIR spectrum of NsZnO-3 as-
synthesized (panel B)  
 
In order to develop a good drug reservoir material, a porous structure with 
a high surface area is desirable. For this purpose, N2 adsorption–desorption 
analysis was carried out on NsZnO-3 as-synthetized to evaluate its surface area 
(SSABET), pore volume and pore size distribution before the drug loading steps. 
Figure 4.3 shows the isotherm of NsZnO-3, which is characterized by a regular 
IV type hysteresis, which is associated with capillary condensation taking 
place in mesopores. The specific surface area (m2/g) and the pore volume 
(m3/g) of the sample were found to be 57 m²/g and 0.135 m3/g, as reported in 
Table 4.2.The pore size distribution resulted homogenous at 10.5 nm, 
confirming the mesoporous nature of the NsZnO-3 material. 
4.3.2 Characterization of the CTZ-loaded NsZnO-3 
Two different techniques were used to load CTZ inside the NsZnO-3, in 
order to compare the innovative supercritical fluid technology to a traditional 
approach, investigating advantages and drawbacks. After the ScCO2 process a 
ready-to-use drug loaded material was obtained, without any further 
purification process. TG analyses of the NsZnO-3 material loaded with CTZ 
(CZT@NsZnO-3) allowed the amount of CTZ to be evaluated, which 
corresponds to 7% w/w (Table 4.2). As far the N2 adsorption analysis is 
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concerned, Figure 4.3 shows the isotherms of NsZnO-3 materials before and 
after the loading of CTZ through scCO2 and the values of surface area, pore 
volume and pore sizes are reported in Table 4.2. 
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Table 4.2 Surface area, pore volume and pore sizes values before and after the 





Figure 4.2. Panel A: N2 adsorption - desorption isotherm of NsZnO-3, before 
(curve 1) and after (curve 2) supercritical impregnation. Panel B: pore size distribution 
of NsZnO NsZnO-3, before (curve 1) and after (curve 2) supercritical impregnation. 
 
As illustrated in Table 4.2, the BET specific surface area decreased from 
57 m2/g, for the as-synthetized material, to 18 m2/g, after CTZ loading, 
whereas the pore volume decreased from 0.135 cm3/g to 0.040 cm3/g. 
Moreover, the pore sizes value decreased from 10.5 to 6.8 nm. The decrease 
of BET specific surface area and pore volume upon CTZ loading for both 
samples is ascribed to the adsorption of CTZ molecules on the surface of 
NsZnO-3 material. These remarkable results confirmed the feasibility of using 
the scCO2 technology as drug loading approach to obtain ZnO-based CTZ 
carrier, as already emerged for the other materials considered in this thesis. For 
the sake of comparison, NsZnO-3 was also loaded with CTZ through a 
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traditional approach, consisting in the adsorption of the drug from an ethanolic 
solution. Briefly the material was incubated for 24 hours under magnetic 
stirring with a CTZ ethanolic solution. After 24 hours, a separation process by 
centrifuge was carried out, in order to divide the drug loaded material 
(CTZ@NsZnO-3 trad) from the solution of not entrapped CTZ. The entrapment 
efficiency (%) of the NsZnO-3 resulted 33%. The precipitate, consisting in the 
CTZ loaded material, was used to determine its drug content by TG analysis, 
as described later. 
 
Figure 4.3 XRD patterns of the samples NsZnO-3 after supercritical drug 
impregnation and after traditional drug loading, in comparison with the material as 




XRD analyses were performed to investigate the form of the drug inside 
the NsZnO-3 material pores. Figure 4.3 reports the XRD patterns of the 
samples NsZnO-3 after supercritical drug impregnation and after traditional 
drug loading, in comparison with the material as-such and the plane CTZ. In 
both cases, the drug loaded materials show the typical hexagonal wurtzite 
structure. The crystallites size determined using the Scherrer equation are 
similar to values reported in Table 4.1. No additional diffraction peaks of the 
crystalline CTZ are observed in both cases. This evidences that the loaded drug 
molecules are not assembled in the crystalline structure. Despite of the two 
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different drug loading approaches, the complete amorphization of CTZ was 
observed in both cases. As underlined in the previous chapter, this behavior is 
ascribed to the interaction between the drug molecules and the ZnO surface. It 
is widely accepted that the amorphization of the drug molecules plays a key 
role in increasing their dissolution rate and solubility 1. This represents a 
further proof that scCO2 can be considered as much efficient as the traditional 
drug loading methods, with the advantage of being a greener and cleaner 
approach. Morevoer, it is worth of noting that the XRD patterns confirmed 
again the lack of reactivity between ZnO and the CO2 used as solvent in the 
drug loading phase. As highlighted in the previous chapter, this result has not 
been taken for granted, considering that the well-known reaction between ZnO 
and CO2, to give ZnCO3 as final product 
10,11. Since the same conclusions were 
achieved study the CTZ incorporation into NsZnO-1 and NsZnO-2 samples, it 
is possible to affirm that scCO2 can be equal effective in the drug loading of 
different ZnO nanostructures, not causing any structure modification of the 
starting nanostructured ZnO and proven the feasibility in using this technology 
with ZnO-based materials. This represents an outstanding conclusion, 
considering that, to the best of our knowledge, this is the first time that the 
loading of drugs on NsZnO by means of scCO2 has been studied.  
After the supercritical-mediated drug loading step, FTIR spectroscopy was 
performed to i) confirm the successful loading of CTZ into NsZnO-3 and ii) to 
study the effect of the supercritical carbon dioxide on the NsZnO-1 surface. 
Figure 4.4 reports the FTIR spectra of NsZnO-3 as such, CTZ@NsZnO-3, 
NsZnO-3 as-such after a scCO2 treatment and pure clotrimazole. FTIR spectra 
of the as-prepared NsZnO-3 and of pure clotrimazole has been previously 
reported and discussed, respectively in Figure 4.2 and Figure 3.8. In order to 
evaluate the effect of the supercritical carbon dioxide on the mesoporous 
NsZnO-3 surface, FTIR analysis was also performed on the sample as-such 
after a treatment in scCO2 for 12 hours, at 100°C and 25 MPa. As emerged in 
the cases of NsZnO-1 and NsZnO-2, the spectrum shows an intensity growth 
of the absorption between the 1600 and 1000 cm-1 due to carbonate-like species 
caused by the adsorption of CO2 on ZnO surface 
9. Notwithstanding the evident 
CO2 adsorption on the surface of the sample NsZnO-3 as -such after the 
treatment in scCO2, the FTIR spectrum of the CTZ@NsZnO-3, impregnated 
through scCO2 process, shows clearly the characteristic peaks of the drug. 
Moreover, the growth of the absorption region between the 1600 and 1100 cm-
1 caused by the adsorption of CO2 on CTZ@NsZnO-3 surface results less 
118 Chapter 4 
 
intense than the NsZnO-3 as-such. In summary, the evidences drawn from the 
FTIR spectroscopy studies endow to confirm the same conclusions highlighted 
for the other ZnO nanostructures: i) a successful loading of CTZ into NsZnO-
3 was achieved by supercritical process; ii) the presence of the drug reduces 
the chemisorption of CO2. 
 
Figure 4.4 FTIR spectra of the samples NsZnO-3 as-synthetized, NsZnO-3 
after a scCO2 treatment, CTZ@NsZnO-3 and crystalline clotrimazole (CTZ). 
 
In order to evaluate the amount of CTZ, TG analyses of the NsZnO-3 
samples loaded with CTZ (CTZ@NsZnO-3) were performed both after scCO2 
impregnation and after traditional adsorption loading from ethanolic solution. 
The characteristic curves are shown in Figure 4.5. The percentages calculated 
as loss of weight after TG analysis indicated that after scCO2 technique the 
drug loading corresponded to about 7% w/w for CTZ@NsZnO-3 while after 
traditional adsorption the drug loading was found to be 8% w/w for 
CTZ@NsZnO-3(trad). Considering the drug loading amount of the sample 
CTZ@NsZnO-3 loaded with supercritical technology, it is important to 
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underline some considerations. As mentioned above, the loss of weight (≈ 3%) 
obtained from the TG analysis of the sample NsZnO-3 as-such after scCO2 
treatment (Fig.4.5, red curve) could be ascribed to the loss of CO2 adsorbed 
onto the material surface. Also in this case, this result confirmed the evidence 
collected by FTIR analysis (Fig. 4.4), from which the adsorption of CO2 on the 
NsZnO-3 surface after the supercritical treatment was clearly displayed by the 
spectrum. Nevertheless, notwithstanding this evidence, it is important to take 
into consideration that the drug plays a protective role towards the NsZnOs 
surfaces, decreasing the adsorption of CO2. This assessment clearly emerged 
from the FTIR analyses of the drug loaded samples and was also reported in 
other research works 12. Consequently, it is reasonable to consider that the loss 
of weight of the sample CTZ@NsZnO-3 is mostly related to the amount of 
CTZ hosted inside the NsZnO-3 nanostructure and only in a small part to the 
contribution of CO2.  In conclusion, from the previous considerations it is 
possible to assess that the amount of CTZ impregnated inside the sample 
NsZnO-3 after supercritical process, ranges from 4% (Fig. 4.5, red curve) to 
7% (Fig. 4.5, green curve) considering the CO2 adsorption or not considering 
the CO2 adsorption, respectively. 
 
Figure 4.5 TG analyses of NsZnO-1 as-such (black curve), NsZnO-1 as-such 
after scCO2 treatment (red curve), NsZnO-1 loaded with CTZ after scCO2 (green 
curve) and after traditional approach (blue curve) 
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In term of CTZ amount hosted into the mesoporous NsZnO-3 material 
emerged that using traditional approach a slight higher amount of drug was 
impregnated, equal to about 8% (Fig. 4.5, blu curve).  
The comparison between the scCO2-based drug loading with the 
traditional absorption method leads to some interesting conclusions, which 
highlight the remarkable advantages of using scCO2 technology. Firstly, as 
mentioned above, after the scCO2 process a ready-to-use drug loaded material 
was obtained, without any further purification process. The possibility to skip 
the purification step results in a more time-effective drug loading procedure. 
Secondly, the scCO2 is a green solvent, which allows to dissolve many poorly-
water soluble molecules. This represents a great advantage, considering that 
huge amounts of organic solvent are usually required in the traditional drug 
loading method to incorporate poorly-soluble drug into carriers. Particularly, 
the use of organic solvents could remarkably affect the scale-up of a drug 
carriers production, when toxic solvents are required. 
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4.3.3 Preliminary in vitro drug release study 
The lack of irreversible adsorption or occlusion of CTZ molecules in the 
NsZnO-3 material was evaluated by a preliminary in vitro drug release study. 
For this purpose, the ability of NsZnO-3 in releasing the loaded CTZ was 
investigated using a multi-compartmental rotating cell, equipped by 
semisynthetic membrane. Figure 4.6 displays the cumulative release curves of 
CTZ from CTZ@NsZnO-3scCO2 loaded through scCO2 (black curve) in 
comparison with CTZ@NsZnO-3trad   loaded by traditional incubation method. 
From the evaluation of the two clotrimazole release curves, it emerged that the 
sample CTZ@NsZnO-3trad displayed a slower drug release kinetic than 
CTZ@NsZnO-3 scCO2. For instance, at 30 minutes from the beginning of the 
experiment, the amount of CTZ released from CTZ@NsZnO-3scCO2  was more 
than double the quantity released from CTZ@NsZnO-3trad , 51% and 19%, 
respectively. This behaviour could be ascribed to aggregations phenomena that 
may occur between the ZnO particles during the traditional drug loading in 
solution, during which the drug may be "trapped" inside the material. On the 
contrary, after scCO2-mediated drug incorporation a faster release may be 
obtained due to the presence of drug on the surface of the nanomaterial. In 
conclusion, this preliminary in vitro release study clearly showed that CTZ is 
not irreversibly confined in the NsZnO-3, confirming the role of NsZnO as 
drug delivery carrier, as previously demonstrated in the CTZ case study 1. 
Moreover, a more efficient drug distribution inside the carrier was gained 
through scCO2 technology. 
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Figure 4.6 In vitro drug-release profiles of CTZ from CTZ@NsZnO-3 loaded through  
supercritical technology (black curve) a9nd after traditional loading (grey curve) 
 
4. 4 Conclusions 
In summary, the possibility to develop mesoporous ZnO particles as 
reservoir of drugs was investigated. A simple synthesis was carried out 
obtaining a material with significant high surface area (56 m2/g) and suitable 
morphology for the biomedical applications (NsZnO-3). Clotrimazole (CTZ) 
was selected as drug model, because of its hydrophobic profile, which usually 
requires the utilizations of organic solvents, and the possibility to enhance its 
topical therapeutic activity in combination with ZnO.  The scCO2 technology 
was studied as greener alternative technology to carry out the drug loading step 
of the mesoporous NsZnO-3. A traditional drug loading method was also 
performed, adopting the absorption from ethanolic solution approach, for sake 
of comparison. The physico-chemical characterization of NsZnO-3 before and 
after the loading of CTZ confirmed that the scCO2 process does not 
significantly affect the structure of the materials. XRD analysis revealed that 
CTZ was distributed in the NsZnO-3 carrier in amorphous form and that the 
wurtiztic phase of ZnO was preserved after scCO2 process, without any 
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structural modification after the contact with CO2. FTIR analysis confirmed 
the successful interaction between the material and the drug and highlighted a 
protective role of the drug molecules towards the NsZnO surface during the 
supercritical process. A similar CTZ amount was hosted in the mesoporous 
NsZnO-3 by scCO2-mediated approach and by traditional absorption method. 
Furthermore, the capability of the materials in releasing CTZ was investigated. 
Results revealed that CTZ is not irreversibly confined in the NsZnO-3 support, 
that can act as a drug delivery carrier. This might play a key role in several 
biological applications where the bioavailability of poorly-water-soluble drugs 
is still a challenging issue.  Different CTZ release profiles were obtained 
comparing NsZnO-3 loaded with the two different methods, underlining a 
possible better dispersion of the drug in the material after scCO2 process. In 
addition to this, the comparison between the scCO2-based drug loading with 
the traditional absorption method leads to some interesting conclusions, which 
highlight the remarkable advantages of using scCO2 technology. Firstly, as 
mentioned above, after the scCO2 process a ready-to-use drug loaded material 
was obtained, without any further purification process. The possibility to skip 
the purification step results in a more time-effective drug loading procedure. 
Secondly, the scCO2 is a green solvent, which allows to dissolve many poorly-
water soluble molecules. This represents a great advantage, considering that 
huge amounts of organic solvent are usually required in the traditional drug 
loading method to incorporate poorly-soluble drug into carriers. Particularly, 
the use of organic solvents could remarkably affect the scale-up of a drug 
carriers production, when toxic solvents are required. 
The investigation described in this chapter was a further proof that 
innovative procedures to obtain nanostructured ZnO-based drug carriers with 
the support of scCO2 technology can be considered as a promising route. 
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 Chapter 5 
Antimicrobial  activity  of  
NsZnO-1, NsZnO-2 and NsZnO-3 




As mentioned previously in this PhD thesis, the choice of ZnO as material was 
driven by several factors, which can be summarized as follow: 
 
i) in Material Science, ZnO is recognised as a multifunctional 
material possessing unique physical and chemical properties (i.e. a 
band gap of 3.28 eV, high exciton binding energy of 60 meV), 
which make it suitable for many attractive applications (i.e 
electronic, optoelectonic, sensoristic, photocatalysis, biomedical 
etc)1,2; 
ii) from a biological point of view, ZnO is an outstanding material, 
due to its intrinsic properties, such as low toxicity, biocompatibility 
and biodegradability3,4.  
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Therefore, the fundamental idea of this research project was based on the 
possibility to combine these two different aspects to develop multitasking ZnO-
based drug delivery systems. ZnO is particularly suitable for this role, because 
its nanostructure can be tailored to host drug molecules and because it can offer 
several biological advantages deriving from its intrinsic properties, such as its 
antimicrobial activity 5. It is well-established in the literature, that ZnO 
displays significant bactericidal properties over a broad range of Gram-positive 
as well as Gram-negative bacteria 6. As already described, several mechanisms 
such as generation of reactive oxygen species (ROS), Zinc ion release, 
membrane dysfunction and nanoparticles penetration are involved in the 
generation of this antibacterial activity. Moreover, it is worth of noting, that 
physicochemical parameters of the ZnO nanomaterials, such as size, 
morphology and specific surface area, remarkably affect the antibacterial 
properties 5. For instance, high surface area and small crystallite sizes of the 
ZnO nanomaterials can greatly enhance their antibacterial properties 7.  
These intrinsic characteristics added to the therapeutic activity of the 
hosted molecule make ZnO a promising material to build powerful drug 
delivery system for many biological applications 8. In fact, as mentioned 
above, the antimicrobial properties of ZnO can be attractive for its use as an 
antimicrobial preservative of pharmaceutical or cosmetic formulations 9. 
In the previous chapters, three nanostructured ZnO powders with different 
morphologies and physico-chemical parameters were synthetized and 
characterized. This chapter is focused on the study of the three developed 
NsZnOs from a biological point of view, in order to highlight their intrinsic 
properties. Particularly, their antimicrobial activity against different microbial 
strains were investigated, and the results were correlated to their physico-
chemical parameters. Also the in vitro Zn2+ release profiles from the NsZnO 
matrices was evaluated, due to the important role of the Zinc in several 
physiological mechanisms, such as acting as cofactor in enzymatic reactions 
and  being cytotoxic to microbial agents 10–12.   
 
The antimicrobial tests were performed by the research group of Prof. 
Vivian Tullio at the Department of Public Health and Pediatrics of the 
University of Turin. I gratefully acknowledge Dr. Janira Roana for her 
precious collaboration. 
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5.2 Experimental 
5.2.1 Microbial strains and culture conditions 
The antibacterial activity of NsZnO-1, NsZnO-2 and NsZnO-3 samples 
was tested against two bacterial strains. In particular, Staphylococcus aureus 
(ATCC 29213) and Klebsiella pneumoniae (ATCC 700603) were selected as 
Gram-positive and as Gram-negative bacteria, respectively. Moreover, the 
antifungal activity of NsZnO-1, NsZnO-2 and NsZnO-3 samples was 
investigated against Candida albicans (ATCC 90023), the most common 
opportunistic fungal pathogen of humans. The strains were purchased from 
American Type Culture Collection (ATCC) (Manassas,Virginia, USA).  
5.2.2 Inocula preparation  
Microorganism inocula were prepared by picking two to three colonies 
from an overnight culture of S.aureus/K.pneumoniae on Brain Hearth Infusion 
Agar (BHA,Merck KGaA, Darmstadt, Germany) or of C. albicans on 
Sabouraud dextrose agar (SABA, Merck KGaA) at 37 °C, and suspending 
them in 5 mL of 0.85 % normal saline, to yield a stock suspension 
of≈5×108cells/mL for bacteria or 5×106cells/mL for yeast by 0.5 McFarland 
standard. A working suspension was made by a 1:10 dilution of the stock 
suspension in RPMI-1640 without sodium bicarbonate and with L-glutamine 
(Invitrogen, San Giuliano Milanese, Milano, Italy), buffered to pH 7.0 with 
0.165 M morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich, Milan, 
Italy) at a concentration of 0.165 mol 1-1 and supplemented with glucose 18 
g/L, for yeast or by a 1:1000 dilution for bacteria in Mueller Hinton  broth 
(MHB,Merck KGaA). The microbial concentration of S. aureus and K. 
pneumoniae suspensions resulted in 105 CFU mL−1 while  C. albicans 
suspension was prepared at a concentration of 103 CFU mL−1, confirmed by 
colony counts in duplicate. 
 
5.2.3 In vitro antimicrobial assays  
Broth microdilution method 
The antimicrobial activity of NsZnO-1, NsZnO-2 and NsZnO-3 was 
determined using a broth microdilution method susceptibility assay, according 
to CLSI document M27-A3 for yeasts 13. The aim of the broth dilution method 
is to determine the lowest concentration of the assayed antimicrobial that 
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inhibits the visible growth of the microrganism being tested (MIC, expressed 
in μg/ml). In this investigation, MIC determination was performed by serial 
dilution using 96-well microtitre plates (Sarstedt, Milan,Italy). Stock 
suspensions of NsZnO prepared at 30000 µg/ml (w/v) in PBS were dispersed 
for 1 h using an ultrasonic bath, in order to minimize sedimentation of NsZnO 
particles. Doubling dilutions of the ZnO ranging from 15000 to 30 µg/ml were 
prepared in 96-well microtitre trays in MHB for bacteria or in RPMI-1640 with 
MOPS for yeasts. After inoculum addition (0.1 mL), the trays were incubated 
under normal atmospheric conditions at 37 °C for 24 h. A sterile medium 
incubated under the same conditions was used as a blank, while the medium 
inoculated with the target microorganisms (without NsZnO) was used as a 
positive control of growth. All determinations were performed in duplicate. 
The lowest concentration of the NsZnO showing complete inhibition of visible 
growth was defined as MIC. The absence of visible growth was determined 
under a binocular microscope. 
The minimal bactericidal (MBC) or fungicidal (MFC) concentration of 
NsZnO, was determined by subculturing 10 μL of broth taken from all the 
wells without visible growth onto SAB agar plates that do not contain the test 
agents. After incubation for 24 h at 37 °C, MFC was defined as the lowest 
concentration of ZnO resulting in the death of 99.9 % of the inoculum in no 
growth on subculture. 
 
Enumeration of viable organisms 
The antibacterial experiments were also performed by the enumeration of 
viable organisms using a method described in the literature 14. Briefly, the 
bacterial cells were grown overnight in Brain Heart Infusion broth (BHI,Merck 
KGaA) or Sabouraud Dextrose Broth (SABB,Merck KGaA) at T = 37°C. The 
cells were harvested by centrifugation, washed, resuspended in a PBS buffer 
solution, suspended in 5 mL of 0.85 % normal saline and diluted to yield a 
stock suspension of ≈ 5×105cells/mL for bacteria and for yeast. All the NsZnO 
samples with concentration of 13000 µg/ml, suspended in a sterilized PBS, 
were incubated with bacterial or yeasts suspension in a shaker incubator at T 
= 37◦C for 24 h. PBS solution was used as negative control. All samples were 
serially diluted and 100  µL of bacterial/yeasts suspension was drawn from 
each sample tube, spread on the BHA or SAB agar plate in duplicate and finally 
129 Chapter 5 
 
incubated at T = 37°C for 24 h for colony forming. The viable colonies were 
counted and reported as colony forming units (CFU) per ml. 
5.2.4. In vitro Zinc Ions release  
Zinc ion release from NsZnO-1, NsZnO-2 and NsZnO-3 was studied using 
vertical Franz diffusion cells and synthetic skin (Dow Corning, 7-4107, 
Silicone Elastomer Membrane). Each NsZnO was singualarly employed as a 
donor phases. The receiving phase consisted of PBS buffer, at pH 7.4. The 
apparatus was maintained at 33°C with stirring, and at scheduled times the 
receiving phase was withdrawn and entirely substituted with fresh receiving 
phase. Zinc ion quantification was performed for each sample using 
inductively coupled plasma mass spectrometry (ICP-MS).  
130 Chapter 5 
 
5.3. Results and discussion 
In order to investigate the antimicrobial activities of the NsZnO samples, 
two different experimental techniques were adopted: broth microdilution 
method and the enumeration of viable organisms’ method. Through the former 
approach, the minimum inhibitory concentration (MIC) and the minimum 
bactericidal concentration (MBC) were determined, as indicated in Table 5.1. 
The MIC is defined as the lowest concentration of NsZnO that leads to full 
inhibition of bacterial growth after 24 hours of contact and is expressed in 
µg/ml (Table 1.1). The minimum bactericidal concentration (MBC) is 
complementary to the MIC, and it expresses the lowest concentration of an 
antibacterial agent required to kill a particular bacterium. It indicates the lowest 
concentration of antibacterial agent that reduces the viability of the initial 
bacterial inoculum by ≥99.9%.  
The latter method allowed the determination of the antimicrobial activity 
of the NsZnOs expressed as CFU/ml of each strain, by counting the viable 
microbial colonies after 24 h of incubation with the NsZnOs  (Fig. 5.1 and 
Table 5.2).  
 
Table 5.1 Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal 
Concentration (MBC) of NsZnO-1, NsZnO-2 and NsZnO-3 determined for the S. 















NsZnO-1 120 > 470 470 1875 >15000 
NsZnO-2 230 > 470 930 > 3750 >15000 
NsZnO-3 930 > 3750 930 1875 >15000 
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Table 5.2 Comparison of antibacterial activities of NsZnO-1, NsZnO-2 and 
NsZnO-3 against S. aureus, K. pneumoniae and C.albicans determined with the 
enumeration of viable microorganism assay and expressed in CFU/ml.  
 
Microbial strain S. aureus K. pneumoniae C.albicans 
NsZnO-1 10 UFC/ml 1.62x107 UFC/ml 1.85x105 UFC/ml 
NsZnO-2 1.65x104 UFC/ml 2.66x108 UFC/ml 1.43x106 UFC/ml 
NsZnO-3 2.03x104 UFC/ml 5.12x108 UFC/ml 2.19x105 UFC/ml 
 
As emerges from Table 5.1, the broth dilution method clearly revealed that 
the three ZnO nanostructures exhibited a stronger bactericidal activity on the 
Gram-positive S. aureus than the Gram-negative K. pneumoniae. Since ZnO 
suspensions appeared cloudy in the case of C.albicans, it was not possible to 
determine the MIC from the visual appearance of the medium. 
Figure 5.1 reports the results of the enumeration of viable organisms 
assessed through CFU assay. As emerges from Fig. 5.1 - A, the bactericidal 
activity of NsZnO-1 against S. aureus (expressed in Log CFU/ml) was greater 
than that achieved by NsZnO-2 and NsZnO-3 (1 vs 4,22 and 4,31, 
respectively). The same trend is evident from Figure 5.1- B, where the Log 
CFU/ml of bacterial load reduction against K. pneumoniae was 7,21, 8,42 and 
8,71 for NsZn0-1, NsZnO-2 and NsZnO-3, respectively. Despite the failure of 
the broth dilution technique, the enumeration of viable organisms’ method 
resulted efficient in the determination of the antifungal activity. The results are 
displayed in Figure 5.1-C. No significant difference was found between the 
NsZnO-1 and NsZnO-3 log counts recovered for C.albicans (5,27 vs 5,34), 
while NsZnO-2 was able to slow down the bacterial growth only of 6.15 log. 
In conclusion, the CFU assay confirmed the results obtained through the broth 
dilution method, revealing that the three ZnO nanostructures exhibited a 
stronger microbicidal activity towards the Gram-positive S. aureus than the 
Gram-negative K. pneumoniae and yeast C. albicans (Figure 5.1).  
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Figure 5.1 Comparison of antibacterial activities of NsZnO-1, NsZnO-2 and NsZnO-
3 against S. aureus (A), K.Pneumoniae (B) and C.albicans (C) expressed in Log 
CFU/ml 
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These experimental evidences agree with the conclusions of Reddy et al. 
15 and Tayel et al. 16 and dismisse the conclusions of Pasquet et al. 7 and 
Applerot et al. 16. In detail, Tayel and Reddy explained that the peptidoglycan 
envelope of Gram-positive bacteria may promote ZnO attachment onto the cell 
wall whereas components of Gram-negative bacteria may oppose this 
attachment.  
Among the NsZnOs investigated, the sample NsZnO-1 showed the higher 
antimicrobial activity compared to NsZnO-2 and NsZnO-3. This trend was 
confirmed by both the in vitro tests carried out. This phenomenon could be 
ascribed to the crystallite sizes of the nanoparticles, which has been reported 
to greatly impact their antimicrobial activity, probably because of a greater 
accumulation of the nanoparticles inside the cell membrane and cytoplasm 6. 
In fact, from the previous characterization, the crystallite sizes were found to 
be 15 nm for NsZnO-1, 30 nm for NsZnO-2 and 18 nm for NsZnO-3. This 
observation can be reinforced by the results obtained against C. Albicans, 
against which NsZnO-1 and NsZnO-3 possessed a higher antifungal activity 
than NsZnO-2. This is clearly showed in Figure 5.2, where the result of the 
CFU assay, expressed in CFU/ml was used to correlate the crystallite sizes of 
NsZnOs with the antifungal activity against C.albicans. These conclusions are 
consistent with the study of Lipovsky et al. 17, who suggested that ZnO 
nanoparticles display a marked activity against C. albicans and that the 
cytotoxic effect is size dependent. In fact, NsZnO-1 and NsZnO-3 are 
characterized by lower crystallite sizes than NsZnO-2.  
 
Figure 5.3 shows a comparison of the antibacterial activities of the three 
NsZnOs against S. aureus and K. pneumoniae, while the physico-chemical 
parameters of the three materials are summarized in Table 5.3. It worth 
noticing that the sample NsZnO-1, characterized by the smallest crystallite 
sizes, the highest SSA and pore volume and by the largest pore sizes possessed 
the best antimicrobial activity against all the investigated strains, S. aureus, K. 
pneumoniae and C.albicans. This result is in agreement with what reported in 
the literature, where it is well assessed that an enhanced antimicrobial activity 
depends on small crystal size, large pore size and high porosity 7.  
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Figure 5.2 Influence of the crystallite sizes on the antifungal activity of NsZnO-
1, NsZnO-2 and NsZnO-3. The plot reports the viable colonies (CFU/ml) of 
C.albicans after 24 hours of incubation with NsZnOs correlated to the crystallite sizes 
of NsZnOs. 
 
 Table 5.3 Summary of the main physicochemical parameters of NsZnO-1, 
NsZnO-2 and NsZnO-3. 
 
 NsZnO-1 NsZnO-2 NsZnO-3 
Specific area (m2/g) 66 19 56 
Mean pore size 
(nm) 
27 5 10 
Volume of pores 
(cm3/g) 
0.230 0.050 0.140 
Crystallite size 
(nm) 
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As far as the antibacterial activities of NsZnO -2 and NsZnO -3 are 
concerned, the enumeration of viable microorganism’ method suggested that 
NsZnO-2 and NsZnO-3 possess an equivalent antibacterial activity, despite of 
the different MIC values. Since their physicochemical parameters are much 
different, the similar activity could be ascribed to the similar morphologies of 
NsZnO-2 and NsZnO-3, both composed by ovoidal assembled nanoparticles 
(Figure 5.4).  
Moreover, as described in the introduction of this thesis, among the key 
mechanisms influencing the antibacterial activity of nanostructured ZnO, it is 
important to consider the release of Zn2+ ions. In this investigation, a simple 
experiment was carried out to study the Zinc ions release from NsZnO-1, 
NsZnO-2 and NsZnO-3, using vertical Franz diffusion cells equipped with 
synthetic skin. The results drawn from the Zinc ion quantification are shown 
in Figure 5.5. The higher amount of Zn2+ ions was released from NsZnO-1 and 
NsZnO-3, confirming the predominant role of the crystallite sizes affecting the 
antibacterial activity. Furthermore, the in vitro Zn2+ release study demonstrated 
the ability of all the three investigated NsZnOs in releasing Zn2+, highlighting 
their potential use as multitasking antimicrobial drug carriers. Furthermore, it 
is well-established in the the literature that also the ROS release into the 
medium by the photocatalytic effect dependes on the crystallinity of the ZnO 
nanostructure 18. Consequently, it is logic to consider that the higher activity 
of NsZnO-1 could also be ascribed to the higher amount of ROS released.  
  






Figure 5.3 The antibacterial activity of NsZnO-1, NsZnO-2 and NsZnO-3 
against S. aureus and K. pneumoniae expressed as MIC  (µg/ml ).  
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 Figure 5.4 Fesem pictures of NsZnO-1 (uppest panels), NsznO-2 (middle 
panels) and NsZnO-3 (lowest panels). 
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Figure 5.5 In vitro Zn2+ ion release study from NsZnO-1, NsZnO-2 and NsZnO-
3 
 
5.4 Conclusions  
 
This chapter was focused on the evaluation of the antimicrobial activity of 
the three NsZnOs developed in this thesis project. Both the antibacterial and 
antifungal activity of NsZnO-1, NsZnO-2 and NsZnO-3 samples was tested 
against two bacterial strains, Staphylococcus aureus and Klebsiella 
pneumoniae, and against Candida albicans, the most common opportunistic 
fungal pathogen of humans. In order to investigate the antimicrobial activities 
of the NsZnO samples, two different experimental techniques were adopted: 
broth microdilution method and the enumeration of viable organisms’ method. 
The results of this investigation revealed that the three ZnO nanostructures 
exhibited a stronger microbicidal activity towards the Gram-positive S. aureus 
than the Gram-negative K. pneumoniae and yeast C. albicans, in accordance 
to the literature. Morevoer, the sample NsZnO-1, characterized by the smallest 
crystallite sizes, the highest SSA and pore volume and by the largest pore sizes 
possessed the best antibacterial activity against all the investigated strains, S. 
aureus, K. pneumoniae and C.albicans. The in vitro release of Zn2+ ions from 
the three NsZnOs was also studied. The results drawn from the Zinc ion 
quantification showed that the higher amount of Zn2+ ions was released from 
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NsZnO-1 and NsZnO-3, confirming the predominant role of the crystallite 
sizes in the enhancement of the antibacterial activity.  
The antimicrobial activity of the three NsZnOs was successful determined 
in this study, highlighting their potential use as multitasking antimicrobial drug 
carriers. The results of this scientific investigation build up the fundamentals 
for the next steps of this research project. In fact, innovative dermatological 
formulations are going to be develop, including in their composition these 
multitasking NsZnO-based drug carriers. 
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 Chapter 6 
Composite materials for wound 
healing: preparation and 
characterization of in situ cross-
linking bionanocomposite 
hydrogels. 
This chapter deals with research carried out in the Department of 
Chemistry and Materials Science Institute at Lancaster University (United 
Kingdom), under the supervision of Dr. John Hardy, for a 6-month period as a 
visiting PhD student. This highly interdisciplinary collaborative project aimed 
to develop composite materials for wound healing. The final result of the 
project will be a multifunctional wound dressing, based on the combination of 
different classes of materials and their properties, to address important public 
health issues (i.e. microbial infection in wound healing). The choice of the 
collaboration topic was driven by the will to combine polymer-based 
biomaterials (the expertise of Dr Hardy), with the ZnO nanostructures studied 
in this PhD thesis. Briefly, the main objectives of the project are: 
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1. To develop robust bionanocomposite hydrogels based on chitosan, zinc 
oxide and conducting polymers. 
2. To characterize the chemical, electrical and mechanical properties of the 
hydrogels. 
3. To carry out in vitro drug delivery studies (e.g. painkiller, anti-
inflammatory, antimicrobial) and in vitro cell culture experiments of a wound 
healing paradigm with/without electrical stimulation. 
 
 
Figure 6.1.  Schematic illustration of the multicomposite conductive material and its 
peculiar properties, which play a key role in wound healing process. 
 
The research work reported in this chapter represents a preliminary 
investigation, inherent to the first objective of the main project. In particular, 
during my research visit at the Lancaster University, the possibility to obtain 
materials with hydrogel-like properties based on modified polysaccharides 
able to assist the wound healing process was investigated. Moreover, 
preliminary composite hydrogels were prepared, by the dispersion of NsZnO, 
developed at Politecnico di Torino, with the purpose to obtain antibacterial 
biomaterials. We gratefully acknowledge financial support from the UK 
Biotechnology and Biological Sciences Research Council BBSRC and a 
Researcher Mobility Grant from the Royal Society of Chemistry (RSC) which 
facilitated the research to be undertaken. 
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6.1 Introduction  
 
Wound dressings are materials designed to cover wounds, prevent 
infection and help injured tissues to repair and regenerate1. A variety of 
different materials have been investigated for application as wound dressings 
designed to improve the healing process and thereby the rate of healing when 
compared to traditional systems. Consequently, wound dressings are generally 
composed of materials that are hydrophilic, porous and swellable, in different 
morphologies such as fibers, films, foams and hydrogels; and the materials 
may be degradable and/or loaded with therapeutically active molecules (e.g. 
drugs and antimicrobials).  
Among the different classes of materials, hydrogels have gained much 
attention in the field of wound treatment, because of their outstanding 
properties. Hydrogels are a polymeric network filled with water, that when are 
applied to a wound site are effective in absorbing exudates and protecting 
wounds from secondary infection 2–4. 
In recent years, several methods have been investigated for the preparation 
of in situ forming hydrogels, such as the use of chemical crosslinking agents 
and the photopolymerization of precursor monomers 5–8. However, both these 
approaches present several drawbacks, concerning toxicity issues and limiting 
their applications.  
To overcome the limitations related to the preparation of in situ forming 
biodegradable hydrogels, innovative approaches, not employing any external 
crosslinking agents, are under investigation. In this chapter, the possibility to 
obtain two different hydrogels matrices, based on the self-crosslinking of 
chitosan and oxidized polysaccharides, is reported. The use of natural materials 
was taken into consideration, due to the enormous interest they have gained as 
biomaterials for human healthcare systems 9. Chitosan, a partially deacetylated 
derivative from chitin composed of glucosamine and N-acetylglucosamine, is 
structurally similar to glycosaminoglycan (GAG) and its analogs. It is of 
significant interest for industrial and biomedical applications because it is a 
cheap abundant waste product of the food industry, with excellent 
biocompatibility, degradability and antimicrobial as well as unique structural 
and physicochemical characteristics. Furthermore, chitosan is involved in 
wound healing and regeneration processes 10,11. 
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Hyaluronic acid is a linear polysaccharide (high-molecular weight), 
composed of repeating disaccharide units of N-acetyl-D-glucosamine and D-
glucuronic acid. It represents the main component of the GAG structures, in 
association with other polysaccharides such as chondroitin sulfate. Due to its 
good biocompatibility, biodegradability, as well as excellent gel-forming 
properties, hyaluronic acid shows potential in biomedically-relevant hydrogel 
systems 12.  
Pectin is a natural polysaccharide, poly (1,4-galacturonic acid), which 
derives from the cell walls of terrestrial plants 9. Thanks to its attractive 
hydrocolloid nature, pectin has been employed in a wide range of traditional 
applications, such as in food industry as a gelling agent, and as component in 
several wound dressings on the market. Both hyaluronic acid and pectin can 
be both oxidized, and the generating in their structures reactive aldehyde 
functions, which can chemically crosslink with amino functions via Schiff’s 
base linkage formation  13–18. 
Thanks to this self-crosslinking method, in this research work the 
properties of chitosan and oxidized hyaluronic acid on one hand, and chitosan 
and oxidized pectin on the other hand, were combined fabricating hydrogels 
with advantages from the different biomaterials. Moreover, the possibility to 
improve these in situ forming hydrogels by the addition of nanostructured ZnO 
was also investigated. Bionanocomposites represent an emerging group of 
advanced materials resulting from the combination of biopolymers with 
inorganic components 19. Particularly, the addition of NsZnO in the polymeric 
matrix aims to impart novel functionality, such as antibacterial activity which 
is attractive for wound dressings 20. In conclusion, the objectives of this work 
were to prepare biocompatible in situ forming composite hydrogels based on 
natural polysaccharides and to characterize them.  Their crosslinking 
mechanism, structure, morphology and swelling behavior were studied. In 
vitro zinc ion release was simulated on synthetic skin. Cytotoxicity of the 
different component was carried out on HaCat cell line. 
  




All the reagents for chemical synthesis were purchased from Sigma-
Aldrich and used as received without further purification. For cell culture, all 
reagents were purchased from Thermo Fisher Scientific. HaCaT cells 
(immortalized human keratinocytes) were purchased from Lonza. 
 
6.2.2. Synthesis  
Synthesis of Hyaluronic Acids Displaying Aldehydes 
Oxidized hyaluronic acid (HA-ALD) was synthesized following a 
procedure previously described by Hardy and colleagues 13. In order to obtain 
a solution of hyaluronic acid (HA) (MW ca. 2 MDa) at a concentration of 10 
mg/ml, 1.0 g of HA was dissolved in ultrapure (Millipore) water (100 mL). 
Sodium periodate (0.535 g, 2.5 mM) was added and the reaction was stirred 
for 24 h at room temperature in the dark. At the end of the oxidizing phase, the 
unreacted periodate was eliminated by the addition of ethylene glycol (140 μL, 
2.5 mM) and stirring the reaction for 1 h at room temperature in the dark. Then, 
dialysis was performed in order to remove low molecular weight contaminants, 
using ultrapure water in dialysis tubing cellulose membrane (MWCO 3500), 
for four days with water exchange every 2 hours during the day time. HA-ALD 
was then freeze-dried.  
Synthesis of Pectine Displaying Aldehydes 
Pectin from citrus peel (poly-D-galacturonic acid methyl ester) (21000 - 
70000 Da) has been oxidized to introduce aldehyde groups using the 
experimental procedure described in the previous paragraph.  The reagents and 
their amounts were not modified, except for the use of 1.0 g of Pectin from 
citrus peel (MW ca. 2 MDa) as starting material. The final product, consisting 
of Pectin displaying aldehydes, PEC-ALD, was isolated by dialysis followed 
by freeze-drying. 
Synthesis and characterization of NsZnO 
In this investigation, nanostructured ZnO is proposed as the inorganic filler 
for hydrogel matrices. The synthesis procedure of the NsZnO was reported in 
the first chapter of this thesis, with an exhaustive characterization (NsZnO-2).  
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6.2.3. Preparation of chitosan stock solution  
 
Commercial chitosan with medium molecular weight (190,000-310,000 
Da, 75-85% deacetylated) was used. A chitosan (CS) stock solution at 2% was 
prepared adding the polysaccharide powder into an acetic acid aqueous 
solution (at 1 vol% acetic acid in water) at ambient temperature. After 
complete dissolution, the pH was adjusted to 5.5 by drop-wise addition of 1M 
sodium hydroxide. The formulation was stirred for 24 h. 
6.2.4. Hydrogel Preparation 
Stock solutions of HA-ALD (1 wt% in PBS), PEC-ALD (1 wt% in PBS) 
and CS (2 wt%) were prepared. In this research work two different hydrogels 
were fabricated: one based on HA-ALD and CS (HA-ALD/CS) and another 
one based on PEC-ALDs and CS (PEC-ALD/CS). Different volume ratios 
were tested, mixing either HA-ALD or PEC-ALD with CS. 
6.2.5. Bionanocomposite Hydrogel Preparation 
To obtain bionanocomposite hydrogels, NsZnO powder was suspended in 
PBS and sonicated for 5 minutes at room temperature to disperse the particles. 
Then the NsZnO suspension was injected into the CS stock solution (NsZnO-
CS), and gently stirred until complete homogenization. All the previous 
formulations were tailored in order to get a final concentration of 1% wt of 
NsZnO in the various hydrogels.  
6.2.6. In vitro swelling test 
The freeze-dried hydrogels were weighed and immersed in PBS solutions 
(pH = 7.4) at 33 °C. After certain times, the swollen hydrogels were removed 
and immediately weighed after the excess of water lying on the surfaces was 
blotted away with filter paper, and until the weight of hydrogels reached an 
equilibrium value. The swelling ratio (SR) was calculated as follows:  
 
Eq. 6.1        SR (%) = (Wt - W0) / W0 × 100% 
 
where, Wt and W0 are the weights of the hydrogels in the swollen state and 
dry state. 





Infrared spectroscopy was carried out on a Thermo Scientific FTIR 
Spectrometer (Thermo Fisher Scientific Inc., USA). Spectra were recorded for 
16 scans in ATR mode at room temperature, with a 1 cm−1 resolution. Spectra 
were corrected for background and atmosphere using OMNIC software 
provided with the spectrometer. 
X Ray Diffraction 
The pattern of X-ray diffraction of the samples was obtained by using a 
PANalytical X’Pert (Cu Kα radiation) diffractometer. Data were collected with 
a 2D solid state detector (PIXcel) from 10 to 80 2θ with a step size of 0.001 2θ 
and a wavelength of 1.54187 Å. 
FESEM measurements 
The surface morphologies of the hydrogelswere analyzed by using a 
FESEM (Zeiss Supra 40) (Carl Zeiss AG, Jena, Germany), equipped with 
Oxford detector for Energy Dispersive X-ray analysis (EDX).  
6.2.8 In vitro Zin Ion release  
Zinc ion release from the bionanocomposite hydrogels was studied using 
vertical Franz diffusion cells and synthetic skin (Dow Corning, 7-4107, 
Silicone Elastomer Membrane). HA-ALD/CS/ZnO and PEC-ALD/CS/ZnO 
were employed as a donor phases. The receiving phase consisted of PBS 
buffer, at pH 7.4. The apparatus was maintained at 33°C with stirring, and at 
scheduled times the receiving phase was withdrawn and entirely substituted 
with fresh receiving phase. Zinc ion quantification was performed for each 
sample using inductively coupled plasma mass spectrometry (ICP-MS). 
6.2.9. Cytotoxicity of CS, HA Derivatives, PEC Derivatives and 
NsZnO 
The cytotoxicity of the CS, HA-ALD and PEC-ALD was determined using 
a cell viability assay, based on the metabolic activity of cells and their 
proliferation. 96-well plates were set up dispensing 100 µL of each compound 
at a starting concentration of 1 mg ml-1. A set of control media (100 µL of 
medium with serum) and control cells (100 µL of suspended cells in medium) 
was also included. Then 104 cells were injected in each well, except the control 
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cells wells and control medium wells. The 96-well plates were incubated at 72 
hours in a humidified CO2 incubator air atmosphere (5%) at 33°C, to allow 
cells to grow.  After the incubation time, the PrestoBlue assay were performed. 
Precisely, 10μL of PrestoBlue solution (ThermoFisher) was added to all wells 
and incubated for at least 30 minutes. Then, the absorbance was read using a 
Magellan plate reader at the required wavelength/s. 
 
6.3. Results and discussion 
 
In situ crosslinking hydrogels preparation and physicochemical 
characterization 
 
The preparation of in situ crosslinking hydrogels proposed in this 
investigation is based on the Schiff base reaction. This reaction takes place 
when the electrophilic carbon atoms of aldehydes and ketones undergo 
nucleophilic attack by amines.  The result of this reaction is a compound in 
which the C=O double bond is replaced by a C=N double bond. This type of 
compound is known as an imine, or Schiff base. In recent years many research 
papers have focused on the preparation of in situ forming hydrogels using the 
Shiff base linkage, because of the simplicity of the mechanism and the 
possibility to involve only the polymeric building blocks without the addition 
of a chemical crosslinking agent. In this project the mechanism of formation 
of the hydrogels was based on the possibility to link the terminal amine groups 
of chitosan with the aldehyde groups displayed on the oxidized HA and PEC, 
through the Shiff base reaction (Figure 6.2). 
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Figure 6.2 Schematic illustration of the Shiff base reaction on the basis of the 
hydrogels formation  
 
To prepare the in situ cross linking hydrogels, stock solutions of the 
various components were prepared. A chitosan (CS) stock solution at 2% was 
prepared, obtaining a viscous polysaccharide solution, with a pH of 5.5. HA-
ALD and PEC-ALD were dissolved in phosphate buffered saline (PBS, pH 
7.4) at 1 wt%, obtaining clear solutions. 
Hydrogels were prepared mixing polymers stock solutions of HA-ALD (1 
wt% in PBS), PEC-ALD (1 wt% in PBS) and CS (2 wt%). Precisely, two 
different gels were obtained by mixing in different volume ratios HA-ALD 
with CS (HA-ALD:CS) and PEC-ALDs with CS (PEC-ALD:CS). The cross-
linking time and consistency of the gels were visually determined. The best 
results were represented by the hydrogels obtained by mixing HA-ALD and 
CS in the volume ratio of HA-ALD:CS = 1:2, while in the case of hydrogels 
based on modified pectin the best formulation resulted from the volume ratio 
PEC-ALD:CS =1:1. Crosslinking was observed to occur within seconds of 
mixing the building blocks polymers, forming a transparent and homogenous, 
semi-solid polymeric matrix in both cases (Fig.6.3).  The results obtained were 
in agreement with those previously demonstrated by other researchers 21,22. 
The selected hydrogels were used in the development of the 
bionanocomposite materials. In particular two different composite hydrogels 
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with a NsZnO final concentration of 1% were prepared, starting from HA-
ALD:CS (1:2)-based gel and PEC-ALD:CS (1:1)-based gel. After the 
dispersion of NsZnO, the polymeric matrices appeared more translucent, due 




Figure 6.3 Representative picture showing the aspect of the HA-ALD/CS based 
hydrogel before and after the dispersion of NsZnO. 
 
 In particular, HA-based composite gels were prepared by mixing HA-
ALD and NsZnO-CS in the volume ratio HA-ALD:CS = 1:2. The same method 
was applied in the preparation of composite gels based on modified pectin.  For 
this purpose, PEC-ALD and the suspesion NsZnO-CS were mixed in the 
volume ratio PEC-ALD:CS =1:1.  
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FTIR analysis    
 
Figure 6.4 Panel A) FTIR spectra of chitosan and HA-ALD as single component, 
in comparison with the neat hydrogels and the composite one. Panel B) FTIR spectra 
of chitosan and PEC-ALD as single component, in comparison with the neat 
hydrogels and the composite one. 
 
The FTIR spectra of both the bionanocomposite hydrogels  are presented 
in Fig. 6.4, aiming to show the formation of the crosslinked hydrogels after the 
Shiff base reaction. Panel 6A shows the spectra of the chitosan, of the 
hyaluronic acid derivative and of the composite hydrogel HA-ALD/CS, with 
and without the NsZnO. Simultaneously, in panel 6B are shown the spectra of 
the chitosan, of the pectin derivative and of the composite hydrogel PEC-
ALD/CS, with and without the NsZnO. Successful crosslinking of the chitosan 
with the aldehyde-functionalized polysaccharides derivatives was confirmed 
by the appearance of a peak at around 1550 cm−1 in the infrared absorption 
spectrum of lyophilized hydrogels, which corresponds to the imine bonds that 
crosslink the hydrogels. This peak is masked by the amide II peaks for the 
acetylated amines present on HA and Chitosan (75-85% deacetylated). 
  




X-ray diffraction analysis was performed to determine the structure of 
chitosan, the oxidized polymers derivatives and of the neat hydrogels in 
comparison with the bionanocomposite materials. The results are displayed in 
figure 6.5, where panel A is related to the HA-ALD/CS based hydrogels and 
the panel B to the PEC-ALD/CS based hydrogels.  
 
Figure 6.5 Panel A) XRD patterns of chitosan, HA-ALD and NsZnO as single 
component, in comparison with the neat hydrogels and the composite one. Panel B) 
XRD patterns of chitosan, PEC-ALD and NsZnO as single component, in comparison 
with the neat hydrogels and the composite one. 
 
The main aim was to identify ZnO nanoparticles loaded in the polymer 
matrix. The diffractogram showing the chitosan structure were typical of a 
partially crystalline structure, exhibiting very broad peaks at 2θ = 10° and 2θ 
= 20° 23. Moreover, XRD analyses show the predominantly amorphous 
character of the building blocks polymers and the of the neat hydrogels. On the 
contrary, the crystalline wurtizitic structure of the NsZnO was clearly 
highlighted by the XRD patterns of the bionanocomposite hydrogels. The 
preservation of the ZnO crystalline structure after its dispersion in the 
polymeric matrix was a significant result, considering the strict link between 
ZnO structural properties and its functionalities. The detailed description of the 
XRD analysis of the nanostructured ZnO has been discussed in the first chapter 
of this thesis. 





Figure 6.6 Panel A shows the FESEM images of both the neat hydrogels, HA-
ALD/CS and PEC-ALD/CS. Panel B and panel C present the FESEM image of the 
bionanocomposite hydrogel HA-ALD/CS/NsZnO and of the bionanocomposite 
hydrogel PEC-ALD/CS/NsZnO, respectively. Moreover, the EDS elemental mapping 
directly associated with the FESEM images is reported for the bionanocomposite 
materials. 
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FESEM analyses were carried out to evaluate the morphology of the neat 
hydrogels matrix in comparison with the bionanocomposite hydrogels. The 
principal goal was the determination of the degree of dispersion of the NsZnO 
particles inside the polymeric matrix. Figure 6.6A shows the FESEM images 
of both the neat hydrogels, HA-ALD/CS and PEC-ALD/CS. Panel 4.6B and 
panel 6.6C present the FESEM image of the bionanocomposite hydrogel HA-
ALD/CS/NsZnO and of the bionanocomposite hydrogel PEC-
ALD/CS/NsZnO, respectively. Moreover, the EDS elemental mapping directly 
associated with the FESEM images is reported for the bionanocomposite 
materials. A uniform and smooth surface morphology can be observed for the 
neat hydrogels (Fig. 6.6A), while ZnO nanostructures can be identified in the 
bionanocomposite hydrogels (Fig. 6.6B and 6.6C). FESEM analyses 
associated with EDS mapping also show that the ZnO particles are uniformly 
dispersed in crosslinked polymeric matrices. The homogenous dispersion of 
the NsZnO is an important factor, playing a key role in the antibacterial activity 
of these multicomposite materials. In fact, a higher ZnO surface area might be 
exposed to the bacteria, enhancing its killing activity.  
  




The swelling behavior was studied soaking the freeze-dried hydrogels in 
PBS at pH = 7.4 comparing the neat hydrogels with the bionanocomposite 
hydrogels. As shown in figure 6.7, the hydrogels have excellent swelling 
properties for both the polymeric matrices. 
 
Figure 6.7 Swelling behaviour of the neat hydrogels in comparison with the 
nanocomposite hydrogels in PBS buffer at pH 7.4. Panel A shows the swelling profiles 
of HA-ALD/CS (purple curve) and of HA-ALD/CS/NsZnO (green curve) based 
hydrogels. Panel B shows the swelling profiles of PEC-ALD/CS (purple curve) and 
of PEC-ALD/CS/NsZnO (green curve) based hydrogels. 
 
It is evident that in both cases the bionanocomposite hydrogels exhibit a 
higher swelling capability in comparison to neat hydrogels. NsZnO may cause 
the expansion of hydrogel network either by diminishing the number of Schiff 
base crosslinks that form or repelling the polymer chains due to electrostatic 
interactions, thereby increasing the pore sizes within the hydrogel, which 
accounts for the absorbance of more water 24. The bionanocomposite hydrogel 
based on the crosslinking between oxidized pectin and chitosan seems to be 
more effective in absorbing water than the composite hydrogel based on 
oxidized hyaluronic acid and chitosan. Since the percentage of NsZnO is the 
same in both the composite matrices, this behaviour is ascribed to a 
combination of diminished number of Schiff base crosslinks that form and 
repelling the polymer chains due to electrostatic interactions. This outstanding 
swelling behaviour can be successfully exploited in a real application in wound 
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healing treatments, where hydrogels able to absorb consistent degree of wound 
exudate are required. In fact, hydrogels absorbing wound exudates, would be 
able to protect wounds from secondary infection. 
 
In vitro zinc release from bionanocomposite hydrogels 
 
Figure 6.8 Zinc release of bionanocomposite hydrogels as a function of time, at 
pH 7.4. HA-ALD/CS/NsZnO and PEC-ALD/CS/NsZnO are represented by the purple 
curve and green curve, respectively. 
 
The release profiles of zinc ions at pH 7.4 from the bionanocomposite 
hydrogels is shown in Figure 6.8.  Exudate pH in wounds normally ranges 
between 4.8–9.8, consequently the PBS buffer was chosen in order to simulate 
the wound environment 25. Both the bionanocomposite hydrogels, based on 
HA-ALD/CS and PEC-ALD/CS matrices, showed zinc ion release constant 
over time. This behaviour is a promising result, which may endow the 
hydrogels with efficient antibacterial activity. It is well known in fact that the 
main mechanism of ZnO antibacterial activity would be ascribed to the Zinc 
ions (Zn2+) released from the surface of the particles. As described in the 
introduction section of this thesis, the released Zn2+ has significant effect on 
bacterial  metabolism and enzyme system disruption 20. 
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Cytotoxicity of CS, HA-ALD, PEC-ALD and NsZnO 
Since this investigation aim at developing of in situ crosslinking hydrogels 
for wound treatment, immortalized human keratinocyte (HaCat) cell line was 
chosen in order to test the cytotoxicity of the various components. HaCaT cells 
have been extensively investigated as model to evaluate the epidermal 
homeostasis and its pathophysiology 26. The HaCaT cells, were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum 
at 33 °C with 5% CO2. The cells were cultured until 100% confluence was 
reached, and then the cytotoxicity tests were performed. In order to test their 
cytotoxicity HA-ALD, PEC-ALD and NsZnO were dissolved in PBS solution 
and conveniently sterilized. HaCat cells were incubated with different 
concentrations of HA-ALD-24 and PEC-ALD-24 for 24 hours, after which the 
cells viability were tested using the PrestoBlue™ Cell Viability method. This 
protocol was adopted due to the possibility to rapidly obtain an evaluation of 
the cell viability and proliferation after their contact with the polymers.  
PrestoBlue™ reagent is quickly reduced by metabolically active cells, 
providing a quantitative measure of viability and cytotoxicity. After an 
incubation time of 1 hours, the absorbance was read using a plate-reader at the 
required avelength (570 nm) associated with Magellan software. 




Figure 6.9 Panel A: Hacat cell viability after incubation with different polymers: 
chitosan m.m.w. (dark grey), HA-ALD-24 (grey) and PEG-ALD-24 (light grey). 
Panel B: HaCaT cell viability after incubation with NsZnO. The viability was assessed 
using a PrestoBlu Cell Viability Assay(ThermoFisher Scientific).  
As it is possible to see in figure 6.9A, in all the evaluated polymers 
concentrations, a high cell viability was observed. The significant results 
suggest that all the polymers in this investigation are promising starting 
materials for in situ crosslinking hydrogels for application in wound healing.  
The viability of HaCaT cells treated with ZnO has already been studied 27–
29, and the results achieved in this investigation are perfectly consistent with 
the previous considerations (Fig. 6.9, panel B). As expected, the NsZnO 
material showed a dose-dependent effect. Interestingly, a recent study 
concluded that the use of nanostructured ZnO on dermatological applications 
would not have any concern since it shows a similar or less pronounced effect 
on keratinocytes than the corresponding bulk form 29. 





In this study a facile synthesis of bionanocomposite hydrogels, able to act as 
multifunctional materials in wound healing applications was demonstrated. 
Future work will include the completion of mechanical testing and cell culture 
studies (with an in vitro wound healing model). Moreover the possibility to 
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 Conclusions and Outlooks 
In Material Science, ZnO nanostructures (NsZnO) have been attracted 
much interest in many fields of application, included the biomedical one, due 
to its outstanding intrinsic properties. Nevertheless, the study of NsZnO as 
drug delivery system is still in its nascent stage, particularly considering the 
administration to the skin. 
In this PhD thesis nanostructured ZnO was selected as material to develop 
innovative drug carriers for future dermatological applications.  
In particular, three different NsZnOs have been investigated: NsZnO-1, 
NsZnO-2 and NsZnO-3. Starting from different synthesis approaches, three 
different ZnO nanostructures were obtained, with different morphologies and 
physicochemical parameters. In this stage, particular attention was focused on 
obtaining materials potentially able to host drug molecules into their structure. 
For this purpose, the morphologies of NsZnO-1, NsZnO-2 and NsZnO-3 were 
tailored for the biomedical applications. Moreover, the investigated NsZnO 
were characterized by significative SSA and pore volume values, both 
important parameters for the role of drug carrier. 
In this PhD project, the supercritical CO2 (scCO2) technology was selected 
to perform the drug loading of the obtained NsZnOs. The choice was driven 
by the need to study innovative method to obtain drug delivery systems, 
focusing on the possibility to use greener technologies, such as the scCO2, able 
to replace organic solvents, toxic for the environment and for the health. In 
addition, at the end of the the scCO2 process, ready-to-use drug carriers are 
obtained, without any further purification process.  
Clotrimazole (CTZ) and Ibuprofen (IBU) were selected as drug models in 
this study, because of their poorly-water soluble profiles and their traditional 
role in dermatological formulations.  
To the best of my knowledge, this was the first attempt of study the scCO2 
assisted drug impregnation of ZnO nanostructures and interesting conclusions 
were drawn. Firstly, the possibility to use scCO2 as solvent to load NsZnO was 
successfully demonstrated. In fact, any structure modification of the ZnO 
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structures was observed after scCO2 process, excluding the transformation in 
ZnCO3. Secondly, both the drugs were successfully incorporated into the 
NsZnOs, reporting significative drug loaded amount. Furthermore, the drugs 
were found to be in their amorphous status, indicating a potential improved 
dissolution profile, suitable for biomedical purposes. Preliminary in vitro 
release studies confirmed that the APIs were not irreversibily confined in the 
NsZnO structures and that they could be released over time. 
The antimicrobial activity of the three NsZnOs was successful confirmed 
in this research project, highlighting their potential use as multitasking 
antimicrobial drug carriers. The study revealed that the three ZnO 
nanostructures exhibited a stronger microbicidal activity towards the Gram-
positive S. aureus than the Gram-negative K. pneumoniae and yeast C. 
albicans, in accordance to the literature. Morevoer, the sample NsZnO-1, 
characterized by the smallest crystallite sizes, the highest SSA and pore 
volume and by the largest pore sizes possessed the best antibacterial activity 
against all the investigated strains. The in vitro release of Zn2+ ions from the 
three NsZnOs showed that the higher amount of Zn2+ ions was released from 
NsZnO-1 and NsZnO-3, confirming the predominant role of the crystallite 
sizes in the enhancement of the antibacterial activity.  
Part of this PhD thesis was dedicated to the study of innovative materials 
for wound healing. In this framework, the development of biocompatible in 
situ forming composite hydrogels was investigated. In particular, the use of 
NsZnO-2 as inorganic nanofiller in the hydrogel matrix was studied, as 
strategy to add antibacterial properties to the material. This successful 
combination led to an enhanced swelling behaviour of hydrogels, indicating a 
possible improved capacity in absorbing exudates from the wound 
compartment. Moreover, the bionanocomposite hydrogels were able to release 
Zn2+ ions over time, suggesting the enhanced antimicrobial activity of the 
materials. 
 
In conclusion, the overall results of this PhD thesis build up the 
fundamentals for the future outlooks of the research project. The next stages 
will consider: 
► a more accurate study of the in vitro release properties of the samples 
NsZnO-1 and NsZnO-3, selected for their advantageous 
phicochemical and biological parameters compared to NsZnO-2; 
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► the impregnation of new APIs in the NsZnO-1 and NsZnO-3 with the 
assistance of scCO2; 
► the development of formulations able to deliver these multitasking 
NsZnO   
to the skin; 
► the addition of IBU@NsZnO into the bionanocomposite hydrogels and 
the study of its ability in enhancing the wound healing process with 






















































From the fundamental research 
to the Proof of Concept: an 
innovative dermatological 
formulation containing Ordered 
Mesoporous Silica for the 
administration of active 
pharmaceutical ingredients. 
The publication of the patent “Eudermic compositions” (WO 2012007906 
A2) in 2012 1, by Prof. Barbara Onida e Dr Renato Mortera, represents the 
starting point of the research work described in this chapter. From the birth of 
this invention, many efforts have been dedicated by Onida’s group to the 
development of innovative dermatological formulations, containing 
mesoporous silica, able to act as skin surface drug reservoir in topical 
applications 2. In the last years, this scientific project has implemented many 
activities and involved different research groups, creating new fruitful 
collaborations and new promising horizons. Within my PhD research project, 
I have taken actively part to the advance of this scientific investigation. The 
most important activity has been represented by the possibility to develop the 
“Proof of Concept” of this innovative dermatological product, thanks to a 
40k€-budget funded by Compagnia di San Paolo in collaboration with 
Politecnico di Torino. It has been an important opportunity for the overall 
progress of the project, assessing outstanding results and opening new research 
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perspectives for the future. In the next chapter, I chose to report a part of this 
activity, which involved me in first person, in order to highlight that the Proof 
of Concept of this research proposal is possible and it is a real prospect.  
Moreover, this successful outcome inspired me and my team in starting a new 
research line focused on the application of the technology proposed in the 
patent to other materials. For this purpose, nanostructured ZnO was selected 
as test material and the possibility to use it as drug reservoir platform in 
dermatological application was mainly investigated during PhD. 
We gratefully acknowledge financial support from Compagnia di San 






In the dermatology field, the administration of topical antibiotics embodies 
a crucial issue and there is significant controversy about their use 3. Generally 
topical antibiotics represent the first choice in several skin infectious diseases, 
due to several advantages, such as the high concentration at the specific site, 
limited systemic absorption and easy application of semisolid formulations 
(i.e. gels, ointments, creams). Despite of all these benefits, there is an open 
debate related to the use of topical antibiotics due to its critical drawbacks, 
such as the need of frequent administrations 4 and the lack of dose accuracy. 
Firstly, it is commonly known that traditional topical antibiotics require at least 
2-3 applications/day in order to ensure the efficacy of the treatment. 
Unfortunately, this high number of applications often affect the patient 
adherence to the therapy, hindering the healing process. Generally, patients in 
treatment with topical antibiotics follow a self-medication regime, where the 
lack of administrations could frequently occur, due to forgetfulness or 
voluntary interruption of the treatment caused by the painful applications. 
Moreover, it has been reported that the administration of topical antibiotic 
should be restricted to no more than 7-14 days, in order to avoid tissue damage, 
systemic toxicity, or even contact sensitivity and allergic reactions 5. Secondly, 
a more important limitation in the use of topical antibiotic is represented by the 
occurrence of bacterial resistance in some bacteria strains 6. As consequence, 
in the last decade several protocols and guidelines have been produced, 
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claiming that topical antibiotics should be avoided because they may cause 
several adverse phenomena, such as hypersensitivity reactions, super-
infections and resistant bacteria 7. As alternative to topical antibiotics, the use 
of systemic antibiotics could be considered, but it is generally avoided due to 
systemic side effects and bacterial resistance issues. A preferred substitute 
therapy is represented by the use of topical antimicrobial agents, such as silver, 
iodine and honey 4, which are frequently recommended in the international 
guidelines for wound treatments. Nevertheless, also this alternative approach 
presents limiting drawbacks in common with the topical antibiotics, such as 
the scarce number of effective agents, the appearance of local hypersensitivity, 
difficult to accurately dose and most significant, the need of frequent 
reapplications.  
 
Figure 7.1 Schematic representation of the composition of the innovative 
dermatological formulation 
 
In this context, the present research work offers a promising solution 
developing the proof of concept of an innovative eudermic formulation, 
potentially able to act as skin surface reservoir of an antibiotic molecule. This 
new technology is based on the use of ordered mesoporous silica (OMS), 
loaded with an active pharmaceutical ingredient (API), delivered by a saturated 
solution of the API. The main aim of OMS loaded with the API, is ensuring a 
reservoir of drug. Briefly, the basic mechanism of this innovative 
dermatological formulation can be sum up in 3 main steps: 1) after the 
administration on the skin site, the API dissolved in the saturated solution is 
released from the vehicle following a traditional release profile, as all the 
commercial creams; 2) then, the concentration of the dissolved API begins to 
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decrease; 3) simultaneously, the API incorporated in OMS start dissolving, due 
to the API lower concentration in the vehicle; in this way, the API released 
from the OMS-based reserve preserves the saturated concentration inside the 
vehicle until the OMS is empty. Consequently, the concentration of the API in 
the site of administration is kept constant for a longer and controlled time.  
In order to test the proof of concept of this technology, OMS was adopted 
as model material due to its wide and proven application as drug delivery 
systems in these last years 8–11. OMS has outstanding properties, such as high 
surface area, high pore volume and significant pore sizes, which make it able 
to host molecules and to release them efficiently. Exploring the literature, it is 
evident that many research works have been addressed to investigate OMS as 
drug delivery system in several administration routes. However, to the best of 
our knowledge, only few papers have been published about the possibility to 
use OMS for drug delivery in dermatological application 12–14. 
In this study, Amikacin Sulfate (AKS) was selected as model antibiotic 
drug. AKS is a semisynthetic aminoglycoside 15, with a broad spectrum of 
activity against the most gram-negative infections. It contains a unique 
structure able to bind the bacterial 30S ribosomal subunit, causing misreading 
of mRNA. These leave bacteria unable to synthesize proteins vital to its 
growth. Since the treatment with parenteral aminoglycosides, to which AKS 
belongs, could cause potential ototoxicity and nephrotoxicity, the topical use 
of AKS has always been preferred in the ulcer and wound treatments. 
Nevertheless, the spreading of news guidelines discouraging the use of topical 
antibiotics has also limited the use of topical amikacin in the clinical practice. 
This research work describes the development of an innovative 
dermatological formulation, containing OMS for the prolonged release of 
AKS, which could represent a promising solution to the current limitations in 
the use of topical antibiotics.  
7.2 Material and methods 
Ordered Mesoporous Silica of MSU-H type, Amikacin sulfate (AKS) (6-
O-(3-amino-3-deoxy-α-D-glucopyranosyl)-4-O-(6-amino-6-deoxy-α-D-
lucopyranosyl)-1-N-[(2S)-4-amino-2-hydroxybutanoyl]-2-deoxy-D-
streptamine sulfate) (MW = 781.76 g·mol-1) (Ph.Eur 8.2), the derivatizing 
agent 1-fluoro-2,4-dinitrobenzene (FDNB), , glycerol, acetonitrile 
CHROMASOLV® gradient grade (≥99.9%) and hydroxyethyl cellulose 
(Natrosol MR) were purchased from Sigma Aldrich (Italy). A commercial 
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formulation of AKS (5% by mass) was purchased from a community 
pharmacy. Bidistilled water has been used throughout this investigation. 
7.3 Experimental 
7.3.1. Drug loading into OMS 
The drug loading was performed by a traditional approach consisting In 
the Incipient Wetness Impregnation (IWI) procedure, based on the capillary 
action 16. Typically, 1 ml of a water saturated solution AKS was added drop by 
drop to one gram of OMS (0.898 cm3·g-1) during mechanical agitation. The 
homogeneous slurry was vacuum dried for 24 hours to 0.1 Pa, in order to obtain 
a dry powder (AKS-loaded OMS). 
7.3.2. Characterization of the AKS-loaded OMS 
AKS-loaded OMS were characterized by means of X-Ray diffraction 
(XRD), Fourier transform infrared spectroscopy (FTIR), thermogravimetry 
(TG) analysis, differential scanning calorimetry (DSC), nitrogen adsorption 
isotherms, field emission scanning electron microscopy (FESEM), dynamic 
light scattering (DLS) and zeta potential. XRD patterns were obtained using a 
Philips X’Pert Powder (Cu Kα radiation) diffractometer. For FTIR 
measurements, powders were pressed in self-supporting wafers and spectra 
were recorded at room temperature with a Bruker Tensor 27 spectrometer 
operating at 2 cm-1 resolution, after outgassing the sample at 100°C for one 
hour (residual pressure equal to 0.1 Pa). FTIR spectrum of crystalline AKS 
was recorded on the powder dispersed in potassium bromide (KBr). TG 
analyses were carried out between 25°C and 800°C in air (flow rate 100 
mL·min-1 with a heating rate of 10 K·min-1) using a SETARAM 92 instrument 
to evaluate the quantity of loaded drug. DSC measurements were performed 
with a DSC1 STARe (Mettler Toledo) System apparatus of TA Instruments 
equipped with a low temperature probe between 25°C and 800°C under 
nitrogen flux (flow rate 60 mL·min-1 with a heating rate of 10 K·min-1). 
Nitrogen adsorption isotherms were measured using a Quantachrome 
AUTOSORB instrument after degassing the sample at 100°C for 2 hours. 
Brauner-Emmet-Teller (BET) specific surface areas (SSA) were calculated in 
the relative pressure range 0.04-0.1 and the pore size distribution (PSD) was 
determined through the non-linear density functional theory method (NLDFT). 
FESEM image were recorded with a FESEM ZEISS MERLIN. DLS and Zeta 
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Potential analysis were performed with 90 Plus Instrument (Brookhaven) on a 
suspended water mixture of OMS after homogenization with a high shear 
homogenizer (Ultraturrax, Ika) for 5 min at maximum velocity.   
Derivatization and Analytical method 
The analytical method for AKS was taken by 17. Particularly, AKS 
derivatized by mixing 100 μl of aqueous solution of the drug with 300 μl of 
methanol, 40 μl of NaOH (0.05 M) and 50 μl of a methanolic solution of the 
derivatizing agent (FDNB) (180 mg/ml). The obtained mixture was heated at 
90 °C in an air-circulating oven for 10 min, then cooled and injected in HPLC. 
Each solution was separately derivatized prior to injection. The HPLC 
apparatus consisted of an isocratic pump (Series 200, Perkin-Elmer instrument, 
Norwalk, CT, USA) equipped with a μBondapack C18 300 mm × 4.6 mm 
column (particle size: 10 μm; pore size: 125 Å; endcapped) (Waters, Milford, 
MA, USA). The mobile phase was a mixture of acetonitrile–water–acetic acid 
(47:53:0.1 v/v/v) pumped at 1.5 ml/min. A spectrophotometric detector (LC 
290, Perkin-Elmer) working at 365 nm was used. 
7.3.3. Preparation and characterization of the AKS-OMS 
reservoir vehicle 
In order to obtain a saturated solution of AKS at the therapeutic 
concentration of commercially available creams (5%), a solution of glycerol 
and water was selected, investigating different volume ratios between the two 
solvents, until a drug saturated solution at 5% wt was achieved. The reservoir 
effect of saturated solution with OMS-API have been evaluated. In the 
saturated solution of API was then dispersed the API-OMS reservoir, 
containing an amount of drug equal to that of the free drug in the saturated 
solution. At regular intervals (1h) small amounts of solution were withdrawn 
and replaced with the same quantity of pure solvent. The extracted solutions 
were then diluted and analysed through UV–Vis spectrophotometry to assess 
the API concentration. The addition of pure solvent causes a dilution of the 
solution and allow us to evaluate the reservoir effect of incorporated OMS.  
7.3.4 Preparation of the topical semisolid dosage form 
In order to deliver AKS-loaded OMS to the skin, a suitable semisolid 
formulation was developed. Among all the possible semisolid preparations, a 
hydrophilic gel was selected, consisting of a liquid phase within a polymeric 
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matrix composed by a suitable gelling agent. Firstly, AKS was added in a 
solution of glycerol and water under magnetic stirring obtaining a saturated 
solution of the drug (5% wt). When AKS was completely dissolved, OMS-
AKS powder was added to the medium, having the same amount of the free 
drug in the reservoir. Then the liquid dispersion was purposely homogenized 
with a high shear homogenizer for 5 min at maximum velocity. Hydroxyethyl 
cellulose was selected as gelling agent, because it is primarily used in topical 
pharmaceutical formulations and it is generally considered as an essentially 
non-toxic and non-irritant material 18. With this purpose, 2% by mass of 
hydroxyethyl cellulose was added to the homogeneous dispersion and it was 
gently stirred for one hour at room temperature. In the next paragraphs, the 
topical gel containing OMS-AKS and free AKS at therapeutic saturated 
concentration will be indicated as AKS-OMS@GEL. 
 
7.3.5. Characterization of AKS-OMS@GEL  
A complete and detailed evaluation of AKS-OMS@GEL properties was 
assessed comparing it with a commercial gel containing 5% of Amikacin by 
mass, over a period of 30 days. The AKS-OMS@GEL macroscopic properties 
were examined by visual inspection of clarity, colour, homogeneity and phase 
separation. The pH of both gels were measured using a digital pHmeter (GLP 
21 of Crison). The measures were replicated three times. Rheological 
properties were evaluated using a rotational Brookfield viscometer (Rheometer 
Model LVDV-III+). About 10 ml of the gels were introduced to the cylinder. 
Readings were taken over a large range of shearing rates (from 0.75 to 1875 s-
1) corresponding to 0.1 to 250 rpm. Viscosity and degree of pseudoplasticity 
(Farrow's constant) were determined. 
 
7.3.6. In-vitro Release studies using vertical diffusion cells 
AKS release from different formulations was studied using  
vertical glass diffusion cells (Franz cell) equipped by a Spectra/Por (12000-
14000 Dalton MWCO) hydrophilic cellulose membrane (Spectrum Lab). In 
particular, AKS-OMS@GEL and the commercial formulation were employed 
as donor phases. The receiving phase was acetate buffer at pH 5.0. The 
apparatus was maintained under stirring for 72 h at 33°C, during which at 
scheduled times the receiving phase was withdrawn and entirely substituted 
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with fresh receiving phase. Each withdrawn aliquot was analysed using high 
performance liquid chromatography (HPLC) analysis. Each sample was 
prepared and analysed in triplicate. 
 
7.3.7.  In-vitro permeation studies using vertical diffusion cells 
AKS transepidermal permeation from the two different gels was also 
studied using vertical diffusion cells equipped by  porcine ear skin. Skin slices 
were isolated using an Acculan dermatome (Aesculap) from the outer side of 
pig ears freshly obtained from a local slaughterhouse and then stored for at 
least 24 h at -18°C. Prior to each experiment, the excised skin was rinsed with 
normal saline solution and pre-hydrated by floating it in 0.002% (w/v) sodium 
azide aqueous solution. The skin was then sandwiched between the two cell 
compartments with the stratum corneum side upwards. Both AKS-
OMS@GEL and the commercial formulation were employed as a donor phase. 
The receiving phase consisted of acetate buffer at pH 5.0. The apparatus was 
maintained under stirring for 72 hours at 34°C, during which at scheduled 
times the receiving phase was withdrawn and entirely substituted with fresh 
receiving phase. Each withdrawn was analysed using HPLC. Each sample was 
prepared and analysed in triplicate. Moreover, parallel Franz experiments with 
AKS-OMS@GEL were performed, stopping the procedure after 6, 24, 48 and 
72 hours, in order to analyse the ex-vivo skin tissues extracted from the cells 
through FESEM microscopy. For this purpose, the pig skin was gently washed, 
deep-freezed with liquid nitrogen, broken in different pieces and analysed with 




7.3.8. Microbiological activity studies 
The antibacterial tests were performed by the research group of Prof. 
Vivian Tullio at the Department of Public Health and Pediatrics of the 
University of Turin. In order to determine the antibacterial activity of the 
innovative AKS-OMS@GEL proposed in this research work, different 
microbiological activity tests were carry on.  
Antibacterial susceptibility tests 
Firstly, the determination of the MIC and the MIB was carried out through 
the broth microdilution method, according to the Clinical and Laboratory 
Standards Institute (CLSI) guidelines 19. The essay was performed on different 
bacterial strains: Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa. Each component of the formulation was singularly evaluated, 
investigating the antimicrobial activity on the free AKS, on the commercial 
product and on the glycerol/water vehicle with and without OMS as such.  
Microbiological determination of the AKS released from the AKS-
OMS@GEL 
A second test was performed, evaluating the microbiological activity of 
the drug amount released over time, during the in vitro release studies 
performed with Franz Cells. The test was carried out comparing the AKS-
OMS@GEL with the commercial Amikacin gel. During the in vitro release 
studies, an aliquot of each samples withdrawn from the Franz cell at 
predetermined times, was used to determine its microbiological activity, using 
the disk diffusion method. Agar plates (Brain Heart Agar) were inoculated 
with a standardized inoculum of the test microorganism, consisting in 108 
UFC/ml of K. pneumoniae. In order to determine the antibacterial activity, the 
diameters of inhibition growth zones were measured, after the incubation of 
each AKS-containing samples at 37 ° C for 24 hours. In order to determine the 
AKS concentrations, the same experiment was previously performed using 
known concentration of drug. 
Determination of the time-kill curves 
The bactericidal effect of AKS-OMS@GEL was investigated using the 
time-kill test. Aliquots of samples withdrawn at predetermined times during 
the in vitro release study were incubated (37°C) with the microbial strain, K. 
pneumoniae 28024.  The bactericidal effect was determined performing the 




7.4 Results and discussion 
7.4.1 Characterization of the AKS-loaded OMS  
In order to assess the physicochemical properties of the AKS-loaded OMS, 
a complete characterization has been done. The wide angle XRD diffraction 
pattern of the OMS as-such presented the typical (100), (110) and (200) peaks, 
related to the hexagonal (P6mm) 2D symmetry of the ordered mesopores 
materials (Figure 7.2.A). The XRD patterns of AKS-OMS showed a complete 
amorphization of the API (Figure 7.2.B); the lack of crystallization in these 
materials is a very well reported and crucial phenomenon 20–22. The pattern of 
the sample containing AKS after the IWI process, shows the same reflections, 
confirming that the drug loading does not affect the mesostructure. 
 
  
Figure 7.2: Panel A) XRD pattern of OMS as-such. Panel B) XRD spectra of 
AKS powder (black) and OMS-AKS (red). Panel C) N2 isotherms of OMS (black) 
and OMS-AKS (blue) Panel D) FTIR spectra of OMS (black), AKS in KBr (red) and 
OMS-AKS (blue).  
 
FT-IR spectra (Fig. 7.2.B) reveal that AKS interacts with the silica surface 
through hydrogen bonds with silanols. In fact, the OMS as such shows two 
main band: a narrow one due to free silanols at 3742 cm-1 and a broader one at 
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3520 cm-1due to H-bonded silanols. In the spectrum OMS-AKS sample no free 
silanols are observable (3742 cm-1) suggesting a direct interaction between 
surface silanols and AKS frequency. The spectrum of AKS in KBr shows a 
broad envelope in the range 3600-2400 cm-1 
. This results from the absorptions due to free and H-bonded -NH2, -NH 
and -OH groups. In the same spectrum absorption at about 2900 cm-1 are due 
to -CH stretching mode of the molecule. At lower frequency narrow bands are 
present at 1640 and 1550 cm-1 due to -CONH- groups 15. As clearly showed in 
in Fig.7.2B, these AKS characteristic peaks are present also in the AKS-OMS 
spectrum. The TG analysis was used to evaluate the amount of API loaded into 
OMS and the result was 47% by mass. This percentage was further confirmed 
by HPLC analyses carried on the total AKS amount released from the reservoir 
carrier. 
Figure 7.2C shows nitrogen adsorption isotherms of OMS as-such and of 
AKS-OMS, from which the specific surface area, the specific pore volume and 
the pore size distribution can be evaluated. Passing from OMS to OMS-AKS, 
BET specific surface area decreased from 625 m2/g to 69 m2/g, while the pore 
volume decreased from 0.898 cm3/g to 0,121 cm3/g. In addition to this, the 
NLDFT PSD shows a reduction of the volume without any significant change 
in pore diameter. These evidences, compared to other literature results 20, 
strongly suggest that AKS molecules are hosted inside the mesopores but not 
uniformly distributed on the OMS surface. 
 
 




Figure 7.3 reports the scanning electron microscopy picture of OMS 
showing aggregates of microns composed by particles of about 500-600 nm. 
The primary particles resemble short prism of hexagonal base with striping 
along the height recalling the ordered hexagonal (P6mm) network of 
mesopores. After IWI, FESEM images exhibit no change in morphologies or 
API crystals outside the mesopores (data not shown). The DLS measurements 
of OMS as such agree with the FESEM image, resulting in aggregates of 1300 
nm mean value. Indeed, after high shear homogenization (5 min at 30 krpm), 
OMS particles result completely disaggregates, giving a mean value of 569±16 
nm.  
7.4.2. Characterization of the AKS-loaded OMS reservoir 
formulation 
 
Figure 7.4 AKS sustained release from the reservoir formulation and from the 
API saturated solution without reservoir  
 
The reservoir effect of the AKS-loaded OMS in a AKS saturated solution was 
successfully confirmed by a simple in vitro release study (Fig.7.4). Generally, 
amikacin is available on the market as hydrophilic topical gel, at 5% by mass 
of API, corresponding to 6,67% by mass of AKS. In this research work, a 
mixture of water and glycerol was investigated, in order to obtain a solvent 
saturated with AKS at the therapeutic concentration. The solvent composition 
was 45:55 = water: glycerol (by weight). In order to confirm the reservoir 
effect of the formulation, the AKS in vitro release profile was determined over 
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time, withdrawing an aliquot every hour from the combined system and 
replacing it with the same amount of pure solvent. Figure 7.4 reports the AKS 
in vitro release profile from the reservoir formulation and from the API 
saturated solutions. It is evident that the reservoir formulation is able to provide 
a more sustained and constant release of drug, preserving the saturated 
concentration as long as there is drug that can be released and solubilized from 
the OMS.  
7.4.3. Characterization of AKS-OMS@GEL  
The type of formulation in which a drug delivery system is dispersed 
represents an important aspect to take into consideration during the 
development of an effective skin product. For this purpose, a hydrophilic gel 
was selected as dosage form in order to administer the reservoir system, based 
on the combination of AKS-loaded OMS and the AKS saturated solution, to 
the skin. This semisolid formulation was selected considering the hydrophilic 
profile of the API and its well-established role in delivering drug carriers to the 
skin 23.  The choice of excipients was driven by the will of using only admitted 
materials able to assure the physico-chemical stability of the preparation. Table 
7.1 reports the qualitative composition of the AKS-OMS@GEL in comparison 
with that of the marketed gel. 
 
Table 7.1.  Comparison between the qualitative composition of the Amikacin 
commercial gel and the AKS-OMS@GEL (reservoir system) 
 
COMMERCIAL GEL AKS-OMS@GEL 
Amikacin 5% Amikacin 5% 
Hydroxyethylcellulose Hydroxyethylcellulose 
Glycerine (E 422); Glycerine 
Water Water 
Methyl parahydroxybenzoate (E 218); 





Hydrophilic gels have been reported as an effective and inert environment 
for drug carriers, assessing their role in the improvement of the drug delivery 
to the skin 23,24. This semisolid dosage form allows a uniform dispersion of the 
particles in the matrix, a longer contact time of the drug carrier with the skin 
and a resultant enhanced drug delivery. After the identification of the 
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qualitative composition, a preparation method was also developed, able to 
assure an easy incorporation of the reservoir system (AKS-loaded OMS) and 
based on technologies traditionally used for the preparation of topical 
pharmaceutical dosage forms. This method is based on the use of a high speed 
homogenisation (Ultraturrax) to mix the excipients, the active ingredient and 
the amikacin-silica reserve, followed by a stirring phase to achieve the correct 
viscosity. The physico-chemical stability of the AKS-OMS@GEL was 
performed over time (30 days) particularly investigating the pH and the 
viscosity through rheological measurements. Moreover, a visual evaluation 
was carried out to highlight any macroscopic alterations in the preparation. As 
results, the characterization of AKS-OMS@GEL confirmed a physico-
chemical profile comparable to the commercially available product. 
Particularly the results showed that the pH value was stable at 4.7 over time, 
resulting compatible with the skin 25. The viscosity of the AKS-OMS@GEL 
resulted compatible with the administration on the skin, as shown in Figure 
7.5. No macroscopic alterations of the preparation was observed. The gel 
shows rheological characteristic of shear-thinning fluid (data not reported), 




Figure 7.5. Pictures of the innovative formulation (left side) containing the 
reservoir system (AKS-OMS@GEL) in comparison with the commercial gel (right 
side). The aspect of the gels, before and after administration to the skin, is illustrated. 
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7.4.4. In-vitro Release studies using vertical diffusion cells 
In order to test the ability of the AKS-OMS in acting as reservoir system on 
the skin surface, the AKS release profile from the semisolid formulation 
containing the reserve technology was evaluated. For this purpose, in vitro 
Franz diffusion experiments were selected for its crucial importance in the field 




Figure 7.6 Schematic representation of a vertical diffusion cell (Franz Cell) 
 
The Franz cells were equipped with a synthetic membrane to model real skin. 
Even though artificial membranes are not able to simulate completely a 
biological system, they are generally preferred to skin tissue, because of their 
cheaper cost and simpler structure. Moreover, synthetic membranes offer more 
reproducibility, eliminating many in vivo variables such as sex, race, skin age 
and anatomical site 26. In these Franz experiments, both the AKS-OMS and the 
commercial gel were used as donor samples. The receiving compartments was 
filled with acetate buffer at pH 5.0, under stirring at 33°C, mimicking the skin 
conditions 27. At predetermined times, the receiving receptor was sampled and 
analyzed to know the amount of amikacin released from the formulations. 
Figure 7.7 reports the AKS release profiles obtained. In the first 100 minutes, 
AKS-OMS and the commercial formulation presented the same AKS release 
behaviour. During this first phase, the AKS-OMS released the free drug 
molecules contained in the saturated vehicle. However, after about 120 
minutes, some differences are evident. While the release rate of the marketed 
gel decreased due to the depletion of API in the formulation, the release rate 
of AKS-OMS remained constant for a doubled time, demonstrating the 
efficacy of the proposed reservoir effect. In fact, the AKS delivered by the 
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OMS particles started replacing the free drug molecules inside the vehicle, 
playing a key role in assuring a constant administration of drug to the skin. 
Moreover, it is worth of noting that at the end of the experiment the amount of 
API released from the AKS-OMS@GEL was double in comparison with the 
commercial gel, confirming that the AKS-OMS is able to totally release the 
incorporated drug. The Franz experiments furtherly demonstrated the proof of 
concept of this technology, as a possible strategy to reduce the number of 
applications during the day.  
 
Figure 7.7 Franz experiments for the in-vitro determination of AKS release from 
AKS-OMS@GEL and from the commercial formulation. Each point is the mean value 





7.4.5. In-vitro permeation studies using vertical diffusion cells 
 
 
Figure 7.8. Franz experiments for the evaluation of the in-vitro permeation of 
AKS release from AKS-OMS@GEL and from the commercial formulation, using ex 
vivo skin tissues. On the left panel, the AKS permeation profiles during the first 6 
hours; on the right panel the overall results over 170 hours. Each point is the mean 
value of three different release tests.  
 
In order to obtain preliminary information about the behaviour of the 
reservoir technology through an ex-vivo skin site, Franz experiments were 
carried out using the same previous procedure, but equipping them with pig 
ear skin. Figure 7.8 reports the resulting AKS release profiles, from the AKS-
OMS GEL in comparison with the commercial formulation. On the left panel 
of the Fig. 7.8 is showed in detailed the API release profiles during the first 6 
hours. It is evident that the permeated AKS profiles during the first 100 minutes 
from both the formulations, confirm the trend of the in vitro release studies and 
the two formulations behaved in a similar way. Nevertheless, after the first 100 
minutes significant differences arose and the AKS permeated amount from the 
reserve formulation exceeded that from the commercial gel. This was caused 
by the depletion of API in the semisolid matrix of the commercial gel, in which 
the concentration gradient decreases gradually overtime. On the contrary, in 
the AKS-OMS gel matrix the API concentration gradient is kept constant due 
to the release of the drug from the OMS, which replaces the drug depleted in 
the saturated vehicle. Despite of the commercial formulation completed its 
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drug release in 24 hours, the experiment furtherly demonstrated the ability of 
the AKS-OMS@GEL of keep releasing the API for at least a doubled time, 
around 48 hours (Panel left, Figure 7.8). These results showed that assuring a 
constant concentration on the skin site for a prolonged time could be a 
promising strategy to extend and enhance the permeation of API. Two different 
interpretations might be drawn from these outstanding results. On one hand, 
the enhancement of the AKS permeation profile could endow to an overdose 
during the treatment, causing some toxicity issues, as described in the 
introduction of this chapter. On the other hand, the constant amount of API 
supplied thanks to the reservoir system of the proposed technology, could lead 
to a decrease of the starting therapeutic amount of API, play a key role in the 
reduction of those skin irritating phenomena and, most important aspect among 
all, to the limitation of bacterial resistance insurgence. 
 
 
Figure 7.9 FESEM images of the ex vivo skin after the in-vitro permeation test 
through Franz experiments, after 6, 24, 48 and 72h.  
 
Figure 7.9 reports the results obtained monitoring the ex vivo skin tissues 
during the Franz permeation experiments at different time intervals.  The aim 
of this study was to perform a preliminary investigation of the interaction 
between the innovative reservoir gel and the skin. In particular, the behaviour 
of the contained OMS was tracked. For this purpose, four Franz cells were 
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equipped with ex vivo ear pig skin and filled with AKS-OMS@GEL as donor 
samples. After 6, 24, 48 and 72 hours the permeation experiment was 
interrupted in one Franz cell per time, extracting the ex vivo skin for the 
FESEM analysis. In literature, several research works have been dedicated to 
the evaluation of the possible permeation of OMS through the skin site of 
application 27–29. After a careful study, to the best of our knowledge, none of 
these papers reports a direct permeation of particles greater than 10 nm. On the 
contrary, as already described in this chapter, it is well known the possibility 
for these particles to enter skin pores and hair follicles, enhancing the drug 
release 27. The FESEM results confirmed the literature conclusions, evidencing 
the present of the OMS particles on the skin surface. It is evident that from 6 
to 48 hours, the OMS particles are organized in aggregated platforms on the 
skin, acting as surface drug reservoir. Probably, some of these aggregates 
might be formed during the samples preparation for the FESEM analysis. 
However, after 72 hours, the image shows a higher OMS dispersion on the skin 
surface, confirming the supporting role of the gel in the dispersion of carrier to 
the skin surface. However, skin penetration the OMS particles can be excluded. 
In fact, it is well-established in the literature and also reported in the EU 
regulation on nanomaterials that no skin penetration has been demonstrated for 
particles with larger size that 10 µm 30,31. In conclusion, no risk of toxicity from 
the use of this innovative drug reservoir formulation is present, also 
considering that amorphous silica is listed in the inactive ingredient guide of 
the FDA as a safe excipient for topical drug products and is compatible with a 
broad range of APIs 32. 
7.4.6. Microbiological activity studies 
In order to determine the antibacterial activity of the innovative AKS-
OMS@GEL proposed in this research work, different microbiological activity 
tests were carried out.  
Antibacterial susceptibility tests 
The antibacterial susceptibility test was performed on different bacterial 
strains: Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa. The essay confirmed that all the tested strains are susceptible to 
amikacin, according to the limits established by CLSI. Moreover, each 
component of the formulation was singularly evaluated, investigating the 
antimicrobial activity of the commercial product and of the glycerol/water 
vehicle with and without OMS as-such. The results showed that the vehicles 
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of the two formulations do not have any self-antibacterial activity and that they 
do not affect the activity of the drug. 
Microbiological determination of the AKS released from the AKS-
OMS@GEL 
This test was carried out comparing the AKS-OMS@GEL with the 
commercial Amikacin gel. During the in vitro release studies, an aliquot of 
each samples withdrawn from the Franz cell at predetermined times, was used 
to determine its microbiological activity, using the disk diffusion method. 
Table 7.2 reports the diameters of inhibition growth zones measured after the 
incubation of each AKS-containing samples at 37 ° C for 24 hours. Pictures of 




Table 7.2. Inhibition zone diameters  
 
  















1 21 177.36 22 246.13 
2 21 177.36 22 246.13 
3 18 72.85 20 137.78 
4 16 40.25 18 77.13 
5 13 16.53 15 32.30 
6 14 22.24 12 13.53 
24 7 2.79 13 18.08 




Figure 7.10 Disk-diffusion method of the AKS-OMS@GEL in comparison with 
the amikacin-based commercial gel with using K. Pneumoniae as test microorganism.  
 
From the evaluation of the results, it is evident that the two gel formulations 
possess a similar bacterial inhibition activity in the first hours of administration. In 
fact, the diameters of the inhibition growth zone are very similar in both cases. 
Nevertheless, after 24 and 48 hours AKS-OMS@GEL is still able in inhibiting the 
bacterial growth in comparison with the commercial gel, not more surrounded from 
any inhibited zone.  
Determination of the time-kill curves 
The bactericidal effect of AKS-OMS@GEL and of the amikacin-based 
commercial gel was investigated using the time-kill test. Aliquots of samples 
withdrawn at predetermined times during the in vitro release study were 
incubated (37°C) with the microbial strain, K. pneumoniae 28024.  Figure 7.11 
reports the results obtained performing the colony count of different aliquots, 




 Figure 7.11 Time-kill plot of Amikacin released from AKS-OMS@GEL and 
from the commercial gel after different time. The test microorganism was K. 
Pneumoniae. 
 
It is evident that the amikacin amounts released from the AKS-
OMS@GEL at 6, 24 and 48 hours from the in vitro application were 
significantly more effective in contrasting the bacterial growth than the 
commercial formulation. On the other hand, blue is the trend of bacterial 
growth without antibiotic interference. In fact, at the end of the test the 
microbial population decreases by about one logarithmic unit with the 
commercial gel, while the reduction induced by the formulation containing the 
reservoir system was about 4.5 logarithmic units. This essay successfully 
confirmed the efficacy of the innovative dermatological formulation, 




The proof of concept of an innovative dermatological formulation 
containing ordered mesoporous silica was successfully demonstrated. The 
possibility to obtain a drug reservoir system, combining API-loaded OMS with 
a saturated solution of the same API was investigated obtaining outstanding 
results from both a physical-chemical and biological points of views. The 
innovative formulation demonstrated a drug sustained release for twice the 
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time of the commercial gel, opening the possibility to reduce the daily number 
of administrations during a real treatment. Moreover, the new reservoir 
technology, maintaining a constant concentration of the API for a longer 
period, might be able to enhance the antibacterial activity in a shorter time 
reducing the insurgence of bacterial resistance.  
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